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ABSTRACT 
Kaposi sarcoma herpes virus (KSHV) is a typical DNA virus that is associated with a 
number of proliferative diseases including Kaposi's sarcoma. The KSHV open 
reading frame (ORF) 4 encodes a complement regulatory protein (Kaposi 
complement-binding protein, KCP) that binds complement proteins and inhibits the 
complement-mediated lysis of cells infected by the virus, thus providing a strategy for 
evasion of the host complement system. Kaposi's sarcoma is an angiogenic skin 
lesion that has been recognized as one of the most abundant tumours found in many 
parts of Southern Africa and which can occasionally become highly invasive, 
aggressive and capable of causing death, particularly amongst AIDS patients. It is of 
major significance to understand how complement control proteins (CCPs) such as 
KCP perform their biological functions at the molecular and structural levels, because 
of their potentials as therapeutic agents, their implications in the pathology and 
importance in the etiology of many disease conditions. This study was therefore 
undertaken to characterise the structure-function relationship of KCP. Based on 
primary sequence analysis and comparison to other functionally and structurally 
similar proteins, oligonucleotide primers were designed to amplify by PCR, three 
regions of the predicted ORF 4 from human herpes virus-8 (llliV-8) DNA isolated 
from a primary effusion lymphoma cell line. The PCR products were inserted by 
ligation into the expression vector pPIC9 to generate three recombinant plasmids for 
heterologous expression in the yeast, Pichia pastoris and to produce separately, the 4 
N-terminal Sushi domains (KCP-S, small), KCP protein lacking the putative 
transmembrane binding domain (KCP-M, medium) and the full-length protein (KCP-
F, full). Expression of the viral proteins was confirmed by SDS-PAGE and Western 
blot analyses using a rabbit polyclonal antibody directed against a selected peptide 
region that is common to all three recombinant KCPs. All the KCP proteins migrated 
electrophoretically as higher bands compared to their expected sizes. The lower 
mobilities of the proteins may be due to g1ycosy1ation since there are potential N-and 
0-glycosylation sites in the protein's primary sequence. Also, diffused bands were 
obtained in all the electrophoretic gels and Western blots carried out, which is 
characteristic of glycoproteins. Furthermore, the antibody recognized several larger 
lll 
and smaller bands that may represent aggregates and/or degradation products 
respectively. Both partially purified KCP-S and KCP-S directly from expression 
media were able to inhibit complement-mediated lysis of sensitized sheep 
erythrocytes by approximately 60% in a hemolysis assay. This result confirms 
previous reports that recombinant KCP is twice more efficient in inhibiting the 
classical pathway-mediated lysis of erythrocytes than the vaccinia virus complement 
control protein (VCP), which also contains 4 Sushi domains. The KCP-F and KCP-M 
proteins did not show any significant complement inhibitory activities. Preliminary 
immunohistochemical studies using the same antibody were carried out to determine 
the expression and distribution ofKCP proteins in Kaposi's sarcoma. 
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CHAPTER ONE 
INTRODUCTION 
The literature survey carried out, comprising of a critical review of a large number of 
previous studies will follow from broad to more project-specific and relevant 
information. It will initially describe the classification, structure, genome, life cycle 
and in vitro cultivation of Kaposi's sarcoma associated herpesvirus (KSHV) and 
KSHV as a model for viral oncogenesis. In section 1.2, the chief KSHV -related 
proliferative disorders such as multicentric castleman's disease. (MCD), primary 
effusion lymphoma (PEL) and Kaposi's sarcoma (KS) will be reviewed with the latter 
being described in more detail. These sections will be followed by a description of the 
complement system and inflammatory responses and how viruses have evolved or 
acquired means to subvert the host immune system in order to succeed as infectious 
agents. Finally a detailed description of the KSHV complement regulatory protein, its 
biochemical characterisation and molecular function within the context of the 
complement system regulation will be presented in this chapter. 
1.1 Kaposi's Sarcoma-Associated Herpesvirus 
Tumour viruses are presently regarded as essential tools in cancer research as many 
have led to the discovery of critical cell regulatory proteins such as p53, p300, E2F, 
just to name a few. KSHV is rapidly becoming one of the chief models of viral 
transformation because its genome has been sequenced and annotated. KSHV is also 
known as human herpesvirus 8 (HHV -8) because it is the eighth human herpesvirus 
identified to date (Russo et al, 1996). This viral strain was initially discovered from an 
acquired immunodeficiency syndrome-Kaposi's sarcoma (AIDS-KS) skin lesion in 
1993 by the molecular biological technique, representational difference analysis 
(RDA). RDA allowed the isolation and identification of two unique herpes-related 
deoxyribonucleic acid (DNA) fragments present inKS-diseased tissue that were not 
present in non-diseased tissue from the same individual (Chang et al, 1994). In order 
to detect and quantify the presence of KSHV DNA from a different number of 
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sources, a convenient and economic polymerase chain reaction (PCR) method has 
been developed by Curreli eta/ (2003) whereby, a different size DNA fragment has 
been synthesised to compete with the target viral DNA in a single PCR reaction. 
1.1.1 KSHV Classification and Structure 
Herpesviruses are typically divided into thiee main subfamilies namely the large, 
heterogeneous alphaherpesv!!us group; which includes herpes simplex virus (HSV), 
the betaherpesvirus group, which includes the human cytomegalovirus (HCMV) and 
fmally the gammaherpesvirus group, which consists of herpesviruses that replicate 
and persist in lymphocytes. The latter induces lymphoproliferation (Albrecht et a/, 
1992) and an example ofthis group is KSHV, which may also become latent in B-
cells (Figure 2). HHV -8 a new human herpesvirus closely related to Epstein-Barr 
virus (EBV), also known as HHV -4, is a large enveloped double-stranded DNA virus 
that belongs to the Rhadinovirus or gamma-2-herpesvirus genus within the subfamily 
Gammaherpesvirinae (Jenner and Boshofl: 2002). Structurally, KSHV has a target-
like ultra structural appearance (Renne et a/, 1996) with an electron-dense 
nucleocapsid core surrounded by an amorphous proteinaceous tegument and a lipid 
bilayer envelope (Moore and Chang, 2001) as represented by Figure 1. 
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Figure 1. Illustrated representation of the KSHV structural components 
KSHV is a large enveloped double-stranded DNA virus composed of a nucleocapsid layer as well as a 
proteinaceous tegument layer followed by an outer lipid bilayer. (Adapted from Henderson, 2002). 
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Figure 2. Characteristics of the members of the alpha, beta and gamma 
subfamilies of the herpesvirinae family (Geraminejad eta!, 2002) 
HHV-8 
I 
KSHV 
Variable 
Lympho 
proliferative 
Lymphoid 
tissue 
Obscure 
KS 
PEL 
MCD 
Both KSHV and EBV belong to the gammaherpesvirinae subfamily of herpes viruses, a group 
recognised for its capacity to sustain latency in lymphocytes. KSHV is the firSt Rhadinovirus known to 
actually infect humans. Unlike all the other members of the herpes Virus family, KSHV is the only type 
of herpes virus that may be regarded as very cryptic and highly difficult to undergo transmission. 
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This virus shares several characteristics of other herpes viruses and based on sequence 
analysis it is particularly closely related to herpes virus saimiri (HVS-2) of squirrel 
monkeys (Albrecht eta!, 1992), known to cause polyclonal T-celllymphoproliferative 
disorders in a number of monkey species (Moore et a!, 1996). Although 
rhadinoviruses are a rather underexploited model of viral tumorigenesis, they are still 
regarded as an important and useful group of viruses. Like other rhadinoviruses, 
KSHV is uniquely suited for studies of virus-cell interactions because of the 
production of viral homo logs to oncoproteins and cell signalling proteins (Russo et al, 
1996). It is believed that the acquisition of host genes by KSHV places the virus at an 
advantage, because by interfering with the host cellular defence mechanisms this virus 
can overcome destructive anti-viral responses (Neipel et al, 1997). 
1.1.2 The KSHV Genome 
Russo et al (1996) successfully sequenced the entire genome of KSHV by mapping 
continuous overlapping virus DNA inserts from body cavity-1 (BC-1) genomic 
libraries, with the exception of an unclonable repeat region at the right end of the 
genome. These results led to the definition of the viral genome structure as well as 
identification of genes that are likely to be responsible for KSHV -related pathogenesis 
(Russo et al, 1996). Encapsulated DNA from KSHV particles isolated from an EBV-
negative body cavity based lymphoma-1 (BCBL-1) cell line was analysed by pulsed-
field gel electrophoresis and the results showed that the KSHV genome is 
approximately 165 kb long (Renne et al, 1996). On the other hand, KSHV genome 
derived from a BC-1 infected cell line is approximately 270 kb long due to a 
duplication of a coding segment, which is inserted into the terminal repeat (TR) 
region (Russo et al, 1996). The structure ofBC-1 KSHV genome is characterized by a 
long unique region (LUR) flanked by 801 bp TR regions, which in addition to having 
84.5% guanine and cytosine (G+C) content, also contains putative packaging and 
cleavage signal sequences. The LUR of the KSHV genome is about 145 kb in length, 
has a 53.5% G+C content and contains all 90 identified KSHV open reading frames 
(ORFs) (Russo eta!, 1996), 66 of which are known to have homologues in the HSV 
genome, and are therefore numbered based on the HSV nomenclature. However, 
KSHV genes that are not homologous to HSV genes are given a K prefix such as K1-
K15 and include many of the cellular homolog genes (Jenner and Boshoff, 2002) 
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often coding for cell cycle regulation and signal transduction proteins (Russo et al, 
1996). Additional sequence analysis of the KSHV genome has revealed the presence 
of two putative lytic replication origins, which are the theoretical initiation sites for 
genome replication (Nicholas et al, 1998). Furthermore, sequence analysis has also 
shown that a large section of the KSHV genome is highly conserved among other 
herpes virus with transforming potential such as murine gammaherpesvirus 68 
(MHV68), EBV and HSV (Sarid et al, 1998). Conserved ORFs coding for supposed 
viral structural proteins and enzymes include genes involved in viral DNA replication, 
regulators of gene expression and five conserved herpes virus structural capsid and 
glycoprotein genes (Russo et al, 1996) as depicted in Table 1. The fourth ORF of the 
KSHV genome encodes a protein, KSHV complement control protein (KCP) also 
known as complement regulatory protein (CRP) predicted to have complement 
regulating activity (Spiller et al, 2003a) and it will be further discussed in 1.3.4. 
Although chimeric genomes have been found, KSHV is an ancient human virus that is 
transmitted mainly in a regular way with consequently very low recombination rates 
(Zong et al, 2002). Phylogenetic analysis of the ORF 75 gene from 41 HHV -8 DNA 
samples has shown that in addition to subgroups NB and C there is a novel subgroup 
present in South Africa which has been termed N. It is thought that this new subgroup 
N may have emerged as a result of continuous reactivation of KSHV in patients also 
. affected by AIDS (Alagiozoglou et al, 2000). 
Many ORFs encoded by the KSHV genome are host cell homologues involved in the 
regulation of the cell cycle and immune responses in tum contributing to the 
oncogenesis/virulence of this virus as described in sub-sections 1.1.5 and 1.3.2 
respectively. 
Table 1. Major KSHV genes of known products and their respective functions 
KSHVGene Protein Product Function 
ORFKI KlST Constitutively activates B-cell signalling pathways through 
syk; down regulates BCR; Oncogenic 
ORFK2 viL-6 Activates gpl30 independently of IL-6R; Autocrine growth 
factor in PEL; Angiogenic 
ORFK4 vMIP-11 CCR-3 agonist; Broad spectrum cytokine receptor 
antagonist; Inhibits leukocyte chemotaxis; Angiogenic 
ORFK4.1 vMIP-III CCR-4 agonist; Induces TH2 chemotaxis; Angiogenic 
ORFK6 vMIP-1 CCR-8 agonist; Induces T~ chemotaxis; Angiogenic 
ORFK8 b-ZIP Lytic transactivator 
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ORF8.1 gp35-37 Glycoprotein incorporated into virion 
ORFK9 viRF-1 Inhibits interferon signaling; Binds CBP/p300 
ORFlO viRF-4 Blocks IFN- and IRF -mediated transcriptional activation 
ORFK10.5 LANA-2 IRF-4 homology; Inhibits p53-mediated apoptosis 
ORF Kl2 Kaposin Oncogenenic 
ORFK13 Vflip Homolog of cellular apoptosis inhibitor (FLIP) 
ORFK15 LAMP Binds 1RAF1, 2 and 3 
ORF2 Dihydrofolate reductase Thymidylate production 
ORF4 Complement Binding Inhibits complement-mediated lysis 
Protein (CBP) 
ORF6 ssDNA binding protein DNA replication 
(SSB) 
ORF8 Glycoprotein B Glycoprotein incorporated into virion 
ORF9 DNA polymerase (POL) Functional DNA polymerase 
ORF 16 vBcl-2 Inhibits bax-mediated and virally induced apoptosis 
ORF17 Prand AP Protease and assembly protein respectively 
ORF21 Thymidine kinase Thymidylate production 
ORF22 Glycoprotein H Glycoprotein 
ORF37 Alkaline exonuclease DNase involved in DNA repair and packaging 
ORF39 Glycoprotein M Glycoproein 
ORF40 Printase-associated factor DNA replication 
(PAF) 
ORF43 Minor capsid protein Capsid 
ORF50 ART Spliced transactivator that initiates lytic gene expression 
ORF54 dUTPase Thymidylate production 
ORF71 v-FLIP Inhibits Fas-mediated apoptosis; Oncogenic 
ORF72 vCYC Associates with cdk6 to phosphorylate pRB and histone HI 
ORF73 LANA-1 Binds to ori-P and maintains viral episome; Inhibits p53 and 
pRB 
ORF74 vGCR Chemokine receptor homolog; Binds IL-8; Oncogenic 
(Jenner and Boshoff, 2002) 
1.1.3 KSHV Lytic Replication and Latent Infection 
Like all other herpesviruses, KSHV has two distinct modes of replication during its 
life cycle namely the lytic phase and the latent phase. The latent mode of infection is 
characterized by entry of the virions into a host cell, re-circularisation of the linear 
KSHV genome at its terminal repeat region and replication of the circular viral 
episome together with host cell DNA. The episome is kept in the replicating cell by 
the latency-associated nuclear antigen (LANA), which binds the episome, possibly 
through histone Hl interactions (Coscoy and Ganem, 2000) thus allowing equal 
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segregation of latent viral genomes to daughter cells during mitosis (Ballestas et al, 
1999). In addition, it has been shown that LANA mediates the replication of plasmid 
DNAs containing viral TRs. LANA 1 N-terminus is indispensable for chromosome 
association, DNA replication and episome persistence to take place in uninfected cells 
(Barbera et al, 2004). Key mechanistic features of latent DNA replication have been 
suggested to be conserved amongst closely related herpes viruses (Grundhoff and 
Ganem, 2002). Therefore, during latency, KSHV gene expression is minimized and 
the virus is dependent on the cellular replication machinery for survival. Furthermore, 
in order to evade the host immune responses, foreign antigen presentation is also 
minimal by maintaining the viral genes silent. On the other hand, during the lytic 
mode of replication, viral DNA, which is replicated by the virus-encoded polymerase, 
is encapsulated into infectious virions (Moore and Chang, 2001). The viral genes 
needed by the virus to carry out these two processes are sequentially activated by the 
master transactivator or by secondary transcriptional molecules in a regulated series 
of early, delayed-early and late patterns of viral gene transcription (Schulz et al, 
2002). Possible master lytic transactivators include the KSHV gene products, K-bZIP 
and ART, encoded by ORF K8 and ORF50 respectively. Northern hybridization 
analysis has shown that ART is likely to first transactivate ORF K8, product of which, 
subsequently acts on other viral promoters to generate proteins involved in capsid 
formation (Sun et al, 1999), as well as release of infectious virions, thus showing that 
the lytic cycle is crucial for the spread of KSHV infection (Wang et al, 2003). 
Although human immunodeficiency virus (HIV-1) Tat has formerly been believed to 
be an activator of KSHV lytic replication, Varthakavi et al (2002) showed that Tat 
alone is incapable of inducing the lytic phase of KSHV and that HIV -1 infection 
strongly induces this phase through activation of the KSHV Rta promoter. Therefore 
this group has concluded that in addition to HIV -1 tat, other factors are needed to 
activate lytic replication ofKSHV. 
Inflammatory cytokines present in KS lesions are capable of inhibiting spontaneous 
KSHV lytic gene expression but not the level of infection and this therefore suggests 
that cytokines add to KSHV pathogenesis by promoting latent KSHV infection of the 
endothelial cells (Milligan et al, 2004). 
Patches of unprompted lytic infection rather than just latent infection has been shown 
to arise within KSHV -infected dermal micro vascular endothelial cell (DMVEC) 
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lines. As a result, a quantitative assay has been developed by Ciufo et al (200 1) to 
directly measure the infectivity of KSHV virion preparations based on varied spindle 
cell colony and plaque formation. 
Although KSHV -infected tissues have been shown to consist primarily of latently 
infected cells, with only a small percentage of cells in the lytic phase, it has also been 
revealed that in addition to being essential for viral transmission, lytic viral proteins 
are also important in causing neoplastic transformations such as Kaposi's sarcoma. 
Therefore, elucidation and full characterization of the signals and mechanisms which 
allow the switch from the latent phase into the lytic phase, such as expression of the 
immediate early Lyta/ORF50 gene believed to be controlled by means of methylation, 
is an important area of research in order to learn how KSHV regulates its life cycle. 
According to Laman and Boshoff (2001), this further knowledge may in turn lead to 
the development of novel antiviral agents. 
1.1.4 In Vitro Cultivation of KHSV 
The BC-1 cell line, which is confected with EBV, was the first reported and 
characterized KSHV cell line. However, the fact that some cell lines derived from 
PEL are EBV negative has suggested that EBV co-infection is not necessary for the in 
vitro cultivation ofKSHV (Cesarman et al, 1995; Renne et al, 1996). 
KSHV can be directly cultured to high copy number in PEL-derived cell lines, which 
are B-cell lymphomas latently infected with KSHV. The efficiency of viral 
transmission to other cell lines and serial propagation of the virus remains extremely 
difficult to carry out. However, KSHV genome transmission from BC-1 cell line has 
been detected by PCR analysis (Moore et al, 1996) but this strain is still regarded as 
infection-incompetent (Sarid et al, 1998). TR analysis of KSHV in BC-1 under 
standard growth conditions correlates with the virus being under a tight latent 
replication control (Russo et al, 1996). Transcripts found under these conditions are 
likely to encode latency-associated proteins which in turn, may be essential for 
maintaining the latent viral genome and transforming virus-infected cells (Sarid et al, 
1998). 
Infected PEL cell lines carrying multicopy KSHV episomes can be induced into the 
lytic cycle by chemical agents such as sodium butyrate, which inhibits histone 
deacetylases involved in transcriptional repression and the phorbol ester, 12-0-
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tetradecanoylphorbol-13-acetate (TP A), which induces expression of histone 
acetyltransferases and activates transcription (Miller et al, 1997; Masumi et al, 1999). 
The ability to induce lytic cycle KSHV infection including the production of some 
mature virions has indeed facilitated the study of the genetics and molecular biology 
ofthis virus (Ciufo et al, 2001). 
1.1.5 KSHV: A Model for Viral Oncogenesis 
It is well known that some tumors are often associated with viral infections such as 
KSHV, which has been shown to be present in 90-95% ofKS lesions as demonstrated 
by DNA and serology-based studies (Gao et al, 1997). The growth and division of 
normal cells is under the control of two types of genes namely the proto-oncogenes, 
which promote growth and the tumor suppressor genes, which restrain the cellular 
growth. Therefore, disruption of the normal functioning of any of these two types of 
genes can cause the cells to grow in an uncontrolled manner thereby leading to 
tumorigenesis (Madigan et al, 2000). Amongst other DNA tumor viruses, KSHV has 
independently evolved precise mechanisms to evade immune responses, including the 
synthesis of a complement regulatory homologue amongst many other important 
cellular proteins. It has also developed strategies to prevent cell cycle shutdown, to 
interrupt activation of apoptotic pathways and to inhibit the tumor suppressor genes. 
In general, the study of tumour viruses is of critical significance as properties of 
oncogenic viruses often lead to a better understanding ofnon-virally induced cancers. 
1.1.5.1 The Cell Division Cycle and its Control system 
In each division cycle a cell must replicate its DNA, undergo M phase during which 
the replicated chromosomes are segregated into separate nuclei by mitosis, must split 
into two by cytokinesis, and fmally the cell must undergo a period of continuous cell 
growth known as the interphase. The cell cycle is known to be composed of four 
phases, the gap before DNA replication (Gt), the DNA synthetic phase (S), the gap 
after DNA replication (G2) and the mitotic phase, which terminates in cell division 
(M) as illustrated in Figure 3. In addition, cells in G1 can enter a specialized resting 
state, often called the Go (Alberts et al, 1994). The cell cycle events are well ordered 
into distinct pathways in which the initiation of late events is dependent on the 
completion of early events (Hartwell and Weinert, 1989). 
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Cell division is the fundamental means by which all living things are propagated 
(Alberts et al, 1994) and it is controlled through a complex network of biochemical 
signals, which regulate specific transitions in the cell cycle (Van den Heuvel and 
Harlow, 1993). It is speculated that each step of the cell cycle is largely regulated by 
complexes formed between cyclin-dependent protein kinases (CDK) and members of 
the cyclin family such that the G liS transition is regulated by Cdk2/cyclin E, 
Cdk3/unknown cyclin, Cdk4/ cyclin D1-D3; Cdk6/cyclin D3; the S phase is regulated 
by Cdk2/cyclin A; G2 phase by Cdc2/cyclin A and G2/M transition by Cdc2/cyclin B 
(Veseley et al, 1994). The control mechanisms that inhibit cell cycle transition after 
DNA damage consist of multiple signalling pathways and are known as cell cycle 
checkpoints (Hartwell and Weinert, 1989). One of these checkpoints is present in G 1 
just before entry into S phase and the other in G2 at the entry to mitosis (Figure 3). 
The proliferation of cells is a highly regulated process that is subject to many external 
and internal stresses, including viral infections such as KSHV, irradiation, toxic 
substances and reactive oxygen species, against which several stabilizing and repair 
mechanisms have been developed by the cells. The cell-cycle control system is based 
on a set of interacting proteins that induce and regulate the essential processes within 
the cell thereby allowing the duplication and division of the cell contents to occur 
(Alberts et al, 1994). As previously mentioned, some of the cellular responses to viral 
infections may result in cell cycle shutdown and induction of apoptosis in order to 
destroy the virus-infected cells and prevent further propagation of the viral disease. 
Russo et al (1996) has shown that KSHV has a large number of functional homo logs 
to cellular genes that play key roles in interfering and disrupting the cell-cycle control 
system. 
1.1.5.2 KSHV Oncogenic Proteins Target the Cell Cycle 
Cell cycle progression is strictly controlled by the expression and activation of 
regulatory molecules, which can either act as accelerators or suppressors (Sato and 
Torigoe, 1998). Key molecules ofthe cell cycle control system include the cyclins, 
cyclin- dependent protein kinase (CDK) inhibitors (CDI), the retinoblastoma protein 
(pRB) and the transcriptional factor E2F, all of which play important roles 
particularly at the starting point ofthe cell cycle (Sato and Torigoe, 1998). 
Like any other DNA virus, KSHV must encourage G 1 phase progression and entry 
into the S-phase of the cell cycle for efficient replication of its genome as depicted in 
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Figure 3. In the G1 phase, pRB, which is one of the major suppressor molecules 
capable of regulating the cell cycle, act as a transcriptional repressor in its 
hypophosphorylated state when it is bound to the E2F family of transcription factors 
(Sellers and Kaelin, 1996). The E2F family mediates transcription of genes required 
for DNA synthesis, such as cyclin E, Cyclin A, dihydrofolate reductase, and 
thymidine kinase (Wang, 1997). 
One of the few proteins that are expressed in latently infected cancer cells is the 
KSHV v-cyclin encoded by ORF 72. Godden-Kent et al (1997) showed that in tissue 
culture cells, this viral protein forms a complex with CDK 6 thereby promoting the 
phosphorylation and inactivation of the pRB suppressor protein. This in turn, causes 
the retinoblastoma protein to release E2F leading to activation of the S-phase genes 
and progression of the cell cycle from the G 1 phase to the S phase. In addition, v-
cyclin-CDK 6 complex is resistant to the physiological inhibitors of the cell cycle 
p 16, p21 and p27 (Swanton et al, 1997), which under normal circumstances inhibit 
the cyclin D2-CDK6 complex (Mann et al, 1999). Furthermore, CDK 6 activated by 
v-cyclin phosphorylates histone H1 implying that the kinase activity initiated by this 
viral cyclin may abrogate cell cycle checkpoints as there may be a change in substrate 
partiality (Godden-Kent et al, 1997). 
Other viral oncogenes acknowledged being widely expressed in the latent state of 
KSHV infection and assumed to be essential for the transforming ability of this virus 
are the fas-ligand-inter leukin 2-converting enzyme inhibitor protein (FLIP) which can 
inhibit Fas- mediated apoptosis and LANA encoded by ORF 71 and ORF 73, 
respectively. Fujimuro et al (2003) showed that the LANA C-terminus has sequence 
homology to the Axin GSK-3P binding domain, and that LANA stabilizes P-catenin 
leading to a cell cycle-dependant nuclear accumulation of GSK-3p, which is in turn, 
associated with entry into the S phase. Therefore, this study provided further 
convincing proof that LANA also contributes to the proliferative- stimulatory 
properties of KSHV. Among a number of other important established functions, 
LANA also has the capacity to avert the tumour suppressor p53 from inducing cell 
death (Friborg et al, 1999). 
It is interesting to note that the KSHV oncogenic group of LANA, v-cyclin and v-
FLIP are encoded on a tricistronic transcript and the function of one protein may 
therefore allow another to play a key role in the development of the tumour. In 
addition to these main oncogenic proteins, KSHV also produces homologues to the 
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interferon regulatory factor and interleukin- 6, which may also induce tumour 
formation via deregulation of growth signalling pathways or through evasion 
strategies of the host immune system (Boshoff, 2003) and the latter will be further 
discussed in section 1.3.2. Tomlinson and Damania (2004) have recently 
demonstrated that activation of the Akt signalling pathway by the KSHV Kl protein 
phorphorylates and inhibit members of the fork head (FKHR) transcription factor 
family, which are also major regulators of the cell cycle. 
r
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Figure 3. The cell cycle and association of KSHV v-cyclin with key regulators 
The KSHV v-cyclin performs the function of 3 separate cyclin-CDK complexes: (l) exit from GO 
(Cyclin D-CDK 6) whereby it phosphorylates and inactivates pRB causing the release of E2F leading 
to DNA synthesis; (2) through G l (Cyclin E-CDK 2) whereby it phosphorylates and inactivates p27 
alleviating its inhibitory effect on cyclin E-CDK 2 and cyclin A-CDK 2 and :finally (3) entry into S-
phase (Cyclin A-CDK 2) whereby it interacts and phosphorylates proteins of the origin recognition 
complex (ORCI and CDC6) which are involved in DNA replication. (Adapted from Alberts eta/, 1994 
and Boshoff and Weiss, 2002). 
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As reviewed here, KSHV seems capable of discovering and interfering with almost all 
established cancer pathways in order to induce tumor formation as Boshoff (2003) 
described it. 
1.2 KSHV -Related Proliferative Disorders 
At present, the proliferative diseases unmistakably related to KSHV infection include 
a tumor of endothelial cell origin known as Kaposi's sarcoma (KS), some plasm·a cell 
forms of multicentric Castleman's disease (MCD) which ts a B-cell 
lymphoproliferative disorder, and a body cavity-based or primary effusion lymphoma 
(BCBL or PEL) which also infects B-cells (Moore and Chang, 2001). Up to a study 
carried out by Pan et al (2001) KSHV was controversially associated with multiple 
myeloma but through the optimization of PCR protocols used for the detection of 
KSHV DNA, this group has acquired strong supportive data pinpointing that KSHV is 
not associated with the latter. It is now believed that KSHV is essential however, not 
sufficient for the development of these proliferative disorders because these diseases 
·are most commonly found in transplant recipients that were already HHV -8 positive 
before they were transplanted, and AIDS-patients showing that immunosuppression is 
the leading cause of tumor development in the presence of the virus (Geraminejad et 
al, 2002). 
1.2.1 PEL and M CD 
As previously mentioned, KSHV is found in the rare form of lymphoma, PEL, which 
is thought to originate from post-germinal center B-cells due to the presence of hyper 
mutated immunoglobulin genes (Matolcsy et al, 1998) as well as markers of late stage 
B-cell differentiation (Gaidano et al, 1997). Also unusual is MCD, which is a non-
malignant lymphoproliferative disorder, characterized by atypical polyclonal B-cells, 
in a microenvironment of intrleukin-6 (IL-6) excess (Parravinci et al, 1997) 
lymphadenopathy, fever and splenic infiltration and is more common in HIV -infected 
patients where it often becomes an aggressive disease (Jenner and Boshoff, 2002) just 
like KS. The mechanism by which KSHV causes these proliferative disorders is not 
yet well understood but is thought to involve several molecular events, the study of 
which should expand our knowledge of viral related cancers (Geraminejad et al, 
2002). 
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Table 2. Outline of the KSHV -related proliferative disorders & their properties 
Disorder Characteristics Degree of association 
KS AIDS- associated, African endemic, Very strong: clearly fulfils commonly used 
classical or Mediterranean and transplant- criteria for causality 
associated 
PEL A subset of body cavity lymphomas, Strong but not as well-defined asKS above; 
often EBV co-infection, most common in likely to be detected by association with EBV 
HIV patients, aggressive disease with 
poor prognosis 
MCD Most common in HIV patients, Moderate: Same as above; disorder can 
sometimes PEL or KS- associated develop in the absence ofKSHV, particularly 
in HIV-negative patients 
Febrile rash Found in children Moderate: few cases reported 
illness 
Acute bone Uncommon- reported in 3 transplant Moderate: few cases reported 
marrow failure recipients to date 
Multiple 4-5 new cases/100 000 persons/year Weak: suggested association not yet 
myeloma Progressive hematologic disease 
substantiated by sufficient laboratory and 
epidemiological data 
Excessive no of abnormal plasma cells 
(Cannon eta!, 2003) 
1.2.2 Kaposi's sarcoma 
KS is a malignant neoplasm of the blood vessels with rather erratic behaviour and 
outcome and it is characterized by prominent angiogenesis because of a discrepancy 
between promoters and inhibitors. Thrombospondin-1 (TSP), a physiological inhibitor 
of angiogenesis was shown to inhibit endothelial cell proliferation induced by both 
KS supernatants and Tat, a product of HIV-1 with angiogenic potential and most 
likely associated with AIDS-KS pathogenesis (Taraboletti et al, 1999). 
KS was first described by Moritz Kaposi, a Hungarian dermatologist, in 1872 as an 
"idiopathic multiple pigment-sarcoma of the skin". For an entire century, it was 
regarded as an indolent tumor, a rare disorder of older men typically of Eastern 
European, Mediterranean or Jewish origin (Geraminejad et al, 2002). However with 
the onset of the AIDS epidemic it is now considered an aggressive tumor capable of 
dissemination and even causing death particularly amongst male homosexuals 
(Geraminejad et al, 2002; Zong et al, 2002). 
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1.2.2.1 Clinical Variants ofKaposi's sarcoma 
There are four main variants of KS namely the classic form, the endemic KS, the 
iatrogenic variant and finally the epidemic type. Classic KS is the type that occurs 
more prevalently in older men of Eastern European, Mediterranean or Jewish origin. 
It is characterized by the slow formation of benign nodules, which result from the 
coming together of the lesions. The endemic KS variant which is also often referred to 
as African KS can in turn be subdivided into four clinical subvariants: a) nodular 
which is similar to the classic type; b) florid and c) infiltrative, both of which are 
more aggressive and d) lymphadenopathic form which unlike all other types of KS is 
very common amongst children particularly young South African Bantu children. On 
the other hand, the iatrogenic variant of KS is closely related to severe 
immunosuppression. Therefore it is the type most commonly found in organ 
transplant recipients who had to take high doses of immunosuppressant drugs, 
however, the lesions tend to develop only a few years later after the organ transplant. 
Finally the epidemic type, also known as AIDS-associated KS, is considered the most 
common proliferative disorder related to AIDS and unlike the classic type, early 
lesions tend to emerge on the face as reddish to pink papules which in prolonged 
cases form larger plaques (reviewed in Geraminejad et al, 2002). 
1.2.2.2 Histology of Kaposi's sarcoma 
The progression of KS can be divided into three distinct stages namely the patch or 
early, the plaque or intermediate stage and the nodular or late stage. During the initial 
stage ofKS (Figure 42 A 1-4), very few spindle cells characteristic of the nodule can 
actually be visualized. There is instead a large degree of jagged and dilated vascular 
empty spaces, which take place mostly in the reticular dermis layer of the skin tissue 
and sometimes may surround normal blood vessels (Jenner and Boshoff, 2002). The 
patch stage is also characterized by flat elongated endothelial cells lining these clear 
slit-like spaces and infusing through dermal collagen bundles. Other morphological 
characteristics of the patch phase include the incidence of perivascular infiltrate of 
lymphocytes together with plasma cells. Furthermore, a few scattered extravasated 
erythrocytes and hemosiderin deposits (which are formed because of the break down 
of hemoglobulin present in the red blood cells) can also be present. The initial stage of 
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KS is at times hard to diagnose but because HHV -8 infection has been shown to occur 
mainly in this phase of the disease, the early immunohistochemical detection ofHHV-
8 with an anti-LANA monoclonal antibody is regarded as a potentially useful tool in 
the diagnosis ofKS (Hong et al, 2003). 
Following the patch stage is the intermediate plaque stage of KS disease progression, 
which is characterized by an elevated number of elongated endothelial cells, as well 
as, by a further development of the spindle-cell proliferation, showing signs of slit-
like blood vessel formation within the deeper section of the dermis. As a result, during 
this phase, almost the entire thickness of the dermis becomes occupied by the more 
profound vascular proliferation (Figure 43 A 1-3). 
At the late and most advanced nodular stage of the vascular tumor (Figure 44 A 1-4) 
there is hardly any dermal collagen present and the lesion is now characterized by 
proliferating fascicles of spindle cells growing in all directions, connecting with one 
another and forming large nodules in the upper half of the dermis, which can clearly 
be visualized at lower microscopic magnification. These proliferating fascicles are 
characterized by slit-like blood vessels, extravasated erythrocytes, fibroblasts, 
inflammatory cells including lymphocytes and plasma cells, and large deposits of 
haemosiderin pigment within the tumor cells as well as macrophages (Chor and Santa 
Cruz, 1992). Furthermore, another prominent feature of nodular KS is the presence of 
hyaline bodies/globules, which are speculated to be defeated or phagocytosed red 
blood cells (RBC) and these can be seen as light pink eosinophilic structures. Nearly 
all the tumor (spindle) cells are latently infected by KSHV suggesting that paracrine 
mechanisms are involved in the progression of the disease (Dupin et al, 1999). 
Studies have shown that KSHV TR sequences in the late stage lesions display all 
patterns of clonality (Judde et al, 2000) implying that KS starts as a polyclonal 
hyperplasia and that through oligoclonality, develops into a true monoclonal 
malignancy (Jenner and Boshoff, 2002). 
1.2.2.3 Current Therapy for Kaposi's sarcoma 
At present, there is no known curative therapy for KS but solely a number of 
treatments capable of preventing tumor development or reducing KS pathogenesis. 
Most of the existent treatments will target either cell proliferation or angiogenesis 
type of mechanisms implicated in tumor growth. Combined chemotherapy, interferon 
16 
administration and radiotherapy are some of the commonly used anti-proliferative 
means of treating KS. Interferons possess anti-angiogenic properties, which have been 
shown to be related with the baseline CD4+ cell implying that interferons may act 
through the immune responses in controlling KS. Administration of IFN-a is a 
systemic therapy for KS and it should only be used in patients with disseminated 
tumour, particularly when involving visceral organs (reviewed in Hermans, 2000). 
Recent in vitro studies conducted by Pozharshkaya et al (2004) indicated that both 
IFN-y and IFN-a induced the expression of cellular antiviral genes in HHV-8 infected 
BCBL-1 cells, it enhanced cell death and decreased the production of infectious virus. 
In Western countries and the USA, where highly active anti-retroviral therapy 
(HAART) is widely used to treat IDV infection, there has been a staged decrease in 
the occurrence of both KS and other AIDS-associated malignancies, which are often 
caused by secondary viral infections. The enhancement of the immune system during 
therapy with HAART is evidently very significant and therefore a useful approach for 
the immune-prevention ofKS. The fact that post-transplant KS lesions regress upon 
cessation of immunosuppressive treatment imply that cellular immune responses are 
undoubtedly significant in keeping KSHV infection under control thereby preventing 
the onset ofKS (Bower et al, 1999). In conclusion, the main approach in treating KS 
is undoubtedly by finding means of keeping the immune system boosted. 
1.3 Complement System and Inflammatory Responses 
Inflammatory responses are characterized by an influx of immune cells, which can be 
mediated by chemoattractants or chemotactic factors (Kotwal, 2000). The 
complement system is part of the innate immune defence system, composed of a 
group of approximately 30 serum proteins, which interact with each other in a 
cascade-type reaction that splits subsequent proteins into fragments (Walport, 2001). 
The explosive nature of the complement system, either in the presence or absence of 
antibodies, can lead to virus neutralization and opsonisation, lysis of virus-infected 
cells and amplification of inflammatory and specific immune responses (Rother and 
Till, 1988) as depicted in Figure 4. The usual activation of complement makes up the 
first line of defence often leading to the release of potent chemotactic complement 
factors such as C3a, C4a and C5a (Blue box, Figure 4), also known as anaphylotoxins 
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which are responsible for attracting inflammatory cells thereby causmg an 
inflammatory response at the site of infection (Kotwal, 1997). 
The complement amplification events can be initiated via three distinct pathways as 
shown in Figure 4: 
a) The classical pathway, which is activated by an antigen-antibody reaction that 
starts with the binding of the Cl complex via C1q to the Fe region of 
immunoglobulin (Ig) (McGeer and McGeer, 1992) 
b) Spontaneously (alternative pathway) as a result of differences in envelope or 
membrane composition compared to the host (Spiller et al, 2003a) as well as an 
inherent flux of the most copious complement factor, C3 and finally c) the lectin 
pathway which recognises a number of saccharide molecules mostly mannose, 
generally only present on the surface of microorganisms (Blom, 2004). 
Irrespective of the complement activation pathway, a membrane attack complex 
(MAC) is formed at the end of the complement cascade. MAC is a large complex of 
proteins that in many cases causes a pore in the membrane of the pathogen leading to 
osmotic differences and therefore lysis of the infectious agent (Muller-Eberhard, 
1986). Activation of bound Cl leads to sequential cleavages ofC4 and C2, forming 
C4b2a, the classical pathway C3 convertase. Cleavage of the bound convertase in 
turn, activates the terminal lytic mechanism, characteristic of both the classical and 
the alternative pathway (Kotwal et al, 1990). 
Complement protein C3 is a fundamental molecule whose activation is vital for all the 
important roles carried out by the complement system (Sahu and Lambris, 2001 ), 
which in turn also requires the formation of the C3 and C5 complement convertase 
enzymatic complexes (Spiller et al, 2003a). In addition, C3 promotes phagocytosis as 
MAC-resistant pathogens are opsonised with C3b and iC3b fragments which bind to 
the complement receptor 1 (CR1) and complement receptor 2,3 and 4 (CR2, CR3 and 
CR4) respectively, found on the surface of phagocytes such as macrophages and 
neutrophils. In addition to triggering immune adherence and phagocytosis, these 
receptor-ligand associations also facilitate B cell signalling and promote antigen (Ag) 
localisation (reviewed in Nielsen et al, 2000). On the contrary, factor !-mediated 
enzymatic degradation of C4b results only in the covalent attachment of C4d fragment 
on the target, referred to as an immunological scar as unlike iC3b, the biological 
activity of C4d has not yet been identified (Barilla- LaBarca, 2002). 
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Figure 4. Overview of the current understanding of the complement pathways 
The complement system is activated by means of three distinct pathways: The classical, alternative and 
the lectin pathway. Complement activation can take place on the surface of antigen: antibody 
complexes (classical), in the absence of antibody on microbial surfaces (alternative) or on cell surface 
carbohydrates (lectin). The complement system can be divided into three key cascade-like events: I. 
The formation of the CJ convertase (yellow box); II. The formation of the C5 convertase (orange box) 
and finally Ill. The formation of the membrane attack complex (MAC) (red box). The anaphylotoxins, 
CJa, C4a and C5a (blue boxes) attract inflammatory cells to the site of infection leading to an 
inflammatory response (Adapted from Kotwal eta/, 1997). 
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Furthermore, C3 supports local inflammatory responses against pathogens and 
instructs the adaptive immune response to select the suitable antigens, for a humoral 
response. The downfalls of this molecule however, is that its unregulated activation 
can lead to host cell damage and its interactions with viral proteins for example, may 
provide a mechanism by which viruses evade the complement system (Sahu and 
Lambris, 2001). 
The fact that patients suffering from the lack of complement components are subject 
to recurring infections sometimes with detrimental consequences, clearly show the 
significance of complement as our frrst line of immune defence. Therefore, it can be 
concluded that the complement system plays a critical role in innate immunity, which 
provides a rapid response against a majority of pathogens without the requirement of 
a previous exposure. In addition, it also plays an important part in forewarning the 
adaptive immunity of a draw near combat. 
1.3.1 Host Complement-Inhibitory/Regulatory Proteins 
Considering the volatile and potentially destructive nature of the complement proteins 
which do not have the ability to differentiate between self and non-self and therefore 
destroy any cell including host cells (Sahu and Lambris, 2001 ), there is an evident 
need for the presence of inhibitors/regulators of the complement system in the host 
tissues. 
In vivo, complement activation IS regulated by a family of structurally and 
functionally related proteins referred to as mediators/regulators of complement 
activation (RCA) (Lambris et a/, 1998) that are encoded by a gene cluster present in 
chromosome 1 (Hourcade et a/, 1992). These proteins are characterised by the 
presence of 4-35 common structural motifs called the short consensus repeats (SCRs) 
or the complement control protein (CCP) domains (Hourcade et a/, 1989 Kirkitadze 
and Barlow, 2001 ). Each CCP module is comprised of approximately 60 amino acids 
and it is characterised by a conserved motif made up of four disulphide-linked 
cysteins, prolines, tryptophan and many other residues which together form a compact 
hydrophobic core in a bead-like structure (Barlow eta/, 1993). 
This family of proteins exist in a balanced manner and include: 
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(i) The plasma proteins, C4-binding protein (C4BP), which is the maJor soluble 
inhibitor, of both the classical and lectin pathways and factor H, which inhibits mainly 
the alternative complement activation pathway; 
(ii) the membrane-bound regulatory proteins, CD35 or CRl , CD55 or decay-
accelerating factor (DAF) and CD46 or membrane cofactor protein (MCP), which are 
generally present at various ratios on all human cells. 
On the whole, all these complement inhibitors act at the level of C3 and C4 and 
function either by accelerating the decay of the C3- and C5-convertases or by 
enhancing the serine protease factor I (FI)-mediated proteolytic degradation of C3b or 
C4b complement fragments (Sahu et a!, 2000). The plasma proteins, factor H and 
C4BP are specific for C3b and C4b respectively, while MCP and CRl are cofactor 
proteins for both C3b and C4b (Barilla- LaBarca eta!, 2002). 
1.3.1.1 The C4-Binding Protein (C4BP) 
C4BP is a 570 kDa protein made up of seven alike a-chains containing eight CCP 
modules. It is also comprised of a single ~-chain, which contains three CCP domains 
and all these structural chains are linked via disulfide bridges. With the use of electron 
microscopy, two decades ago, Dahlaback and Mi.iller-Eberhard , (1 984) described the 
conformation of this CRP as spider-like whereby the seven a-chains appear as 
extended tentacles. Blom et a! (1999) have identified a cluster of positively charged 
amino acids which are essential for C4b binding and FI cofactor function. C4BP 
prevents the deposition of C4b and the assembly of the classical C3-convertase. In 
tum, it can also accelerate the decay of this convertase and it can serve as a cofactor in 
the PI-mediated cleavage of C4b and C3b (reviewed in Blom, 2004). In the case of a 
pathogenic infection, the functions of C4BP mentioned here, lead to decreased 
opsonisation of the virus particles or other pathogens with C3b therefore discouraging 
phagocytosis. Furthermore, it also leads to a diminished level in the formation of 
MAC, in other words, level of lysis and/or neutralisation ofthe infectious agent. 
1.3.1.2 Other Host Complement Inhibitors- An Overview 
The functions of CD35/CR1 include: 
(i) Cofactor activity for the PI-mediated degradation ofC3b; 
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(ii) Binding of C4b thereby enhancing its cleavage into other C4 complement 
factors, C4c and C4d; 
(iii) Obstruction of the complement cascade by accelerating the decay of both 
the C3 and C5- convertases; 
(iv) Binding of all complexes that are opsonised with C3b and C4b resulting in 
phagocytosis by the CR1-containing cells (reviewed in Fishelson et al, 
2003). 
CD46/MCP is an extensively dispersed type 1 transmembrane glycoprotein that 
regulates complement activation, basically, in the same way as CD35 for the 
exception that this particular regulator of complement does not possess decay-
accelerating activity (Kojima et al, 1993). Liszewskin and collaborators (2000) have 
predicted the crystal structure of MCP and shown that it consists of four extracellular 
adjacent CCP modules all of which contain sites that are important for the 
complement inhibitory ability of this molecule. 
CD55/DAF is an integral membrane protein attached to the cell surface by a glycosyl 
phosphatidylinositol (GPI)-anchor (Medof et al, 1986) and as implied by its name, 
DAF enhances the decay of both C3 and C5 convertases (Nicholson-Weller and 
Wang, 1994). 
It is worthwhile mentioning that there is an additional host complement inhibitor 
known as CD59, even though at the DNA level it does not share significant homology 
to the other complement regulators (Sawada et al, 1990) reviewed above. CD59 is 
very important however, because it provides the last line of defence against 
undesirable complement activation on host tissues as it interferes with the formation 
ofMAC by preventing C9 polymerisation (Meri et al, 1990). 
Viruses are compulsory intracellular parasites and ultimately depend on the cell 
machinery of the host to survive and propagate. Since the complement proteins 
implicated in the cascade activation process are not able to discriminate between self 
and non-self, viruses are highly vulnerable to the complement system upon evading 
the host. Therefore, during co-evolution, viruses have developed and acquired cleaver 
means of overcoming the complement system of the host, which will be described in 
the section to follow. 
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1.3.2 Viral Strategies of Immune System Evasion 
In order to combat the host defence mechanisms and succeed as pathogens, certain 
viruses, including KSHV have developed/acquired strategies of defence against the 
complement system and other host defence mechanisms (Spiller et al, 2003a). These 
strategies can be divided into two main categories, namely active strategies, in which 
the virus has obtained immunomodulatory genes, and passive strategies during which 
error-prone replication allows for rapid antigenic evolution and therefore, consequent 
evasion of the host immune system (Chaston et al, 2001). 
One of the mechanisms of immune system evasion by viruses is the sequestering or 
modulation of the expression of host complement inhibitors by capturing CCPs from 
the RCA loci of the host. As an example, Spiller et al (1996) showed that human 
cytomegalovirus-infected cells were encouraged to inhibit the complement system 
when compared to virus-free cells. In the presence of the virus there was an increase 
in the cell surface expression of host membrane-bound complement inhibitors like 
DAF and MCP. Like human cytomegalovirus, HIV and vaccinia virus incorporate in 
their envelope host complement control proteins when they are being released from 
infected cells. In this way they prevent their opsonization by inhibiting the effects of 
complement on them (Montefiori et al, 1994 and V anderplasschen et al, 1998). 
On the other hand, members ofthe herpesvirus (KSHV, HSV-1 , HVS) and poxvirus 
(vaccinia, cowpox, smallpox) family have developed the ability to encode their own 
homologues of complement regulatory proteins, capable of binding key complement 
subunits and inhibiting the complement-mediated destruction of infected cells (Dietz, 
2000). Indeed, sequence analysis of these DNA viruses has confirmed the presence of 
genes with remarkable homology to complement control proteins containing short 
consensus repeats (SCRs) (Sahu et al, 1998a). Furthermore, certain viruses benefit 
from the complement system by using host complement receptors to infect a range of 
cells (Sahu et al, 1998b ). 
The protein products of viral "pirated genes", the immunomodulators, distinctively 
subvert the immune response by targeting specific cellular signal pathways, and thus 
facilitating pathogenesis and persistent viral infection within the host (Sahu et al, 
1998a). In addition to causing persistent infections, herpesviruses tend to modulate 
more strongly the specific secondary host responses aimed at them, for example by 
blocking antibody attack or antigen presentation to major histocompatibility complex 
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(MHC) molecules (Hengel et a/, 1998; Nagashunmugan, 1998). It has been shown 
recently that KSHV also uses the mechanism of auto-activation to regulate the 
expression of a viral transforming protein thereby efficiently evading host tumour 
suppressor pathways (Wang and Gao, 2003). 
In conclusion, certain viral genes, which are likely to have been captured from host 
cells during viral evolution, have undoubtedly been modified to confer an advantage 
in viral replication, transmission and survival (Dietz, 2000). 
1.3.3 Immunomodulators of Viral Infection 
Immunomodulators (Table 3) have the ability to conserve the vrrus by blocking 
apoptosis until the virus has replicated to high titers and found a new host, and by 
protecting it against damage from the inflammatory response (Kotwal, 2000). 
Many DNA virus produce two major groups of proteins that take place in evasion of 
the host's immune responses, namely the cell-associated cytokine response-modifying 
proteins or serpin-related proteins (Kotwal and Moss, 1989) and the secreted proteins 
also known as virokines (Kotwal and Moss, 1988). In addition, the virokine family 
consists of a number of cytokine-chemokine-binding proteins or viroreceptors (Upton 
et a/, 1992), a neurovirolence factor (Kotwal et a/, 1989) and a complement control 
protein (Kotwal and Moss, 1988). Virokines which are often homologous to host 
proteins are very small and potent virally encoded proteins that are secreted from 
infected host cells. These are capable of modulating several features of the host 
immune system, thus creating a favourable habitat for viral replication (Smith and 
Kotwal, 2001). 
1.3.3.1 Examples of KSHV Chemokine Homologs 
Virokines include the chemokines, which are significant chemoattractants that play a 
major role in the initial host immune response to infection and injury (Dietz, 2000). 
KSHV encodes a number of proteins homologous to many cellular chemokines for 
example, the viral macrophage inflammatory protein, vMIP-II, which exhibits broad-
spectrum chemokine receptor binding ability (Smith and Kotwal, 2001 ). Chemokine 
vMIP-II binds predominantly to the CC-chemokine receptor (CCR-3) causing human 
eosinophil activation as measured by intracellular calcium mobilization and 
chemotaxis (Moore et a/, 1996; Boshoff et a/, 1997). It has also been shown, that this 
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particular chemokine can prevent the entry of several strains of HIV -1 into cells by 
blocking the virus chemokine coreceptor (Luttichau et a!, 2000). 
Table 3. Examples of Viral Immunomodulators of Complement Pathways 
Virus Virokine Host homologue Functional activity 
KSHV Kaposi cal CCPs: CRJ , Enhances the decay of classical C3 convertases; 
CRP/KCP C4bBP, Factor H, acts as a cofactor for factor 1-mediated C4b & C3b 
DAF cleavage; Inhibits C3b deposition 
HVS ORF4 C4bBP, DAF, MCP Inhibits C-mediated lysis, regulates activation of 
(CCPH) C9 
HVS ORF15/ CD 59 Inhibits C-mediated lysis; regulates activation of 
ORF-LS C9 
HSV gCl and CRI , OAF Binds to C3b & iC3b; accelerates decay of ACP 
gC2 C3 convertase 
HSV 1/2 gEl gl Fe receptors Binds Fe & decreases detection of bound Abby 
complement 
EBV gp 335/ C3d Competes with C3d for binding to CR2 
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HIV gp41 C3 Incorporates CD59, DAF, factor Hand properdin 
on surface; prevents complement activation , binds 
Cl 
Vaccinia VCP CRI , C4bBP, Binds C3b & C4b, Cleaves C3b in presence of 
Factor H factor I; inhibits formation & speeds up the decay 
of C3 convertases 
Cowpox IMP CCPs Inhibits complement- mediated lysis & decreases 
inflammatory response 
Myxoma T2 TNF receptor Reduces inflammation 
(Kotwal , 1997) 
It is believed that viral chemokines add to mechanisms that block the host defence and 
contribute to virus-induced cellular transformation resulting in the development of 
proliferative disorders such as KS (Dietz, 2000). In addition, KSHV encodes 
chemokine receptor homologs also known as G-protein-coupled receptors (GCRs), a 
category of proteins thought to attract macrophages and monocytes via the 
chemokines bound to their surface. This in turn, results in viral entry and subsequent 
induced viral replication as well as dissemination of the virus throughout the host 
(Kotwal, 2000). 
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1.3.3.2 Examples of KSHV Cytokine Homologs 
The first line of defence following KSHV infection in an immunocompetent host is 
the activation of complement, the influx of immune cells and ultimately the secretion 
of cytokines, which are responsible for the recruitment of even larger numbers of cells 
to the infected site. The cytokine receptor-like virokines regulate the improved 
macrophage influx resulting from proinflammatory cytokines secreted by the initial 
immune response (Kotwal, 2000). In 1994 Chang et al, discovered that KSHV 
encodes viral interleukin 6 (viL-6) with 25% amino acid identity with its human 
homolog, which has been associated with the development of several 
lymphoproliferative disorders as IL-6 is known to enhance B-cell survival, 
differentiation and proliferation oflymphatic cells (Hideshima et al, 2000). Therefore, 
it is thought, that the expression of this viral gene is involved in the pathogenesis of 
KSHV -related diseases namely MCD and PEL (Geraminejad et al, 2002). 
1.3.3.3 Examples of Complement Regulatory Proteins 
The most well studied example of a viral homologue to the family of complement 
regulatory proteins is the vaccinia virus complement control protein, best well known 
as VCP, which is a 35 kDa soluble protein composed of four CCP modules (Kotwal 
and Moss 1988). The crystal structure of VCP was successfully elucidated by Murthy 
et al (2001) and it revealed an extremely extended molecule with the ability to bind 
heparin and regulate complement activation simultaneously, as shown by surface 
plasmon resonance (SPR) studies ofrecombinantly expressed VCP (rVCP) constructs 
(Smith et al, 2003). Nuclear magnetic resonance (NMR) analysis of VCP after 
exposure to a number of adverse conditions demonstrated that VCP is a very robust 
complement regulatory protein most likely because of its structural conformation 
(Smith et al, 2002). Functionally, VCP has been shown to inhibit the classical 
pathway-arbitrated lysis of sheep erythrocytes, to bind C3b and C4b and to function 
as a cofactor for their FI-mediated cleavage. In addition, VCP also plays a role in the 
acceleration of the decay of both the classical and alternative pathway C3 convertase 
complexes (Mckenzie et al, 1992). Furthermore, the ability of VCP to bind heparin 
sulphate proteoglycans on the surface of human endothelial cells enables this protein 
to inhibit specific antibody binding to MHC class I molecules (Smith et al, 2000). 
The cowpox virus (CPV) homologue of VCP is called the inflammatory modulatory 
protein (IMP) and like VCP it has been shown to down-regulate chemotactic 
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complement factors, C3a, C4a and C5a, thereby resulting in diminished cellular influx 
and inflammation. This function of IMP was demonstrated by injecting the footpad of 
BALB/c mice with CPV expressing IMP (Miller eta/, 1997 and Kotwal eta/, 1998). 
In addition to the two poxviruses examples reviewed above, a number of 
herpesviruses are known to encode for regulators of the complement system. The first 
herpesvirus complement regulatory protein identified was glycoprotein C of HSV -1 
(gC-1) (Friedman et a/, 1984) which has also been most extensively studied. 
Similarly, HSV-2 also encodes for a gC-2. Interestingly none of these two 
glycoproteins are homologous to the proteins of the RCA family suggesting that in 
general their mechanisms through which they inhibit complement activation must be 
peculiarly diverse from the RCA molecules. On the other hand, HVS encodes for a 
protein with remarkable homology to VCP and other RCA proteins, the HVS 
complement control protein homolog (CCPH), which due to differential splicing of 
the primary transcript exists as a membrane and secretory form (Albrecht and 
Fleckentein, 1992). In addition, HVS also encodes a CD59 homologue capable of 
interfering with the assembly of MAC (Rother eta/, 1994). Furthermore, like KSHV, 
the murine gammaherpesvirus-68 (MHV -68) also possesses an ORF 4, which encodes 
for a CCP with the ability to regulate both the classical and alternative pathways of 
complement activation (Kapadia et a/, 1999). 
1.3.4 The KSHV Complement Regulatory Protein (KCP) 
As mentioned above, KSHV encodes several proteins that potentially contribute to the 
disruption of the immune response. One of these virokines was determined by 
sequence analysis to be encoded by ORF 4 since it shares homology with the cellular 
proteins known as RCAs (Russo et a/, 1996). 
KSHV ORF 4 is a secondary lytic gene (Jenner eta/, 2001), which is expressed on the 
surface of KSHV infected cells (Spiller et a/, 2003a). Analysis of the primary 
sequence as deduced from the ORF 4 revealed that the KCP is predicted to be 551 
amino acid (aa) residues in size including a 15 aa signal peptide (Figure 6). 
KCP is a type 1 membrane-bound protein and structural analysis based on 
bioinformatics revealed that KCP is comprised of a number of distinct regions: (i) 
four N-terminal tandemly repeating CCP domains projecting into the extracellular 
space, which are present within the first 270 aa (Figure 5). The presence of these CCP 
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domains, therefore render this protein homologous to members of the RCA family, 
particularly to human DAF. 
SCR1 2 CSQK--TLIGYRLKHSRDGDIAVGETVELRCRSGYTTYARNITATCLQGGT----WSEPTATCNKKS 62 
SCR2 63 CPNPGEIQNGKVIFHGGQDALKYGANISYV EGYFLVGREYVRYCHIGASGQHAWSSSPPFCEKEK 129 
SCR3 130 CHRP-KIKNGD--FKPDKDYYEYNDAVHFE EGYTLVG-PHSIACAVNNT----WTSNHPTCELAG 188 
SCR4 189 CKFP-SVTHGYP-IQGFSLTYKHKQSVTFACNDGFVLRG-SPTITCNVTE-----WDPPLPKCVLED 248 
Figure 5. Clustal W multiple sequence alignment of the SCRs ofKCP 
Each SCR module is comprised of approximately 60 amino acids and it is characterised by a conserved 
motif made up offour disulphide-linked cysteins. 
Immediately after the SCR region is a (ii) proline-rich region of about 70 aa ending in 
a dicysteine motif which is in turn (iii) followed by a 202 aa serine/threonine rich 
region speculated to be heavily 0-glycosylated. Finally, (iv) a carboxy terminal 
hydrophobic region of 26 aa was identified as a putative transmembrane domain that 
anchors the protein to the cell membrane (Figure 6). 
Spiller et a/ (2003a) showed that transfected mammalian cell lines expressed the 
KSHV ORF 4 gene as a full-length transcript and as two alternatively spliced 
transcripts, all of which were shown to only differ m length between the CCP 
domains and the potential transmembrane region. In other words, the three isoforms 
maintained the conserved SCR motifs needed for complement regulation as well as 
the putative transmembrane region. According to this research, the KSHV ORF 4 is 
the most complex spliced gene encoding a viral complement regulatory protein 
described to date. On this note, recombinant KCP proteins were produced 
corresponding to the naturally expressed isoforms as both membrane-bound and 
soluble truncated fusion proteins with the Fe region of human immunoglobulin, which 
were in tum conveniently purified by affmity chromatography. 
Spiller eta/ (2003a) demonstrated that the three KCP isoforms inhibit C3b deposition 
on the surface of cells under complement-activating conditions thereby preventing 
lysis ofthe infected cells. 
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1 MAFLR TL WIL WTFTMVIGQDNEKCSQKTLIGYRLKMSRDGDIA VGETVE 
51 LRCRSGYTTY ARNITATCLQGGTWSEPTATCNKKS CPNPGEIQNGKVIFH 
101 GGQDALKYGANISYVCNEGYFL VGREYVRYCMIGASGQMA WSSSPPFCEK 
151 EKCHRPKIKNGDFKPDKDYYEYNDA VHFECNEGYTL VGPHSIACA VNNTW 
201 TSNMPTCELAGCKFPSVTHGYPIQGFSLTYKHKQSVTF ACNDGFVLRGSP 
251 TITCNVTEWDPPLPKCVLEDIDDPNNSNPGRLHPfPNEKPNGNVFQRSNY 
301 TEPPTKPEDTHT AATCDTNCEQPPKILPT5EGFNETTTSNTITKQLEDEK 
351 TISQPNTHITSAL TSMKAKGNFTNK TNNS TDLHIAS TPT5QD D A TP5IP5 
401 VQTPNYNTN APTR TL TSLHIEEGPSNS TTSEKA TSS TL ~HN~HKNDTGGI 
451 YTTLNKTTQLPSTNKPTNSQAKSSTKPRVETHNKTTSNPAISLTDSADVP 
501 QRPREPTLPPIFRPPASKNRYLEKQL VIGLLTA VALTCGLITLFHYLFFR 
Figure 6. Primary Structural Features of KSHV complement regulatory protein 
Conserved motifs of the primary structure of KCP are depicted in Figure 6. The four conserved SCR 
domains are underlined and the disulphide-linked cysteines are shown in bold and red. The signal 
peptide and the putative transmembrane domain are highlighted in pastel pink and yellow boxes 
respectively. The potential N-glycosylation sites as determined by primary sequence analysis are 
represented in blue. The 5 proline residues within the proline rich region are bold and italicised in 
black. Immediately following the proline-rich region is an S/T region containing 26 serines and 38 
threonine residues shown in bold and two different shades of green respectively. 
KCP expression at the cell surface and on the virion itself is likely to contribute to the 
viral evasion ofthe complement component ofthe innate immune response, facilitate 
KSHV infection, persistence and pathogenesis and finally aid in targeting KSHV to 
one of its host reservoirs, since C3d is a ligand for complement receptor 2 present on 
B-cells (Spiller eta/, 2003a). 
Additionally, Spiller eta/ (2003b) showed that all three forms of KCP-Fc strongly 
enhanced the decay of classical C3 convertase and in spite of KCP 's ability to bind 
both C3b and C4b its affmity for C4b was shown by SPR to be 10-fold higher. This 
fmding correlates with the fact that KCP is a more efficient inhibitor of the classical 
than the alternative pathway of complement activation. Furthermore, all cell-bound 
and soluble forms of KCP in this study were generally comparable in their 
performance as cofactors for FI-mediated cleavage ofboth C4b and C3b into C4d and 
iC3b (further cleaved into C3d) respectively. 
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On the other hand, Mullick et al (2003) have called the KSHV inhibitor of 
complement, kaposica which they expressed as a recombinant shorter secreted form 
(encompassing SCRs 1-4 only) in the yeast Pichia pastoris expression system. 
Similarly, this study confirmed the KCP-dependent mechanism by which KSHV can 
subvert complement attack by the host as the purified protein was shown to (i) repress 
human complement-mediated lysis of erythrocytes, (ii) prevent the deposition of C3b 
on the cell surface and (iii) act as a cofactor for FI-mediated cleavage of C3b and 
C4b. The latter reveals that the KSHV inhibitor of the complement cascade regulates 
the formation of C3 convertase by turning its subunits, C3b and C4b, into their 
inactive forms. Furthermore, hemolysis assays carried out by Mullick et al (2003) 
revealed that KCP is twice as efficient in inhibiting the classical pathway-mediated 
lysis of erythrocytes and approximately five times stronger than VCP in inhibiting the 
alternative pathway-mediated lysis of erythrocytes. 
Most recently, in order to characterise the structure-function relationship of KCP, 
Mark et al (2004) carried out a broad analysis of the CCP domains at the amino acid 
level by generating twelve mutants, which were in tum analysed for their ability to 
bind C3b and C4b, act as FI cofactors and to accelerate the decay of convertase 
complexes. According to Market al (2004), KCP has undoubtedly evolved in such a 
way as to maintain the spatial structure of its functional sites, particularly the 
positively charged regions which are similar to the functional sites present in other 
common human regulators of the complement system (Figure 7). 
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SC:RI 
SC:R2 
SC:R3 
Figure 7. Illustration of the predicted Crystal Structure of the four SCR motifs 
ofKCP 
The tertiary structure model of KCP was predicted by homology modelling using the VCP crystal 
structure contained in the PDB (Protein Data Bank) as a template. The 3D structure of the four SCR 
motifs of KCP was created using the freely available RasMol software. The amino acid at the N-
terminus shown as a red stick represents the first amino acid of CCP where the signal peptide was 
cleaved off, and it is labelled using the single letter code plus the number that relates to its position in 
the primary amino acid sequence. 
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1.4 STATEMENT OF HYPOTHESIS 
1.4.1 Broad Hypothesis: 
The KSHV (HHV -8) complement regulatory protein (CRP) is involved 
in the establishment of the viral infection leading to Kaposi's sarcoma 
in HIV patients. 
1.4.2 Specific Hypothesis: 
The KSHV (HHV-8) putative complementary ORF4 encodes a-
functional protein that has an in vivo role in the complement inhibition 
strategy of the virus immune system evasion. 
1.5 AIMS AND OBJECTIVES 
The primary objective of this work was to characterise the structure-function 
relationship of KCP. In order to undertake these studies, the following specific aims 
were pursued: 
1) To produce three recombinant versions of KCP, namely a soluble truncated 
protein comprising of the 4 CCP domains (KCP-S, small), KCP protein 
lacking the putative transmembrane binding domain (KCP-M, medium) and 
the full-length ORF 4 protein (KCP-F, full) using the methylotrophic yeast P. 
pastoris expression system; 
2) To confirm the secreted expression of the viral proteins by SDS-PAGE, 
Immunodetection and Western blot analysis; 
3) To synthesised a polyclonal anti-KCP antibody directed against a selected 
peptide region that is common to all three recombinant KCPs; 
4) To test the partially purified proteins of interest in a hemolytic assay for 
complement binding function; 
5) To carry out preliminary immunohistochemical studies usmg the same 
antibody in order to determine if there's a link between KCP and KS. 
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CHAPTER TWO 
MATERIALS AND METHODS 
Materials 
Plasmids and P. pastoris strains used in this study can be found in Appendix A. All 
materials and their respective suppliers are listed in Appendix B. 
2.1 Preparation of the KSHV ORF 4 DNA Constructs 
For easy cloning of the genes of interest as well as for possible future site-directed 
mutagenesis work, the KSHV ORF 4 gene products were first inserted into the 
expression vector pGEMT -easy (Promega) to generate three recombinant plasmids, 
pGEMT/KSHV ORF 4 (735), pGEMT/KSHV ORF 4 (1436) and pGEMT/KSHV 
ORF 4 (1581), coding for a soluble protein containing the 4 Sushi domains (735 bp), 
the whole extra cellular domain (1436 bp) and the full ORF 4 containing the putative 
transmembrane domain (1581 bp) respectively (Figure 8). 
The Escherichia coli strain XL-1 blue was used for transformation and propagation of 
the recombinant plasmids. E. coli is the most frequently used prokaryotic host for 
recombinant DNA technology because it is easy to grow and manipulate in large 
quantities in a controlled manner. In addition, it has been both genetically, and 
biochemically unravelled, thus providing a favourable alternative for the effective 
cloning of the genes of interest. 
For the heterologous production of the KSHV ORF 4 complement regulatory protein 
(KCP) in P. Pastoris, the KSHV ORF 4 gene products were then inserted into the 
yeast expression vector pPIC9 to generate three recombinant plasmids as described 
above. 
2.1.1 Primer Design 
Oligonucleotide primers (Table 4) for the in vitro amplification of KSHV ORF 4 
genes by PCR were carefully designed using the computer software Gene Runner. A 
sequence-specific forward and three consequent reverse primers were designed and 
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analysed for the PCR. The G/C content and the melting temperatures (Tm) values of 
the selected primers were automatically calculated. 
Table 4. Design of primers for PCR amplification ofKCP from KSHV DNA 
Restriction endonuclease sites are indicated underlined and stop codons are in boldface. 
Primer Primer sequence Tm Cone Mw 
(DC) (OD/ml) 
Fwd 5' -GAATICAAGTGTICCCAAAAAACC-3' 68.8 501.7 7393.9 
03-0668 
Rev 1 5' -GCGGCCGCTTACAAAACACACTIAGG-3' 78.9 548.5 8029.3 
03-0669 
Rev2 5' -GCGGCCGCCGATITITAGACGCTTACGGTGGCCTG-3' 96.4 614.7 10851.1 
03-0670 
Rev3 5' -GCGGCCGCCTAACGAAAGAACAG-3' 78.4 494.8 7156.7 
03-0671 
Fwd 5'-TGGCCAGGACAATGAAAAGTGTTCCC-3' 78.7 699.7 8084.3 
03-1420 
Rev 5' -CTAACGAAAGAACAGATAGTGAAATAAGG-3' 69.1 590.80 9105.0 
03-1421 
2.1.2 PCR amplification of KSHV ORF 4 gene from KSHV DNA 
The three ORF 4 proteins (Figure 8) encompassing SCRs 1 to 4 were amplified from 
KSHV DNA isolated from a KSHV-infected PEL cell line (kindly provided by Prof. 
Chris Boshoff, University college London, UK), with specific primers (Fwd) 5'-
GAATTCAAGTGTTCCCAAAAAACC-3' (EcoRI site is underlined), (Revl) 5'·-
GCGGCCGCTTACAAAACACACTTAGG-3', (Rev2) 5'-
GCGGCCGCCGATTTTTAGACGCTTACGGTGGCCTG-3' and (Rev3) 5'-
GCGGCCGCCTAACGAAAGAACAG-3' (Notl site is underlined and stop codon is 
in boldface) as represented by Figure 8. The PCR amplification of the KSHV ORF 4 
genes was carried out using an enzyme mix containing thermostable Taq DNA 
polymerase and Tgo DNA polymerase, which has proof reading activity [Expand™ 
High Fidelity PCR System (Roche)]. 
Two separate master mixes were prepared on ice, the components of which are 
described in Table 5. The master mixes were thoroughly mixed on ice and centrifuged 
briefly to collect the samples at the bottom of each tube. Master mix 2 [25~-tl] was 
added to each one of the master mix 1 [25~-tl] on ice and mixed thoroughly in order to 
produce a homogenous reaction. The samples were then placed in a thermocycler 
(ThermoHybaid cycler) and thermocycling was performed using the parameters 
described in Table 6. 
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Table 5. Master Mix Components used in the PCR of the KSHV ORF 4 genes 
Master Mix 1 Rxn" 1 Rxn"2 Rxn"3 Rxn"4 Final 
Components Cone" 
dddH20 22.7 22.7 22.7 22.7 -
dNTP mix (10mM each) 1 1 1 1 200!-LM 
each 
KSHVORF 4-specific Fwd 
primer (1 00 pmoli!-Ll) 0.5 0.5 0.5 0.5 50 
pmoli!-Ll 
KSHVORF 4-specific Rev 
primers (1 00 pmoli!-Ll) 0.5 0.5 0.5 0.5 50 
I 
pmoli!-Ll 
KSHV DNA template (360 ng/!-Ll) 
0.3 0.3 0.3 0.3 IOOng/f..!l 
Total Volume (J.d) 25 25 25 25 -
Master Mix 2 Volume added (~Ll) Final Concentration 
Components 
dddH10 77 -
lOxExpand High fidelity 20 lx 
buffer with 15 mM MgCh 
Enzyme mix (3.5 U/~Ll) 0.75x4 = 3 2.6U/50~tl reaction 
Total Volume (J.LI) 100/4= 25 -
Table 6. Thermo cycling parameters used in the PCR of the KSHV ORF 4 genes 
Step Temperature (OC) Time Number of Cycles 
Hot Start 94 2min lx 
Denaturation 94 30 s 
Annealing 56 1 min 30x 
Extension 72 2min 
Final Extension 72 7 min lx 
The KSHV ORF 4 PCR products were purified usmg the Wizard® SV system 
(Promega), which is a silica membrane-based system designed to extract and purify 
DNA fragments directly from PCR reactions or agarose gels. 
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Figure 8. Schematic diagram of the recombinant KSHV ORF 4 transcript map 
This figure represents the KSHV ORF 4 gene showing theN and C-terminus as well as the 
signal peptide (red), the SCRs-containing region (yellow) and the putative transmembrane 
region (blue). Three sets of primers were carefully designed consisting of a sequence-specific 
forward and three consequent reverse primers in order to flank three different sized DNA 
· fragments, as represented by the purple, magenta and navy blue transcripts. 
2.1.3 Purification of the PCR products 
The KSHV ORF 4-specifi.c PCR products were purified with the Wizard® SV system. 
One SV minicolumn was placed in a collection tube for each PCR reaction above. 
The prepared PCR products were then transferred to each respective minicolumn 
followed by incubation at room temperature for one minute. The SV minicolumns 
were centrifuged in a micro centrifuge at 10 000 x g for 1 minute and the flow-
through was then discarded. The columns were washed by adding 700 J..ll of the 
membrane wash solution [10 rnM potassium acetate pH 5.0, 16.7 J..lM 
ethylenediaminetetraacetic acid (EDTA) pH 8.0], which was initially diluted with 
95% ethanol to a final concentration of 80% ethanol. The SV minicolumns were 
centrifuged and the flow-through discarded as before. The wash step was repeated 
with 500 J..ll of membrane wash solution followed by centrifugation ofthe columns for 
5 min at 10 000 x g. The flow-through was discarded and the columns were 
centrifuged for an additional minute. The minicolumns were then carefully transferred 
to a clean 1.5 ml microcentrifuge tube and the bound DNA was eluted in Tris-2-
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amino-2-(hydroxymethyl)-1, 3 propandiol (Tris)-EDTA (TE) buffer [50 J.d] (10 mM 
Tris-HCL pH 8.0 and 1 mM EDTA) and after incubating at room temperature for 5 
min, the tubes were micro centrifuged at 10 000 x g for 1 minute. The mini columns 
were discarded and the microcentrifuge tubes containing the purified PCR products 
were stored at 4°C until later use. 
2.1.4 Measurement of DNA concentration 
The concentration of the above eluted DNA was determined by UV spectrometry 
using disposable Ultravette® cuvettes {Merk). The DNA was diluted 1:60 in TE buffer 
and the DNA concentration was calculated using the following formula: 
DNA concentration (J..Lg/ml) = A26o x 50 x dilution factor 
Where, 1 A260 unit of dsDNA =50 J..Lg/ml = 0.15 mM (in nucleotides) 
The absorbance at 280 nm was also measured and the A26o: A26o ratio calculated in 
order to assess the purity of the DNA preparation. A ratio less than 1. 8 is indicative of 
protein or phenol contamination of the nucleic acid. 
2.1.5 Preparation of competent bacterial cells 
Preparation of competent bacterial cells lacking an antibiotic resistance selectable 
marker was carried out in the absence of antibiotics such as ampicillin. Competent E. 
coli XL-1 Blue cells [genotype: F' Tn 10 proA"13+ laclq L\(lacZ) M15/recA1 gyrA96 
(Nan thi hsdR17 (rk-mk+) supE44 relA1 lac] were prepared by diluting an overnight 
culture [5 ml] 1: 200 in sterile Luria Broth (LB) liquid media [50 ml] (16M tryptone, 
10M yeast extract and 5 M NaCl) in a flask 10 x the culture volume. The cells were 
grown until they reached the early exponential growth phase as determined by the 
measurement of the optical density (OD) of the culture at 600 nm (OD600) to be 
between 0.3 and 0.6. The cells were then transferred to 2 x 50 ml [25 ml culture] pre-
chilled falcon tubes and the cultures were cooled to 0°C by incubation on ice for 5-10 
min. The cells were recovered by centrifugation ( 4000 rpm, 15 min, 4 °C) and kept 
ice-cold for all subsequent steps. All solutions used for the preparation of the 
competent bacterial cells namely 0.1M CaCb, 0.1M MgCb and 20% Glycerol were 
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sterile and pre-cooled to 4°C. The cells were resuspended in one culture volume [25 
ml each] of ice-cold O.IM MgCh and left on ice for 20 min. The ceiis were coiiected 
as before and resuspended in half culture volume [12.5 mls each] of ice-cold 0.1M 
CaCb followed by incubation on ice for 5 h (30 min minimum) as efficiency of 
transformation depends on prolonged CaCb exposure. The cells were recovered as 
before and gently resuspended in1/10 of initial culture volume [25 ml] of ice-cold 
0.1M CaCh solution [2.5 m1]. The ce11s were dispensed into 250 f..d aliquots and 
competent cells were prepared by adding one volume [250 f..!l] ice-cold sterile 20% 
(v/v) glycerol to the resuspended cells and mixing gently, followed by freezing at 
70°C. 
2.1.6 pGEMT-easy DNA ligation 
The Wizard® SV-purified Eco RI!Not IKSHV ORF 4 PCR products were ligated into 
the pGEMT -easy vector. This vector is prepared by linearization of Promega' s 
pGE~-T easy vector with Eco RV at base 60 of the vector's DNA sequence, and 
addition of a 3 'terminal thymidine to both ends. It is these 3 '-T overhangs at the 
insertion site, which greatly improves the efficiency of ligation of the gene of interest 
or PCR product into the plasmid, as it prevents re-circularization of the vector. 
Furthermore, these single 3 '-T overhangs provide a compatible overhang for PCR 
products generated by certain thermostable polymerases as these enzymes often add a 
single deoxyadenosine to the 3 '-ends of the amplified fragments, independent of the 
template used. 
The chosen ratio of insert to vector used in the ligation reation was 8: 1 as it has been 
successfully used. The appropriate amount of PCR product (insert) used in the 
ligation reaction was calculated as the follows: 
(ng of vector x kb size of insert) 
(Kbp size of vector 
X (insert: vector molar ratio)= ng of insert 
The ligation reactions were mixed on ice and made up to volume with ddH20 and the 
components of the reaction were added in the following order: 2 x rapid ligation 
buffer containing adenosine triphosphate (ATP) was added to a 1 x working 
concentration, followed by the addition of 50 ng of vector DNA, and the appropriate 
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amount (ng) of the insert DNA. Lastly, bacteriophage T4 DNA ligase (10 Weiss 
units/ml) was added to each one of the ligation reactions, which were then incubated 
overnight at 4°C. In order to assess the activity of the T4 ligase and therefore the 
efficiency of the ligation reaction, a control insert DNA was used in place of the PCR 
product. In addition, a background control ligation reaction was also set up with 50 ng 
of the vector and no insert in order to compare the number of background colonies 
resulting from non-t-tailed or undigested vector alone to the number of successful 
transformants. The ligation reactions were transformed into competent E. coli XL 1-
Blue cells. 
2.1. 7 Transformation of competent bacterial cells 
Each ligation reaction [2 j..!l] were added to 100 j..!l of competent XL 1-Blue cells, 
which were gently thawed on ice. The tubes were gently flicked to mix the contents 
and incubated on ice for 30 min. A separate transformation reaction in which ddH20 
[2 j..!l] was added instead of the ligation reaction, was carried out in order to assess the 
transformation efficiency of the competent cells as well as for sterility of the 
transformation. The cells were then heated-shocked for 45 seconds-1 minute in a 
water bath at exactly 42°C followed by incubation on ice for 2 min. Pre-heated (37°C) 
sterile LB liquid culture media [0.9 ml] was added to the cells followed by incubation 
for 1 h at 37°C with shaking allowing for further growth of the cells as well as for 
expression of P-lactamase. This enzyme is expressed by the AmpR gene present in the 
pGEMT -easy vector and has the ability of cleaving the ampicillin rings conferring the 
cells with ampicillin antibiotic resistance. The tubes were microcentrifuged and 900 
j..!l of the medium discarded while the cell pellet was resuspended in the remaining 
100 j..!l of the culture medium. The cells were then plated onto LB agar plates 
containing the appropriate antibiotic for selection of the successful transformants. 
Therefore, the Eco RW\Tot I fragments ligated into pGEMT -easy and transformed into 
competent E. coli XL 1-Blue cells were selected with ampicillin (100 j..!g/ml). 
2.1.8 Small-scale preparation of plasmid DNA 
Purified preparations ofpGEMT/KSHV ORF 4 (735), pGEMT/KSHV ORF 4 (1436) 
and pGEMT/KSHV ORF 4 (1581) plasmid DNA (labelled Al-4, Bl-4 and Cl-4 
respectively) were obtained using a modified alkaline lysis procedure (Qiagen 
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miniprep plasmid isolation kit). Single colonies of each plasmid DNA transformed E. 
coli cells were inoculated overnight into sterile LB liquid culture media [5 ml] 
containing ampicillin (0.1 mg/ ml) in a shaker with agitation at 250 rpm. Aliquots of 
each overnight cell culture [3 ml] were centrifuged at 9000 x g for 1 minute, and the 
bacterial cell pellets were resuspended in 250 J.!l suspension buffer P1 (50 mM Tris-
HCl pH 8.0, 10 mM EDTA, 0.1 mg/ ml Rnase A). 250 J.!l lysis buffer P2 (0.2 M 
NaOH and 1% SDS) was added and the suspension gently mixed by inversion and 
incubated for 5 min at room temperature (RT). 350 J.!l chilled binding buffer N3 (4 M 
guanidine hydrochloride and 0.5 M potassium acetate pH 4.2) was added and the 
suspension imme4iately mixed gently by inversion followed by microcentrifugation 
for 10 min at 13 000 x g. The pellets were discarded and the supernatants transferred 
to silica ion- exchange columns (QIAprep column), which were in turn 
microcentrifuged for 1 min at 13 000 x g. The unbound fraction was discarded and 
500 J.!l wash buffer PB (5 M guanidine hydrochloride, 20 mM tris- HCl pH 6.6) was 
added and the filter tube columns were microcentrifuged for ·1 minute at 13 000 x g. 
The unabsorbed fraction was discarded and the columns were washed with 750J.!l 
wash buffer PE (20 mM NaCl, 2 mM Tris- HCl pH 7.5) and centrifuged as before. 
Finally, the bound plasmid DNA was eluted in 50 J.!l TE buffer (10 mM Tris-HCl pH 
8.0 and 1 mM EDTA) and the tubes were microcentrifuged at 13 000 x g for 1 
minute. The concentration of the purified plasmid DNA was determined by UV 
spectrometry as described above in section 2.1.4 followed by storage at - 20°C until 
later analysis. 
2.1.9 DNA sequencing of the KCP gene encoded by KSHV ORF 4 
Sequencing of the KSHV ORF 4 gene was carried out in Stellenbosch using the ABI 
PRISM big dye terminator cycle sequencing reaction kit (Applied Biosystems), which 
is based on the dideoxy chain-terminating method (Sanger et a!, 1977). The sequencer 
used was the ABI PRISM 3100 genetic analyser, based on capillary electrophoresis. 
The sequencing samples were carefully prepared for optimum results. For cycle 
sequencing, 5 Ill of QIAGEN-purified pGEMT/KSHV ORF 4 (1581) plasmid DNA 
(1 00 ng/J.!l) and 1.1 pmol!J.!l primer were used. In addition to the pGEMT forward and 
reverse primer, the sequence-specific primers used for the PCR reaction (section 
2.1.2), Fwd and Rev 3, were also used for sequencing ofthe complete KSHV ORF 4 
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gene. The cycle sequencing reaction was carried out by 25 cycles of 96°C for 10 
seconds, 50°C for 5 seconds and 60°C for 4 min, according to the ABI PRISM big 
dye terminator cycle sequencing protocol. 
2.1.10 RE digestion analysis of the pGEMT -easy constructs 
Plasmid DNA isolated from E. coli transformants as described in section 2.1.8 was 
screened for the constructs pGEMT/KSHV ORF 4 (735), pGEMT/KSHV ORF 4 
(1436) and pGEMT/KSHV ORF 4 (1581) by double-restriction endonuclease 
digestion with Eco RI and Not I. All the DNA fragments were analysed by 1% 
agarose gel electrophoresis. The diagnostic digestion of the double-stranded ( ds) 
DNA was performed using purified plasmid DNA in the range of 100-500 ng and in 
each digestion the volume of DNA to be digested did not exceed 10% (v/v) of the 
total reaction volume. All the required components to carry out the restriction 
endonuclease digest were mixed on ice in the following order: 
Table 7. Components used in theRE analysis of the pGEMT DNA constructs 
~ Final AI A2 A3 A4 Bl B2 B3 B4 Cl C2 C3 C4 Cone" DNA 
up to 
ddd H20 15.3 1.4 14.4 15.1 15.1 11 15.6 15.6 15.3 14 10 12.4 total 
volof 
20 !J.l 
lOx 
restriction 2 2 2 2 2 2 2 2 2 2 2 2 lx 
buffer 
Plasmid 1.7 3.0 2.6 1.9 1.9 6 1.4 1.4 1.7 3.0 7 4.6 -400ng 
DNA I,.U 
EcoRI(l5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 7.5U 
UI!J.l) 
:Vot I (10 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 5U. 
Ulf.Ll) 
Total Vol 
(!J.I) 20 20 20 20 20 20 20 20 20 20 20 20 -
The DNA restriction digests were incubated overnight at 37°C in a heating block 
apparatus. The digestion of the plasmid DNA was stopped by the addition of the 
appropriate volume of 6x gel loading buffer [0.25% (w/v) bromophenol blue and 30% 
(v/v) glycerol]. 
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2.1.11 Agarose Gel Electrophoresis 
Agarose gel electrophoresis analysis was performed according to standard protocol 
(Sambrook et al, 2001). The DNA (100-500 J.tg) was resolved by 1% agarose gel 
electrophoresis in 1 x Tris-Borate EDTA (TBE) buffer (0.045 M Tris base, 0.045 M 
borate and 0.001 M EDTA) at 1-10 V/cm of gel until the bromophenol blue dye front 
migrated to the bottom of the gel. In order to visualize the position of the DNA 
fragments, ethidium bromide (1 mg/ml) was incorporated in the agarose gel mixture 
prior to gel solidification, to a final concentration of 0.5 ~J.g/ml. Ethidium bromide 
chelates to the DNA nucleotide bases and fluoresces under a short wavelength UV 
transluminator. 
2.1.12 Directional analysis of the cloned genes by RE digestion 
GeneRunner software was used to determine which restriction endonuclease cuts the 
insert once within the first 735 bp (short soluble portion of the protein of interest). 
The RE selected was Bam HI which is ideal for a quick check of any of the inserts' 
direction with respect to the vector. This enzyme cuts the insert at position 643 bp and 
does not cut the pGEMT-easy vector. Similarly, the RE Eco RV was the selected 
enzyme that can cut the vector once at position 60 but does not cut any of the three 
inserts anywhere in their DNA sequence. 
The restriction digest reactions were treated exactly as per section 2.1.1 0. 
Table 8. Components used in the Bam HI restriction digest analysis 
Reagents A2 B2 B4 C2 C3 C4 Final ~ Concentrat' 
ddd H20 14 11 16.1 14.5 11.5 14.5 up to total 
vol of 20 Jll 
IOxrestr. 2 2 2 2 2 2 lx 
buffer 
Plasmid 3 6 1.4 3 6 3 -400ng/~tl 
DNA 
Bam Hl or 0.5 0.5 0.5 0.5 0.5 0.5 5U 
Eco RV 0.5 0.5 0.5 0.5 0.5 0.5 7.5U 
Total Vol 20 20 20 20 20 20 -
(Jll) 
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PCR product: 
(T) 
5' G I AATTCJ\lNNNNNNGC I GGCCGCA 3' 
3' ACTTAAlGNNNNNNNCGCCGG..lrCG 5' 
(B) 
EcoRI Not I 
A. DNA insert in the correct orientation: 
(T) 3' (B) (T) 
5'=====ACTTAAGNNNNNNNCGCCGGCG ====3' 
3'==== GAATTCNNNNNNNGCGGCCGCA 5' 
(B) 5' (T) 3' (B) 
B. DNA insert in the incorrect orientation: 
(T) 3' (T) 5' 
5' ACGCCGGCGNNNNNNNCTTAAG 
3' GCGGCCGCNNNNNNNGAATTCA 
(B) 5' (B) 
Where, 
NNNNNNN represents the PCR Product/DNA insert; 
(T) =Top strand: (B)= Bottom strand: 
=== represents the pGEM-T--ea~- DNA sequence: 
3' 
= 3 ·terminal thym.i.diues characteristic of pGEM~·-T ea~- Yectors: 
(T) 
(B) 
3' 
5' 
A = Single deo:.\.·yadenos.i.nes often added by thermostable polymerases to the 3 ·--ends of 
amplified frngments 
Figure 9. Significance of determining the direction of the insert when ligated into 
the pGEMT-easy vector 
In case A above, the top strand of the insert goes from 5'~ 3' therefore restriction sites are recognised 
by the Eco RI & Not I REs. As a result, in addition to obtaining a 2981 bp DNA fragment, the correct 
size insert with cohesive Eco RI & Not I ends is also released upon RE digestion of the pGEMT 
constructs. However, in case 8 above, the top strand of the insert goes from 3'-7 5' therefore 
restriction sites are no longer recognised by the Eco RI & Not I REs. As a result, in addition to 
obtaining a 2981 bp DNA fragment, an insert with cohesive Eco RI & Not [ ends is also released but 
with additional DNA sequence from the vector itself 
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2.1.13 Small-scale isolation and RE analysis of pPIC9 plasmid 
Individual XL 1-blue cell colonies transformed with pPIC9 were inoculated into 
sterile LB liquid culture media [ 4ml] containing the appropriate antibiotic for 
selection of the plasmid DNA The cells were grown overnight with agitation at 225 
rpm in a 37°C incubator room. The pPIC9 plasmid DNA was obtained and its 
concentration determined as per sections 2.1.4. In order to confirm that the DNA 
isolated was indeed pPIC9 plasmid DNA, in other words, the authenticity of the 
plasmid, two restriction endonuclease digests, using suitable REs readily available in 
the laboratory (Hind ill and Pst I), were carried out. The DNA restriction digests 
were treated exactly as per section 2.1.1 0. 
Table 9. Components used in the Hind ill and Pst I analysis of pPIC9 plasmid 
~ pPIC9 pasmid pPIC9 pasmid pPIC9 pasmid Final DNA (275 ng/J.LI) DNA (700 ng/J.LI) DNA (925 ng/J.ll) Concentration DNA 
ddd HP 15.5 16.4 16.6 llp to total vol of 
20 J.Ll 
1 Ox restriction buffer 2 2 2 lx 
Plasmid DNA 1.5 0.6 0.4 
- 400 ng/Jll 
Hind ill 1 1 1 5 U or 7.5 U 
or Psti 
Total Volume (J.ll) 20 20 20 -
2.1.14 pGEMT DNA Isolation from low-melt 1 °/o agarose gel 
Successful pGEMT -easy clones containing the DNA fragments of interest were 
digested with Eco RI and Not I as described in section 2.1.1 0. The Eco RI!Not I 
KSHV ORF 4 DNA fragments were recovered from a low melting temperature 
agarose gel using the Wizard® SV system. Post electrophoresis the agarose gel was 
briefly exposed to long wavelength UV radiation in order to detect the DNA of 
interest. The DNA fragments of the correct molecular mass were excised from the 
agarose gel using a sterile scalpel blade. The gel slices containing the DNA fragments 
of interest were transferred to pre-weighed 1. 5 ml microcentrifuged tubes. Membrane 
binding solution (4.5M guanidine isothiocynate, 0.5M potassium acetate pH 5.0) was 
added at a ratio of 10 ~1 of solution per 1 Omg of agarose slice, followed by incubation 
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at 65°C for 10 min or until the gel slice was completely dissolved. The solution was 
centrifuged at R T to ensure that all the contents were at the bottom of the tubes and 
the DNA was recovered and its concentration determined as described in section 2.1.4 
2.1.15 Vector pPic 9 DNA ligation 
The gel purified Eco RI!Not I KSHV ORF 4 DNA fragments were ligated into the 
Eco .R11Vot !-digested yeast expression vector pPIC9. The ligation reactions were 
mixed on ice and made up to volume with ddH20 and the components of the reaction 
were added in the following order: 
Table 10. Components used in the set up ofthe pPIC9ligation reactions 
~ KSHVORF4 KSHVORF4 KSHVORF4 Background Final (735 bp) gene (1436 bp) gene (1581 bp) gene control Concentration A 
2x rapid ligation 5 5 5 5 lx 
buffer 
pPIC9 vector 1 1 1 1 384 ngi!J.l 
Insert DNA 3 "' "' - ~ 1000 ng/ 1-f.l .) _) 
T4 DNA ligase l 1 1 1 10 weiss units/ml 
ddH20 
- -
-. up to total vol of 
-
.) 
10[!1 
Total Volume (!d) 10 10 10 lO -
All 4 ligation reactions were incubated overnight at 4°C. In order to compare the 
number of background colonies resulting from non-t-tailed or undigested vector alone 
to the number of successful transformants, a background control ligation reaction was 
also set up with ddH20 instead ofDNA insert. The ligation reactions were transformed 
into competent E. coli XL 1-Blue cells and the plasmid DNA of interest obtained as 
described in section 2.1. 7 and 2.1.8 respectively. 
2.1.16 RE digestion analysis of the pPIC9 DNA constructs 
Plasmid DNA isolated from E. coli transformants as per section 2.1.8, was screened 
for the constructs pPIC9/KSHV ORF 4 (735), pPIC9/KSHV ORF 4 (1436) and 
pPIC9/KSHV ORF 4 (1581), by double-restriction endonuclease digestion with Eco 
RI and Not I using standard reaction conditions as described in section 2.1.1 0. All the 
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required components to carry out the restriction endonuclease digest were mixed on 
ice in the following order: 
Table 11. Components used in the RE analysis of the pPIC9 DNA constructs 
I~ AI A2 A3 Bl B2 B3 Cl C2 C3 Final Cone" DNA 
up to total 
ddd H20 15.2 14.87 14.83 15.63 15.78 13.1 14.78 15.02 15.36 vo1 of20 
J.!l 
lOx 
restriction 2 2 2 2 2 2 2 2 2 1x 
buffer 
Plasmid 1.7 3.0 2.6 1.9 6 1.4 1.7 3.0 7 ~400ng/J..Ll 
DNA 
EcoRI 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 7.5U 
Xotl 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 5U 
Total Vol 
(J..LI) 20 20 20 20 20 20 20 20 20 -
2.2 Transformation of P. pastoris and Selection for Positive 
Clones 
Integration of the three different sized KSHV ORF4 genes into the P. pastoris genome 
was carried out by homologous recombination with pPIC9/KSHV ORF4 DNA 
constructs (Figure 20). Before the transformation procedure, the yeast expression 
vector pPIC9 was digested with Sac I and the expected product was visualised by 
agarose gel electrophoresis and used to transform P. pastoris GS 115 competent cells. 
2.2.1 Linearization of pPIC9 and pPIC9/KSHV ORF 4 constructs 
After successfully cloning the genes of interest, the pPIC9 parental plasmid as well as 
the pPIC9/KSHVORF 4 constructs, were linearised with the RE Sac I in order to 
encourage homologous recombination during the transformation step. The DNA 
restriction digests were carried out as described in section 2.1.1 0. All the required 
components to carry out the linearization of the plasmid were mixed on ice in the 
following order: 
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Table 12. Components used in the Sac I RE linearisation of pPIC9 constructs 
Reagents AI: pPIC9/ B2: pPIC9/ CJ: pPIC9/ pPic 9 Uncut Final ~ KSHV KSHV KSHV parental pPIC9 Cone" ORF 4 (735) ORF 4 (1436) ORF 4 (1581) plasmid vector 
Up to final vol 
ddd H20 0 3.5 0.2 1.5 16 of20 J.Ll 
lOx 
restriction 2 2 2 2 2 lx 
buffer 
Plasmid DNA 14.5 11 14.3 l3 2 3500 ng/~tl 
Sac I 3.5 3.5 3.5 3.5 - 35 u 
(10 U/J.Ll) 
Total Vol (J.Ll) 20 20 20 20 20 -
2.2.2 pPIC9 plasmid DNA isolation from low-melt 1 °/o agarose gel 
The Sac I linearised pPIC9 DNA was recovered from a low melting temperature 
agarose gel using the DNA purification kit (Amersham) exactly as described in 
section 2.1.8 for the exception that a different kit based on the same DNA purification 
principle was used. 
2.2.3 Preparation of yeast competent cells 
Competent Pichia past oris GS 115 competent cells were prepared by diluting an 
overnight culture [10 ml] to an OD600 of 0.1-0.2 in 10 ml of yeast extract peptone 
dextrose medium (YPD) [1% yeast extract, 2% peptone, 2% dextrose (glucose)]. The 
cells were grown for a further 4-6 h at 28°C-30°C in a shaking incubator until the 
OD6oo reached 0.6-1.0. The cells were recovered by centrifugation (500 x g, 5 min, 
RT). The cell pellet was then resuspended in 1 ml of solution I [1M sorbitol, lmM 
bicine, 3% ethylene glycol, 5% dimethyl sulfoxide (DMSO), pH 8.0]. The competent 
cells were dispensed into 50 J...Ll aliquots and slowly frozen at -80°C wrapped in 
several layers of paper towels. 
2.2.4 Transformation of competent yeast cells 
One tube of competent yeast cells prepared as described in section 2.2.3 was thawed 
at room temperature for each transformation reaction. Sac I-linearised pPIC9 vector 
DNA (3 J...Lg) recovered from a low-melt agarose gel was added to the competent cells. 
47 
In this transformation reaction the volume of the DNA should not exceed 5 111 
therefore the cells were gently centrifuged (5000 x g, 5 min, RT) and 50 !J.l of the 
supernatant was discarded before the addition of the necessary DNA volume (!J.l). 
Solution II [1 ml] was added to the DNA/cell mixture and all the components were 
mixed by vortexing. The transformation reactions were then incubated for 1 hat 30°C 
in a water bath or incubator. During the incubation period, each transformation 
reaction was mixed every 15 min by vortexing for a few seconds. After incubation, 
the cells were heat shocked at 42°C in a water bath for 10 min. The cells were 
recovered (3000 x g, 5 min, RT) and the supernatant was discarded. The cells were 
resuspended in solution III [1 ml] because transformation was carried out with the 
pPIC9 expression vector. The cells were once again recovered as above and finally 
the cell pellet was resuspended in 100-150 !J.l of solution III. The transformation 
reactions were then plated onto appropriate selection plates such as regeneration 
dextrose (RDB) agar plates [1 M sorbitol, 1% dextrose, 1.34% YNB (13.4% yeast 
nitrogen base with ammonium sulphate without amino acids), 4 x 10-5 biotin, 0.005% 
amino acid mix containing glutamic acid, methionine, lysine, leucine and isoleucine], 
which were then incubated for 4 days at 30°C. 
2.2.5 Isolation of genomic DNA from Picltia yeast transformants 
Genomic DNA from the desired His+ recombinant Pichia strains obtained in the 
transformation procedure was isolated using the DNeasy® DNA purification kit 
(QIAGEN). This case is based on an advanced silica-gel-membrane technology, 
which allows for rapid and efficient recovery of genomic DNA The Pichia 
transformants under investigation were grown at 30° C to an OD600 of 5-10 in 10 ml 
buffered glycerol-complex medium [(BMGY) 1% yeast extract, 2% peptone, 100 mM 
potassium phosphate buffer, pH 6.0, 1.34% YNB, 4 X w-5 biotin, 1% glycerol]. A 
maximum of 5 x 107 cells [1 ml] were harvested (5000 x g, 10 min, RT) and the 
supernatant discarded. The cell pellet was resuspended in 600 111 freshly prepared 
sorbitol buffer [1 M sorbitol, 100 mM EDTA, 14 mM ~-mercaptoethanol], followed 
by the addition of84 !J.l (200 units) 10 x lyticase stock solution. The reaction samples 
were incubated at 30°C for 1 h and the spheroplasts were then recovered by 
centrifugation (300 x g, 10 min, RT). Buffer ATL [180 !llJ was used to resuspend the 
spheroplasts. Proteinase K [20 !J.l] was added to each reaction ,sample, which were 
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then incubated at 55°C overnight in a water bath. The samples were then subjected to 
RNase treatment by adding 40 f ..d of the enzyme (10 mg/ml), vortexing and incubating 
at RT for 2 min. After this short incubation, the tubes were vortexed for 15 seconds 
and buffer AL [200 J..tl] was added followed by immediate thorough mixing of the 
samples by vortexing. All samples were incubated at 70°C for I 0 min in a heat block 
and then 200 J..ll ethanol (96%) was added and the samples mixed as above. Each 
mixture was transferred to a DNeasy mini spin column placed in a 2 ml collection 
tube that was then centrifuged at 8000 rpm for 1 minute and the flow-through was 
discarded. The columns were placed in the same collection tubes and buffer AWl 
[500 J..ll] was added to each column followed by centrifugation as above. The columns 
were then placed in new tubes and buffer AW2 [500 J..tl] was added to each column. 
The samples were centrifuged at maximum speed (13 000 rpm) for 3 min and the 
flow-through as well as the collection tubes were discarded. Finally, the columns were 
placed in clean 1.5 ml eppendorf tubes and buffer AE [1 00 J..ll] was pipetted directly 
onto the membrane and the columns were incubated for approximately 30 min at 
room temperature. To elute the yeast genomic DNA in the AE buffer, the tubes were 
centrifuged at 8000 rpm for 1 minute. This elution step was repeated and the second 
DNA eluates were collected in a series of new eppendorf tubes in order to prevent 
dilution of the first eluate. 
2.2.6 Screening for Mut+ and Mut8 transformants 
The phenotype of the transformed P.. pastoris colonies was investigated in order to 
discriminate between the types of recombination that can take place: integration at the 
HIS4 gene yields a functional AOXJ gene that will give a methanol utilisation 
phenotype (Mut), whereas integr~tion at the AOXJ gene produces either a functional 
AOXl gene (Mutl or AOX2 gene that will give a slow methanol utilisation phenotype 
(Mut8). Therefore, growth rates in the presence of methanol were tested for a large 
number of His+ colonies picked from the RDB selection plates and streaked in a 
regular pattern on both a minimal methanol (MM) (1.34% YNB, 4x10-5% biotin, 
0.5% methanol) and minimal dextrose (MD) (1.34% YNB, 4xl0-5% biotin, 2% 
dextrose) agar plates. A new sterile loop was used for each transformant and the MM 
plates were always streaked first. Furthermore, to differentiate Mut from the Mut8 
phenotype, a patch for each of the controls, GS1151His+ Mut8 Albumin and 
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GS115/His+ Mut+ ~-galactosidase, was carried out onto the MD and MM plates. All 
the plates were incubated at 30°C for 2 or longer days after which, the plates were 
analysed. The Mut transformants should grow well on both plates, while the Mut8 
transformants should only grow well on MD plates but show little or no growth on the 
MMplates. 
2.2. 7 PCR analysis of Picllia transformants 
All the Pichia transformants were analysed by PCR to determine if the respective 
genes of interest integrated into the Pichia genome. Genomic DNA was isolated from 
the His+ clones as described in section 2.2.5 using the DNeasy® DNA purification kit. 
The genes under investigation were then amplified by PCR with 5 '-
GACTGGTTCCAATTGACAAGC- 3' and 5'- GCAAATGGCATTCTGACATCC-3' 
specific for the AOXJ promoter and terminator sequences respectively. In the 
reactions where KSHV DNA from PEL was used as PCR positive controls, the genes 
of interest were amplified by priming with the forward primer 03-0668 (F) and reverse 
primers 03-0669 (R1), 03-0670 (R2) and 03-0671 (R3) for the 735, 1436 and 1581 bp 
PCR products respectively. 
Table 13. Master mix components used in the PCR of the 735bp gene from Pichia 
transformants 
Master Mix 1 8 X pPIC9/ pPIC9+ Final 
Components KSHVORF4 GS115/ pPIC9 735bp pPIC9 KSHV Cone" 
(735) Pichi a (no insert) =BC gene alone DNA 
recombinants 
dddHzO 18 I8 22.54 22.86 22.7 up to final vol 
of25 ).!1 
dNTP 1 I 1 I I 200 ~each 
5'AOXJ 0.5 0.5 0.5 0.5 0.5 F 50 pmol!J..Ll 
3'AOXJ 0.5 0.5 0.5 0.5 0.5 Rl 50 pmol/Jll 
DNA 5 5 0.46 O.I4 0.3 variable 
Total Vol (jll) 25 25 25 25 25 -
Master Mix 2 Components Volume added (JLI) Final Concentration 
dddH20 234.96 up to tina! \··ol of 300 ~tl 
10 x buffer with 15 mM MgCh 60 lx 
Pfi1 (3Uf~ll) 0.42 X 12 = 5.04 l.25ti/ 50~tl reacti<'n 
Total Volume ().!1) 300/ 12=25 -
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Table 14. Master mix components used in the PCR of the 1436 and 1581 bp genes from 
Pichia transformants 
3x 3x 
Master pPIC9/ pPIC9+ KSHV pPIC9/ pPIC9+ KSHV GS115/ pPIC9 Final 
·Mix1 KSHV 1436bp DNA KSHV 1581bp DNA pPIC9 vector Cone" 
ORF4 gene ORF4 gene (BC) 
Components (1436) (1581) 
Pichia Pichia 
I 
dddHzO 18 22.66 22.7 18 22.45 22.7 18 22.86 Up to 
final vol 
of25 t-tl 
dNTPmix 1 l 1 I I 1 I I 200 JlM 
each 
' 
5'AOXJ 0.5 0.5 0.5F 0.5 0.5 0.5 0.5 0.5 F 50 
pmoVJ.Ll 
3'AOXJ 0.5 0.5 0.5 R2 0.5 0.5 0.5 0.5 0.5 R3 50 
i pmol/J.Ll 
DNA 5 0.35 0.3 5 0.55 0.3 5 0.14 variable 
Total Vol 25 25 25 25 25 25 25 25 -
(t-tl) 
Master Mix 2 Components Volume added (J.d) Final Concentration 
dddH20 234.96 UjJ to final vol of 300 ~tl 
10 x buffer with 15 mM MgC(z 60 lx 
Pfil (3TJ/ftl) 0.42 X 12 = 5.04 1.25U! 50~tl re3ction 
Total Volume (tJ.I) 300/12-25 -
The master mixes were thoroughly mixed on ice and centrifuged briefly to collect the 
samples at the bottom of each tube. Master mix 2 [25J.d] was added to each one of the 
above master mix 1 [25J.1l] on ice and mixed thoroughly in order to produce a 
homogenous reaction. The samples were then placed in a thermocycler 
(ThermoHybaid cycler) and thermocycling was performed using the parameters 
described in Table 15. Each PCR sample [10 J.!l] was analysed on a 1 x TBE, 0.8% 
agarose gel as described per section 2.1.11. 
This is a very useful analysis as it confirms whether or not the gene of interest is 
integrated into the Pichia genome. This experiment does not however provide 
information on the site of integration. Nevertheless, if screening Mut+ integrants, two 
bands should be visualised as one corresponds to the gene of interest and the other to 
the intact AOX1 gene, which is approximately 2.2 kbp. On the other hand, if screening 
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Mut8 integrants only the band corresponding to the gene of interest should be 
visualised as the AOXI gene is replaced and therefore lost during the integration 
event. 
Table 15. Thermocycling Parameters used in the PCR of the Pichia His+ 
Transformants 
Step Temperature (°C) Time Number of Cycles 
Hot Start 94 2min lx 
Denaturation 94 30 s 
Annealing 55 1 min 30x 
Extension 72 4min 
Final Extension 72 5min lx 
2.3 Expression of the rKCPs in P. pastoris 
The methylotrophic yeast P. pastoris strain of choice, GS115 (his4) (Invitrogen) was 
used for the heterologous production of the recombinant KSHV complement 
regulatory proteins. 
2.3.1 Small & medium-scale expression of recombinant Picllia 
strains 
Small-scale expression experiments were carried out to test whether the transformed 
P. pastoris recombinant colonies were suitable for KSHV ORF 4 protein expression. 
Post-PCR analysis of the Pichia integrants as described in section 2.2. 7, the 
transformants containing the insert of interest were selected and screened for 
expression levels first in small-scale according to their Mut8 and Mut phenotype. The 
wild-type AOXl gene was shown to be present in all of the pPIC9/KSHV ORF 4 
(735bp) and pPIC9/KSHV ORF 4 (1436bp)-recombinant Pichia strains analysed by 
PCR (Figure 25, 26) making these transfonnants more likely to be Mut. Therefore, 
for Mut + secreted expression, 5 ml BMGY were inoculated with each respective 
verified recombinant clone in a 250 ml conical flask. The yeast cultures were 
incubated overnight at 30°C in a shaking incubator (250 rpm) and growth was 
allowed to continue until the cells reached the logarithmic phase of ~00 2-6 as 
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determined by spectroscopic measurement of the absorbance at 600 nm. The cells 
were then harvested (3000 x g, 5 min, RT) and the supernatant discarded. The cell 
pellet was resuspended to an OD6oo of 1.0 in buffered methanol-complex medium 
[(BMMY) 0.1% yeast extract, 0.2% peptone, 100 mM potassium phosphate buffer, 
pH 6.0, 1.34% YNB, 4 X 10-5 biotin, 1% methanol]. In order to maintain induction, 
100% methanol was added to the cultures every 24 h to a final concentration of 2%. 
On the other hand, PCR analysis ofthe pPIC9/KSHV ORF 4 (158lbp)-recombinant 
Pichia strains showed the absence of the wild-type AOXI gene (Figure 27) making 
these transformants more likely to be Mut8. Therefore, for Mut8 secreted expression, 
25 ml BMGY were inoculated with each respective verified recombinant clone in a 
250 ml conical flask. The yeast cultures were incubated as described above and in 
order to induce expression, the cell pellets were resuspended in 1/5 BMMY of the 
original culture volume. Similarly, in order to maintain induction, 100% methanol 
was added to the cultures every 24 h to a final concentration of 1%. 
Colonies from the small-scale experiments were selected for medium-scale [ 100 ml] 
production of the KSHV complement regulatory proteins. After 5 days (96-h post-
induction) the cultures were centrifuged at 3000 x g for 5 min and the supernatant 
obtained was further centrifuged at 10 000 rpm for 45 min-1 h. 
2.3.2 Optimisation of methanol-induced production of the 
recombinant proteins 
A sample of the cell culture was taken before cell induction by resuspension of the 
harvested cells in BMMY (I %methanol) followed by the colJection of samples [1 
ml] taken every 24 h over a period of 4-5 days. These samples were centrifuged at 
maximum speed for 5 min at room temperature and both the supernatant and the cell 
pellets were quickly frozen in liquid nitrogen and stored at -80°C until ready for 
further analysis. These samples were used to analyse expression levels and determine 
the optimal time post-induction to harvest the cells. Sodium dodecyl polyacrylamide 
gel electrophoresis (SDS PAGE) 5 x gel loading buffer [4 J..Ll] (62.5 mM Tris-HCl pH 
6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) P- mercaptoethanol, 0.05% (w/v) 
bromophenol blue) was added to the supernatants [20 J..Ll], which were in tum heated 
at 95°C for 5 min and analysed by SDS PAGE electrophoresis. 
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2.3.3 Concentration of the Media containing the Secreted KSHV 
ORF 4 Proteins 
The supernatant obtained was concentrated approximately three times by 
ultrafiltration through Pellicon®XL filtration unit (Millipore) (Figure. 10) with a 
molecular weight exclusion limit of 10 kDa. The device was used according to the 
operating instructions. The concentrated supernatant was clarified by passing through 
0.22 f...Lm filter to remove contaminating particles. 
Figure 10. Illustration of the Pellicon XL-device 
The supernatant (feed) was concentrated 3-fold under low pressure and the concentrated sample was 
collected through the retentate while the fraction below 10 kDa was excluded through the permeate. 
2.3.4 Small-Scale Ammonium Sulphate Protein Precipitation 
In order to determine the optimum precipitation conditions, ammonium sulphate 
powder was added to the supernatant in a small-scale [500- 1000 f...Ll] at 4°C with 
shaking for 1 h to final saturations of20, 30, 40, 50, 60, 70, 80 and 90%. The samples 
were then microcentrifuged at 3000-x g for about 40 min and the supernatant 
discarded while the pellet was resuspended in 50 f...Ll of sterile saline. 
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2.3.5 Estimation of Protein Concentration 
Intensities of SDS-PAGE bands were scanned with a densitometer (Chemilmager™ 
5500) and the concentration of the P. pastoris-expressed KCP protein was 
quantitively estimated by comparison with a standard curve obtained with known 
amounts of protein. 
2.4 Synthesis of a Polyclonal Anti-KCP Peptide Antibody 
2.4.1 Peptide Selection for the Synthesis of the Polyclonal Antibody 
The first step in the design of a suitable peptide antibody directed against the protein 
under investigation was the selection of an appropriate peptide sequence. When 
examining the protein sequence for potential antigenic epitopes, sequences which are 
hydrophilic, surface-orientated and random coil were taken into consideration. 
Therefore, algorithms were used to predict protein characteristics in terms of 
hydrophilicity/hydrophobicity and secondary structure regions such as a- helix, ~­
sheets and turns (Figure 11 ). GeneRunner and DNASTar™ software, which contains 
all the necessary algorithms including hydrophilicity and surface probability plots, as 
well as antigenic index, were used to select a potentially exposed immunogenic 
internal sequence for the generation of the peptide antibody. 
After the identification of the protein region of interest, the length of the peptide was 
also considered and an 11-residue peptide, CHRPKIKNGDY, was chosen because it 
falls within the typical 10-20 residue peptide range. Shorter peptides are also easier to 
synthesise and are reasonably soluble in aqueous solutions and finally they may still 
possess some degree of secondary structure. 
The chosen amino acid sequence was chemically synthesised in a Brazilian laboratory 
and it was then sent to Washington Biotechnology (USA) where it was used to 
generate an immunogen conjugated with the carrier protein, keyhole limpet 
hemocyanin (KLH), which is a large but non-immunogenic protein. This immunogen 
was in turn used to produce a rabbit polyclonal peptide-antibody for Immunoenzyme-
histochemical assays, Immunodetection and Western blot analysis of the KSHV 
complement regulatory protein, KCP. 
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Figure 11. Criteria for the selection of a suitable KCP peptide 
Figure 11 represents the algorithms that were used in order to select a suitable peptide for the synthesis 
of the rabbit anti-KCP peptide polyclonal antibody. High probability of surface exposure was analysed 
by algorithms A-G, which shows the structural components of the peptide, in other words, the potential 
to form turns or loops. These structures have a higher probability of surface exposure, whereas the 
more "rigid" structures such as the a.-helices and P-strands are more likely to form the internal core of a 
protein. Positive peaks of hydrophilicity are represented by algorithm H that shows that this selected 
peptide is composed mainly of polar hydrophilic regions, which coincides with the lack of helix and P-
strand structures depicted above. Also important is the immunogenecity of the peptide, which is 
measured by algorithm L, the antigenic index, showing that the selected sequence is composed of a 
larger number of highly immunogeneic residues such as, His, Lys, Leu, Asp, Arg and Tyr. 
2.4.2 HiTrap Protein A Purification of the Polyclonal Anti-KCP 
Peptide Antibody 
The anti-KCP peptide polyclonal IgG was purified from 5 ml of rabbit serum with a 
protein A HP column (Amersham) that has a very great affinity for binding IgGs 
especially produced in rabbits. A 5 ml syringe was filled with binding buffer (20 mM 
Sodium phosphate, pH 7.0) and after removing the stopper, the column was connected 
to ,the syringe with the provided adaptor. The twist-off end of the column was 
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removed and the 1 ml column was washed with 10 column volumes of binding buffer 
at approximately 1 ml/min flow rate. The serum sample was applied to the column 
using the syringe fitted to the luer adaptor. After application of the sample, the 
column was washed with 6 column volumes ofbinding buffer and 1 ml wash samples 
were collected for later analysis. The IgG antibodies was eluted with 3 column 
volumes of elution buffer (0 .1 M Citric acid, pH 3. 0) and 200 )..ll of purified fractions 
were collected in tubes containing 40 )..ll of neutralising buffer (1 M Tris-HCL, pH 
9.0) and stored at 4°C until further SDS-PAGE analysis and estimation of antibody 
concentration. Before storage, the column was washed with 5 column volumes of 
20% ethanol and it was stored at 4°C in 20% ethanol to prevent microbial growth. 
2.4.3 Bio-Rad Protein Microassay for Antibody Quantification 
The concentration of the purified IgG was determined by the Bio-Rad protein assay, 
which is based on the standard method ofBradford assay (Bradford, 1976). The assay 
was carried by making up a series of bovine serum albumin (BSA) dilutions between 
125 )..lg/ml and 2000 )..lg/ml final BSA concentration using a microtiter plate (wells 2-
8). Brilliant blue G based Bradford dye reagent [200 )..ll] was added to all the 
standards and to each purified fraction of unknown antibody concentration. The 
solutions were mixed by pipetting and the colour reaction was allowed to develop for 
at least 5 min at RT. The colour intensity of the samples was measured with a plate 
reader (Anthos 2010) at 595 nm. The A595 readings of the standards were plotted 
against the known BSA concentrations and a standard curve was generated (Figure 
32). The unknown antibody concentrations of the purified fractions were directly 
· determined from this standard curve. The fractions containing the purified antibody 
were aliquoted and stored at -20°C. 
2.5 Immunological Detection, SDS-PAGE and Western 
blot Analysis 
2.5.1 Immunological detection of KSHV ORF 4 proteins 
The production of the proteins of interest in the supernatant of the yeast culture medium 
was analysed by slot-blot using the manifold II slot-blot system (Schleicher & Schuell). 
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Aliquots [100 J.!l] of supernatants were vacuum-blotted onto nitrocellulose Hybond-ECL 
membranes (Amersham), which were in turn incubated overnight at 4°C in blocking 
solution [5% (w/v) not-fat milk powder in Tris-buffered saline (TBS)]. After blocking, the 
membranes were incubated with the rabbit anti-KCP peptide polyclonal antisera at 1:1000 
in Tris-buffered saline/Tween 20 (TBST). After two washes in TBST followed by two 
washes with blocking solution (10 min each), the membranes were incubated for 30 min 
with horseradish peroxidase-conjugated anti-rabbit IgG (Roche) at 1:12 000 in blocking 
solution. The membranes were rinsed thoroughly four times with TBST for 15 min each 
and bound antibodies were detected using the Chemiluminescence Western Blotting Kit 
(Mouse/Rabbit) system (Roche). 
2.5.2 SDS PAGE Electrophoresis 
Prepared protein samples were resolved by discontinuous (0.1% (w/v)] SDS and [12% 
(w/v)] PAGE according to the method ofLaemmli (Laemmli, 1970) and O'Farrel (0' 
Farrel, 1975), using a Biorad electrophoresis set. The resolving gel was cast and 
layered with water to prevent oxidation of the gel, and it was allowed to polymerise 
for 25-30 min at room temperature. Immediately after casting the stacking gel (5 %), 
the comb was inserted and the gel polymerised as described above. The resolving and 
stacking gels were prepared by the mixing of the following components: 
Table 16. Components used in the preparation ofSDS- PAGE gels 
Solution components Resolving (12%) Resolving (10%) gel Stacking (5%) gel 
gel 
dH20 4.9ml 5.9m1 3.4m1 
30% acry1amide solution 6.0ml 5.0ml 0.83 ml 
1.5 M Tris pH 8.8 3.8m1 3.8ml -
1.0 M Tris pH6.8 - - 0.63 m1 
10%SDS 0.15 ml 0.15 ml 0.05 ml 
10% Ammonium persulphate 0.15 m1 0.15 ml 0.05ml 
TEMED 0.006 ml 0.006 ml 0.005 ml 
The protein samples were resolved in running SDS-PAGE buffer (0.025 M Tris base, 
0.0192 M glycine, 1% (w/v) SDS) at 150 V until the dye front migrated to the end of 
the gel. 
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After electrophoresis, the gel was removed and stained in Coomassie blue stain [0.1% 
(w/v) Coomassie brilliant blue R250, 40% (v/v) methanol, 10% (v/ v) glacial acetic 
acid] for 2 h with gentle agitation. The gel was then incubated in high-methanol 
distain [ 40% (v/v) methanol, 10% (v/v) glacial acetic acid] for approximately 3 h or 
low-methanol distain for 24 h. 
2.5.3 Western Analysis of the expressed KSHV ORF 4 proteins 
The KSHV ORF 4 proteins were analysed by [0.1% (w/v)] SDS and [10% (w/v)] 
PAGE gel electrophoresis according. to standard methods. Proteins resolved by 
discontinuous SDS-PAGE were transferred to a nitrocellulose Hybond-ECL 
membrane using the Mini Trans-Blot Protean II cell apparatus set (Bio-Rad). During 
electrophoresis, the nitrocellulose membrane, the sheets of 3MM Whatman filter 
paper (cut to size) and the fibre pads were pre-equilibrated in ice-cold transfer buffer 
[192 mM Glycine, 25 mM Tris base and 20% (v/v) methanol]. Following 
electrophoresis, the gel was also equilibrated in ice-cold transfer buffer. Three sheets 
of 3MM Whatman filter paper were mounted on a fibre pad, which was in turn 
mounted on the black panel. The equilibrated polyacrylamide gel was placed on the 
filter paper and overlaid with the nitrocellulose membrane. The membrane was in 
turn, overlaid with another three sheets of 3MM Whatman filter paper followed by a 
fibre pad. This transfer cassette was arranged in transfer buffer such that no air 
bubbles were trapped between the gel and membrane. The Western transfer was 
allowed to occur for 1 h at I 00 V in the presence of a magnetic stirrer and a heat trap 
unit. In order to determine whether the transfer was successful, the nitrocellulose 
membrane was stained with Ponceau S mix [0.5% (w/v) Ponceau S, 1% (v/v) glacial 
acetic acid] for 5-10 min, followed by rinsing with ddH20. The membranes were 
scanned and washed twice in TBS before subject to immunodetection. 
2.5.4 Chemiluminescence-based Immunodetection of the rKCPs 
The immunodetection of KSHV ORF 4 proteins on nitrocellulose membranes was 
performed using the BM Chemiluminescence Western Blotting Kit (Mouse/Rabbit) 
(Roche). The membrane was incubated overnight at 4°C in blocking solution [5% 
(w/v) not-fat milk powder in TBS] in order to prevent non-specific binding of 
antibody to the nitrocellulose membrane. The polyclonal rabbit anti-KCP peptide 
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primary antibody was appropriately diluted 1:500 in TBST [0.1% (v/v) Tween-20 in 
TBS]. The proteins of interest were detected by incubating the membranes with the 
primary antibody dilution for 1 h and 30 min at RT with gentle shaking. After 
incubation, the primary antibody dilution was removed and stored at 4°C for repeated 
use if necessary. The membranes were washed twice in TBST and twice in blocking 
solution at RT with shaking for 10 min each. The membrane was then incubated for 
30 min with the horseradish peroxidase (POD)-conjugated secondary antibody (anti-
mouse/rabbit IgG) diluted 1:12 000 in 0.5% (w/v) TBS blocking solution. Following 
incubation with the secondary antibody, the membranes were washed four times in 
large volumes of TBST with shaking for 15 min each. For the chemiluminescent 
detection, the BM Chemiluminescence Western Blotting Kit starting solution B was 
added to substrate solution A in a 1:100 ratio and the mixture was incubated at RT for 
at least 30 min. In the dark room with the red safety light on, the membrane was 
covered in detection solution for approximately 1 minute. After draining of the excess 
fluid, the membranes were placed in a specialized developing cassette, followed by 
exposure of the membranes to X-ray film for different time intervals (1 minute-1 0 
min) depending on the strength of the signal obtained. The X-ray film was developed 
in developer solution (Agfa reagents) for 1-2 min, rinsed in stop solution (2% glacial 
acetic acid), fixed in fixer solution (Agfa reagents) and rinsed in water before drying. 
2.6 Functional and Structural Analysis of the Expressed 
KSHV ORF 4 recombinant proteins 
2.6.1 Biological Activity Test of the Secreted Proteins 
The activity of the three different sized secreted rKCPs was tested by means of a 
hemolysis assay, which measured their ability to inhibit complement-mediated lysis 
of sensitized sheep red blood cells (ssRBCs) (Kotwal et al, 1990). The first step was 
to carry out a serum assay whereby a 50 J.!l aliquot of human serum, which was stored 
at -80°C, was gently thawed and diluted at 1:30, 1:60 and 1:90. Four reactions were 
set up as the follows: 3 x 75 Jll ssRBC, 10 Jll DGVB2+ [2.5 mM veronal buffer, (pH 
7.3) 72 mM NaCl, 140 mM Glucose, 0.1% gelatine, 1 mM MgCh, and 0.15 mM 
CaCh] and 15 J..tl of each pre-diluted serum respectively and 1 negative control, 
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whereby the serum was replaced with DGVB2+ buffer. The reaction samples were 
incubated for 1 h at 37°C and centrifuged at 7000 rpm for 30 seconds. After 
centrifugation the positive samples were analysed with respect to the negative control 
which showed no cell lysis, in order to determine the dilution of serum known to 
disrupt ~95% of ssRBCs. The components of the hemolysis assay reactions were then 
added in the following order: 
Table 17. Components used in the set up of the Hemolyis Assay reactions 
Sample ssRBC (JJ.I) Buffer (JJ.I) Sample (J.ll) Serum (1:60) (J.ll) 
Negative Control 75 25 
- -
Positive Control 75 10 15 
-
BC 75 6 4 15 
KCP-S 75 6 4 15 
KCP-S 75 8 2 15 
KCP-S 75 9 1 15 
KCP-M 75 6 4 15 
KCP-M 75 8 2 15 
KCP-M 75 9 1 15 
KCP-F 75 6 4 15 
KCP-F 75 8 2 15 
KCP-F 75 9 1 15 
The test samples (KCP-S, KCP-M and KCP-F) were carried out in duplicate and upon 
1 h incubation of the reaction samples at 37° and centrifugation at 7000 rpm for 30 
seconds, 70 J.ll of the supernatants were transferred to a 96 well plate. The amount of 
hemoglobulin from the lysed cells was determined by measuring the absorbance at 
405 nm using a microplate reader (Anthos 2010). In order to determine percentage 
hemolysis inhibition, the OD4os reading of each sample was divided by the OD405 
reading of the positive control: 
Sample OD4os I Positive control OD4os = Xt x 100 = X2- 100 = % Inhibition 
A bar graph was drawn to show percentage hemolysis inhibition (Y-axis) versus the 
different volumes/amounts of the rKCPs (X-axis) (Figure 36). 
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2.6.2 N-Deglycosylation Analysis of the Truncated KCP 
The supernatant [60-90 IJ.l] from cultures of recombinant strains containing 
approximately 30 IJ.g of protein of interest was made up to 100 111 with 50 mM sodium 
phosphate solution pH 7.5. The protein sample was concentrated using a Speed Vac 
apparatus. The concentrated protein was then resuspended in 25 111 of 50 mM sodium 
phosphate solution, pH 7.5, after which 2.5 111 of denaturation buffer (0.2% SDS with 
100 mM J3-mercaptoethanol) was added. The reaction mixture was denatured by 
heating at 1 00°C for 10 min followed by incubation with 3 111 of peptide-N-
glycosidase F (PNGase F) (Figure 12) enzyme solution (500 units/ml) for 3 -18 hat 
37°C to allow de-glycosylation to occur, and then stopped by heating to 100 °C for 5 
min. The samples were then assessed by SDS-PAGE. The glycoprotein, gp120 was 
run with the deglycosylation experiment as a positive control substrate since the 
composition of the reaction buffer may interfere with the deglycosylation of a 
glycoprotein. Similarly, purified VCP (from the WR strain) which does not contain 
any N-linked carbohydrate sites was used as a negative control to show that any shift 
in molecular weight was not due to contaminating proteases but as a result ofPNGase 
F activity. 
x-Man 
' ! 
Man -G lc NAc -G lc NAc -Asn-
/ 
x-Man 
Figure 12. Schematic diagram ofPGNase F N-deglycosylation 
PNGase F is an amidase that cleaves between the innermost GlcNAc and asparagine residues of high . 
mannose, hybrid, and complex oligosaccharides from N-linked glycoproteins. In other words, it 
hydrolyses nearly all types of N-glycan chains from glycopeptides/proteins [X= H or sugar (s)] (Maley 
et al, 1989). 
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2.7 Immunohistochemical Detection of the KCP in 
Kaposi's sarcoma 
Coded human tissue samples from the pathological archives were kindly provided by 
Prof D. Govender from the division of anatomical pathology, University of Cape 
Town. Furthermore, the specimens used in this study were completely anonymous 
therefore there was no knowledge of the patient identification. 
All of the 12 KS cases under investigation were first subjected to Hematoxylin and 
Eosin (H & E) immunostaining which is a histological staining system commonly 
used for visualization of the cellular morphology of the tissue sections. This stain 
system is known to carry a positive charge because of a dye lake of hematein, which 
is an oxidation product of Hematoxylin, functioning as a basic dye. Therefore cell 
nuclei which are basophilic are stained blue. On the other hand, Eosin acts as a 
counter stain staining all the remaining tissue sections in different shades of red. 
2.7.1 Coating of Slides with 3-aminopropyltriethoxyethylsilane 
Tissue samples tend to float off the slides when subjected to wet heat and high 
temperature antigen retrieval methods, therefore in order to prevent this from 
happening, slides were coated with 3-aminopropyltri-ethoxyethylsilane [APES 
(98%)]. An approximately 3.3% solution of APES was prepared by adding 10 mls 
APES and 300 mls acetone together. The slides were packed into metal racks and 
washed in 1% aqueous detergent solution by soaking and some agitation, followed by 
a thorough wash in running tap water for about 60 min. The slides were then dried 
overnight at 37°C (or at 60°C for 4 h). Suitably sized dishes containing APES 
solution, acetone, and water were placed next to each other and the slide rack was 
dipped into each of the solutions as fol1ows: APES I 0 dips, acetone 3 dips, acetone 3 
dips and water 3 dips. Finally, the slides were allowed to dry overnight at 37°C. 
2.7.2 Immunohistochemistry of KS Tissue Samples with anti-KCP 
Paraffin-embedded sections were cut at 2-4 J..Lm, mounted on APES-coated slides and 
heat fixed on a hot-plate at approximately 75°C for 30 min. Heat-induced epitope 
retrieval (IllER) was carried in lmM EDTA (pH 8.0) using a pressure cooker. Upon 
boiling of the buffer, the slides in a metal rack were immersed in the buffer and the 
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pressure cooker was sealed. Once at full pressure, a timer was set for 2 min followed 
by release of the pressure with running cold water. The slides were then washed in 
running tap water until the next step. After blocking of endogenous peroxidase 
activity with aqueous 1% H202 for 15 min, the sections were washed in phosphate· 
buffered saline containing 0.05% Tween-20 (PBS-T), and non-specific binding of 
secondary antibody was blocked with 5% normal goat serum for 15 min. The normal 
goat serum was drained off and the sections were incubated for 60 min at room 
temperature with a rabbit polyclonal antibody directed against a selected N-terminus 
peptide of the KCP (section 2.4.1) at 1:10 000 dilution, which was found to be 
optimal after a series of dilutions of the primary antibody ranging from 1: 250-1: 100 
000 were tested. The primary antibody was substituted with PBS in sections used as 
negative controls and with anti-CD34 (1 :50) (Novocastra), anti-CD31 (1 :40) 
(DakoCytomation), anti-cyclin Dl (1: 1 00) (NeoMarkers) and anti-LANA (1 :25) 
(Novocastra) in sections used as positive controls. The sections were well rinsed with 
PBS-T and incubated for 30 min at room temperature with goat anti-rabbit secondary 
antibody-conjugated to peroxidase (En Vision). The slides were then rinsed with PBS 
followed by 5 min incubation with liquid 3, 3'-diaminobenzidine (DAB) substrate 
chromogen that was diluted according to instructions. The slides were rinsed in 
running tap water, counterstained with haematoxylin, dehydrated and mounted in 
Entellan. 
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CHAPTER THREE 
RESULTS 
3.1 Preparation of the KSHV ORF 4 DNA Constructs 
3.1.1 Preparation of the pGEMT/KSHV ORF4 Gene Constructs 
Background Information 
The chosen vector for easy and convenient cloning of the genes of interest was the 
pGE~-T easy system. The KSHV ORF4 PCR products were ligated into this 
expression vector to generate three recombinant plasmids, pGEMT /KSHV ORF 4 
(735), pGEMT/KSHV ORF 4 (1436) and pGEMT/KSHV ORF 4 (1581) (Figure 13, 
B-D). The pGE~-T easy vector contains multiple restriction sites within the 
multiple cloning region, which allow for the release of the insert by digestion with a 
single restriction enzyme (Figure 13, A). However, two different restriction enzymes 
from the multiple cloning region (Eco RI and Not I) were selected and used in the 
creation of the pGEMT/KSHV ORF 4 constructs and therefore, a double-digestion 
was carried out to release the inserts from the vector. If desired, insertional 
inactivation of the a-peptide could have been used as a tool for color screening of the 
recombinant clones on indicator plates containing the P-galactosidase substrate 5-
bromo-4-chloro-3-indolyl-P-D-galactopyianoside (BCIG; X-gal). 
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Figure 13. Restriction Plasmids Maps of the pGEMT -easy vector and constructs 
A: pGEMT easy vector circle map showing the most important sequence reference points such as the T7 and SP6 
RNA polymerase transcription sites, and a double multiple cloning region for easy and convenient ligation of the 
genes of interest to the vector. B: Double-restriction endonuclease digestion of the 3750 bp pGEMT/KSHV ORF 
4 (735) construct with the REs &o RI and Not I produces 4 fragments of sizes 2981 bp, 735 bp, 9 bp and 7 bp. C: 
Double-restriction endonuclease digestion of the 4491 bp pGEMTIKSHV ORF 4 (1436) construct with the REs 
&o Rl and Not I produces 4 fragments of sizes 2981 bp, 1436 bp, 9 bp and 7 bp. D: Double-restriction 
endonuclease digestion of the 4596 bp pGEMTIKSHV ORF 4 (1581) construct with the REs &o RI and Not I 
produces· 4 fragments of sizes 2981 bp, 1436 bp, 9 bp and 7 bp. 
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3.1.2 PCR amplification of KSHV ORF 4 gene from KSHV DNA 
Three DNA-sections ofthe KSHV ORF4 encompassing SCRs 1 to 4 (Figure 8) were 
amplified from a KSHV DNA template by PCR using a KSHV ORF4-specific 
forward primer and three consecutive KSHV ORF4-specific reverse primers. The 
PCR products (1 OJ.Ll) were resolved by gel electrophoresis on 1% (w/v) agarose gel 
(Figure 14). 
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Figure 14. Agarose gel Analysis of the KSHV ORF 4 PCR products 
Ethidium bromide stain of electrophoretically resolved [1% (w/v) agarose gel] PCR products; Lane 1: 
1kb DNA ladder molecular weight marker (Promega); Lane 2: VCP amplified from Vaccinia virus 
DNA with the VCP-specific forward and reverse primers, used as a PCR positive control. A faint band 
of expected fragment size, 700 bp can be visualised; Lane 3: KSHV ORF 4-specific 1597 bp PCR 
product amplified from KSHV DNA template with the forward primer 03~1420 and the reverse primer 
03-1421; Lane 4: KSHV ORF 4-specific 735 bp PCR product amplified from KSHV DNA template 
with the forward primer 03-0668 and the reverse primer 03-0669; Lane 5: KSHV ORF 4-specific 1436 
bp PCR product amplified from KSHV DNA template with the forward primer 03-0668 and the reverse 
primer 03-0670; Lane 6: KSHV ORF 4-specific 1581 bp PCR product amplified from KSHV DNA 
template with the forward primer 03-0668 and the reverse primer 03-0671. 
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3.1.3 Small-scale preparation of plasmid DNA 
Uncut double stranded plasmid DNA template, pGEMT/KSHV ORF 4 (735), 
pGEMT/KSHV ORF 4 (1436) and pGEMT/KSHV ORF 4 (1581) (labelled A1-4, B1-
4 and C1-4 respectively) isolated from E. coli transformants using a modified alkaline 
lysis procedure [(QIAprep miniprep plasmid isolation kit (Qiagen)], was analysed by 
agarose gel electrophoresis (Figure 15). As expected a number of different bands of 
low electrophoretic mobility were obtained corresponding to the various 
conformations of DNA, namely the relaxed circular/nicked open circular or linear 
form and the supercoiled/covalently closed circular (CCC) form. 
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Figure 15. Agarose gel analysis of the isolated pGEMT plasmid DNA 
Ethidium bromide stain of electrophoretically resolved [1% (w/v) agarose gel] isolated pGEMT-easy 
DNA using the QiaPrep small scale plasmid purification kit; Lane 1: 1kb DNA ladder molecular 
weight marker; Lanes 2-5: Uncut pGEMT/KSHV ORF 4 (735) (sample A1-A4); Lanes 6-9: Uncut 
pGEMT/KSHV ORF 4 (1436) (sample B1-B4); Lanes 10-13: Uncut pGEMT/KSHV ORF 4 (1581) 
(sample C1-C4). All lanes (2-13) show the different possible conformations of DNA, namely the 
nicked open circular (top band) and supercoiled (bottom band). 
3.1.4 RE Digestion Analysis of the pGEMT -easy DNA Constructs 
Double stranded plasmid DNA template, pGEMT/KSHV ORF 4 (735), 
pGEMT/KSHV ORF 4 (1436) and pGEMT/KSHV ORF 4 (1581), labelled A1-4, B1-
4 and C1-4 respectively, isolated from E. coli transformants was subjected to 
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restriction endonuclease digestion and the DNA fragments were analysed by agarose 
gel electrophoresis (Figure 16) 
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Figure 16. Agarose gel ofthe pGEMT/KSHV ORF 4 constructs REanalysis 
Ethidium bromide stain of electrophoretically resolved [1% (w/v) agarose gel] Eco RI and Not I 
digested pGEMT/KSHV ORF4 DNA constructs; Lane 1: 1kb DNA ladder molecular weight marker; 
Lanes 2, 4 and 5: Eco RI and Not I digested pGEMT/KSHV ORF 4 (735) into which the KSHV 
ORF4-specific 735 bp PCR product was not ligated; Lanes 3: Eco RI and Not I digested 
pGEMT/KSHV ORF 4 (735) into which the KSHV ORF4-specific 735 bp PCR product was 
successfully ligated; Lane 6 and 8: Eco RI and Not I digested pGEMT/KSHV ORF 4 (1436) into 
which the KSHV ORF4-specific 1436 bp PCR product was not ligated; Lane 7 and 9: Eco RI and Not 
I digested pGEMT/KSHV ORF 4 (1436) into which the KSHV ORF4- specific 1436 bp PCR product 
was successfully ligated; Lane 10: Eco RI and Not I digested pGEMT/KSHV ORF 4 (1581) into 
which the KSHV ORF4- specific 1581 bp PCR product was not ligated; Lanes 11-13: Eco RI and Not 
I digested pGEMT/KSHV ORF 4 (1581) into which the KSHV ORF4-specific 1581 bp PCR product 
was successfully ligated. 
The Eco RI- and Not I- cut pGEMT/KSHV ORF 4 (735) (Figure 16, lane 3) resolved 
into two visible bands corresponding to the expected 2981 bp and 735 bp DNA 
fragments while that of the Eco RI- and Not I- cut pGEMT/KSHV ORF 4 (735) 
(Figure 16, lane 2, 4 and 5) resolved into only one visible band corresponding to 2981 
bp DNA fragment showing that only one out ofthe four constructs contained the 735 
bp insert of interest. 
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Similarly, the Eco RI- and Not 1- cut pGEMT/KSHV ORF 4 (1436) (Figure 16, lanes 
7 and 9) resolved into two visible bands corresponding to the expected 2981 bp and 
1436 bp DNA fragments while that of the Eco RI- and Not 1- cut pGEMT/KSHV 
ORF 4 (1436) (Figure 16, lane 6,9) resolved into only one visible band corresponding 
to 2981 bp DNA fragment showing that two out of the four constructs contained the 
1436 bp insert of interest. 
Furthermore, the Eco RI- and Not 1-cut pGEMT/KSHV ORF 4 (1581) (Figure 16, 
lanes 11-13) resolved into two visible bands corresponding to the expected 2981 bp 
and 1581 bp DNA fragments while that of the Eco RI- and Not 1- cut pGEMT/KSHV 
ORF 4 (1581) (Figure 16, lane 10) resolved into only one visible band corresponding 
to 2981 bp DNA fragment showing that three out of the four constructs contained the 
15 81 bp insert of interest. 
3.1.5 Directional Analysis of the Cloned Genes by RE Digestion 
All of the pGEMT/KSHV ORF4 constructs digested with Bam HI resulted in the 
expected linear fragments of 3750bp, 4450 bp and 4596 bp corresponding to the 
pGEMT -easy constructs containing the 735bp, 1436 bp and 1581 bp genes 
respectively. The restriction enzyme Bam HI does not cut the pGEMT -easy vector but 
it cuts all three inserts at position 643 bp as determined by GeneRunner software. The 
fact that this RE linearised all the constructs under investigation shows that the inserts 
were ligated in the correct orientation, in other words, the top strand ofthe insert goes 
from 5' 7 3' and therefore the restriction enzyme is capable of recognising its 
respective restriction site (Figure 9). 
The RE chosen as a linearization positive control, Eco RV, capable of cutting the 
vector once but not the insert was not a good choice because in the preparation of the 
pGEMT-easy vector, the vector was linearised at base 60 with Eco RV and aT added 
to both 3 '-ends as previously described in section 2.1.6. This site is not recovered 
upon ligation of the vector with the insert and as a result, digestion of the constructs 
with Eco RV did not yield any linear product as seen in Figure 17. 
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Figure 17. Agarose gel of the directional analysis of the inserts by RE digestion 
Ethidium bromide· stain of electrophoretically resolved [1% (w/v) agarose gel] Eco RI and Not I 
digested pGEMT/KSHV ORF4 DNA constructs; Lane 1: 1kb DNA ladder molecular weight marker; 
Lane 2: Uncut pGEMT/KSHV ORF 4 (735 bp) (negative control showing the different possible 
conformations of DNA); Lane 3: Eco RV cut pGEMT/KSHV ORF 4 (735 bp) (Unsuccessful positive 
control as Eco RV does not linearise the contruct); Lane 4: Bam HI linearised pGEMT/KSHV ORF 4 
(735 bp) (expected fragment obtained of size 3750 bp); Lane 5 and 7: Eco RV cut pGEMT/KSHV 
ORF 4 (1436 bp) (Unsuccessful positive control as Eco RV does not linearise the contruct); Lane 6 
and 8: Bam HI linearised pGEMT/KSHV ORF 4 (1436 bp) (expected fragment obtained of size 4450 
bp); Lane 9, 11 and 13: Eco RV cut pGEMT/KSHV ORF 4 (1581 bp) (Unsuccessful positive control 
as Eco RV does not linearise the contruct); Lane 10, 12 and 14: Bam HI linearised pGEMT/KSHV 
ORF 4 (1581 bp) (expected fragment obtained of size 4596 bp). 
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3.1.6 DNA Sequencing Results 
Rev 
Fwd 
;:mw 
Rev 
Fwd 
KSHV 
Rev 
Fwd 
i,SHV 
Rev 
Fwd 
KSI!\' 
Rev 
Fwd 
1\ShV 
Rev 
Fwd 
K.StiV 
Rev 
Fwd 
KSH'/ 
Rev 
Fwd 
KSHV 
Rev 
Fwd 
KZHV 
Rev 
Fwd 
KSH'I 
Rev 
Fwd 
KSHV 
Rev 
Fwd 
KStN 
Rev 
Fwd 
KSHV 
Rev 
Fwd 
Y.~'!!l'l 
Rev 
Fwd 
KSHV 
Rev 
Fwd 
KSH\ 
Rev 
Fwd 
K:3HV 
Rev 
Fwd 
K:':Ir1 
Rev 
Fwd 
KSHV 
22 
':1 
112 
1 
181 
202 
1 
.~il 
292 
1 
!61 
382 
1 
4'il 
472 
1 
54: 
562 
1 
f53!. 
652 
1 
?~1 
742 
54 
a11 
832 
144 
~l'l 
234 
~9: 
324 
10€1 
414 
1171 
504 
12o1 
594 
1351 
694 
1441 
774 
loJl 
864 
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Figure 18. Multiple Sequence Alignment of the Cloned KCP Gene with the 
pGEMT primers DNA Sequencing Results 
The sequences of the cloned gene obtained from amplification with the pGEMT forward and reverse primers 
shown in blue and red respectively was compared to the KSHV ORF 4 sequence from the database (green) using 
Clustal W (Higgins eta/, 1994). The results are represented in box shade fonnat 
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pGEMT/KSHV ORF 4 (1581 bp) plasmid DNA was isolated from several colonies of 
E. coli cells and sequencing was done from both ends of the inserted full length KCP 
gene using pGEMT -easy specific forward and reverse primers. Similarly, 
pPIC9/KSHV ORF 4 (1581 bp) plasmid DNA was also subject to DNA sequencing 
using the standard 5' and 3' AOXJ primers. The DNA sequencing results obtained 
were fairly precise for the exception of three sequence-specific base mutations at 
positions 575 (grey), 1055 and 1305 (white) as shown in Figure 18. 
·To investigate these mutations at the protein level, Clustal W was also used to 
compare the protein sequence of the cloned KSHV ORF4 as obtained from the DNA 
sequencing results, with that of the database (Figure 19). The protein multiple 
sequence alignment shows that the base mutations present at the DNA level caused 
non-conservative amino acid changes as denoted by the red text in Figure 19. 
KCP 1 MAFLRQTLWILWTFTMVIGQDNEKCSQKTLIGYRLKMSRDGDIAVGETVELRCRSGYTTY 
rKCP 1 MAFLRQTLWILWTFTMVIGQDNEKCSQKTLIGYRLKMSRDGDIAVGETVELRCRSGYTTY 
KCP 
rKCP 
KCP 
rKCP 
KCP 
rKCP 
KCP 
rKCP 
KCP 
rKCP 
KCP 
rKCP 
KCP 
rKCP 
KCP 
rKCP 
61 
61 
121 
121 
181 
181 
241 
241 
301 
301 
361 
361 
421 
421 
481 
481 
************************************************************ 
ARNITATCLQGGTWSEPTATCNKKSCPNPGEIQNGKVIFHGGQDALKYGANISYVCNEGY 
ARNITATCLQGGTWSEPTATCNKKSCPNPGEIQNGKVIFHGGQDALKYGANISYVCNEGY 
************************************************************ 
FLVGREYVRYCMIGASGQMAWSSSPPFCEKEKCHRPKIKNGDFKPDKDYYEYNDAVHFEC 
FLVGREYVRYCMIGASGQMAWSSSPPFCEKEKCHRPKIENGDFKPDKDYYEYNDAVHFEC 
************************************** ********************* 
NEGYTLVGPHSIACAVNNTWTSNMPTCELAGCKFPSVTHGYPIQGFSLTYKHKQSVTFAC 
NEGYTLVGPHSIACAVNNTWTSNMPTCELAGCKFPSVTHGYPIQGFSLTYKHKQSVTFAC 
************************************************************ 
NDGFVLRGSPTITCNVTEWDPPLPKCVLEDIDDPNNSNPGRLHPTPNEKPNGNVFQRSNY 
NDGFVLRGSPTITCNVTEWDPPLPKCVLEDIDDPNNSNPGRLHPTPNEKPNGNVFQRSNY 
************************************************************ 
TEPPTKPEDTHTAATCDTNCEQPPKILPTSEGFNETTTSNTITKQLEDEKTISQPNTHIT 
TEPPTKPEDTHTAATCDTNCEQPPKILPTSEGFNETTTSNTITKQLEDEKTTSQPNTHIT 
*************************************************** ******** 
SALTSMKAKGNFTNKTNNSTDLHIASTPTSQDDATPSIPSVQTPNYNTNAPTRTLTSLHI 
SALTSMKAKGNFTNKTNNSTDLHIASTPTSQDDATPSIPSVQTPNYNTNAPTRTLTSLHI 
************************************************************ 
EEGPSNSTTSEKATSSTLSHNSHKNDTGGIYTTLNKTTQLPSTNKPTNSQAKSSTKPRVE 
EEGPSNSTTSEKATASTLSHNSHKNDTGGIYTTLNKTTQLPSTNKPTNSQAKSSTKPRVE 
************** ********************************************* 
THNKTTSNPAISLTDSADVPQRPREPTLPPIFRPPASKNRYLEKQLVIGLLTAVALTCGL 
THNKTTSNPAISLTDSADVPQRPREPTLPPIFRPPASKNRYLEKQLVIGLLTAVALTCGL 
************************************************************ 
KCP 541 ITLFHYLFFR 
rKCP 541 ITLFHYLFFR 
********** 
Figure 19. Recombinant and Wild-type KCP Multiple Sequence Alignment using 
Clustal W 
Figure 19 shows 99.5% identity in the 550 residues overlap between the recombinant and the wild-type KSHV 
ORF 4 protein sequence. The remaining 0.5% accounts for the three amino acid changes, Lysine to Glutamic acid 
at position 159, Isoleucine to Threonine at position 352 and finally Serine to Alanine at position 435. 
73 
3.1. 7 Preparation of the pPIC9/KSHV ORF4 Gene Constructs 
A 
c 
pPIC9 
8.023 kb 
pPIC9/ 
KSHY ORF 4 (1436) 
9.499 kb 
B 
Stu I 
Fco Rl 1222bp 
. \or I 2698bp 
pPIC9/ 
KSH\. ORF 4 (735) 
8.758 kb 
D 
pPIC9/ 
KSH\. ORF 4 (1581) 
9.604 kb 
Fc·n Rl 
1222bp 
\' ' I 
1957bp 
Yor I 
2803b 
Figure 20. Restriction Plasmids Maps of the pPIC9 vector and constructs 
A: Vector circle map showing the location and size of each feature of pPIC9, including a multiple 
cloning site for easy ligation ofthe genes of interest to the vector. B: Double-restriction endonuclease 
digestion of the 8758 bp pPIC9/KSHV ORF 4 (735) construct with the REs Eco RI and Not I produces 
2 fragments of sizes 8023 and 735 bp. C: Double-restriction endonuclease digestion of the 9499 bp 
pPIC9/KSHV ORF 4 (1436) construct with the REs Eco RI and Not I produces 2 fragments of sizes 
8023 bp and 1436 bp. D: Double-restriction endonuclease digestion of the 9604 bp pPIC9/KSHV ORF 
4 (1581) construct with the REs Eco RI and Not I produces 2 fragments of sizes 8023 bp and 1581 bp. 
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3.1.8 Small-scale Isolation andRE Analysis of pPIC9 Plasmid DNA 
Double stranded plasmid DNA template, pPIC9 isolated from E. coli transformants 
using the QIAprep miniprep plasmid isolation kit, was subject to Hind III and Pst I 
RE digestion and the DNA fragments were analysed by agarose gel electrophoresis 
(Figure 21). Uncut pPIC9 DNA was used as a negative control and as expected, a 
number of different bands of low electrophoretic mobility were obtained (Figure 21 , 
lanes 1 and 5). 
1 2 3 4 5 6 7 8 
-
-
21 226 
5148/4973 
3530 
'l0'l"7 
1904 
1584 
1375 
947 
Figure 21. Agarose gel of the pPIC9 Restriction endonuclease analysis 
Agarose gel [0.8 % (w/v)] electrophoresis was used to analyse the restriction enzyme digestion 
products of the pPIC9 plasmid DNA; Lanes 1 and 5: Uncut pPIC9, negative control showing the 
different possible conformations of DNA; Lanes 2 and 6: Sac I linearised pPIC9, expected fragment 
obtained of size 8023 bp; Lanes 3 and 7: pPIC9 cut with Hind III, only one of the four expected 
fragments is visible of size 7302 bp; Lanes 4 ad 8: Pst 1-cut pPIC9, expected fragments obtained of 
sizes 6361 bp and 1662 bp; Lane 9: A DNA/Eco Rl and Hind Iri molecular weight marker (Promega). 
The pPIC9 plasmid DNA was linearised when digested with Sac I and therefore 
resolved into a single band of expected molecular size 8.023 kbp (Figure 21 , lanes 2 
and 6). The Hind III-cut pPIC9 (Figure 21 , lanes 3 and 7) should resolve into 4 
fragments (7302, 370, 339 and 12 bp) but only the DNA fragment corresponding to 
size 7.302 kbp is visible in Figure 21 as the other three fragments are too small. On 
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the other hand, the Pst I-cut pPIC9 (Figure 21, lanes 4 and 8), resolved into two 
visible bands, corresponding to the expected 6.361 and 1.662 kbp DNA fragments. 
3.1.9 DNA Isolation from Low-melt Gels 
Successful pGEMT-easy clones containing the DNA fragments of interest were 
digested with Eco RI and Not I as described in section 2.1.1 0. The Eco RI!Not I 
KSHV ORF 4 DNA fragments were recovered from a low melting temperature 
agarose gel using the Wizard® SV system. 
21226-
51-48/-4973 -
2027 
190-4 
158-4 
137-4 
9-47 
831 
-
1 2 3 4 A B c 
Figure 22. Agarose gel of the genes of interest recovered from low-melt gel 
Ethidium bromide stain of electrophoretically resolved [1% (w/v) agarose gel] Eco R1 and Not I 
digested pGEMT/KSHV ORF 4 DNA constructs; Lane 1: A. DNA!Eco R1 and Hind III molecular 
weight marker; Lane 2: Eco RI and Not I digested pGEMT/KSHV ORF 4 (735) (expected fragments 
obtained of sizes 2981 bp and 735 bp ); Lane 3: Eco RI and Not I digested pGEMT/KSHV ORF 4 
(1436) (expected fragments obtained of sizes 2981 bp and 1436bp); Lane 4: Eco RI and Not I digested 
pGEMT/KSHV ORF 4 (1581) (expected fragments obtained of sizes 2981 and 1581 bp); Lanes A-C: 
Exactly as per lanes 2-4 respectively for the exception that a greater volume of DNA was loaded 
instead for extraction of the marked DNA fragments from the agarose gel. 
3.1.10 RE Digestion Analysis of the pPIC9 DNA Constructs 
Double stranded plasmid DNA template, pPIC9/KSHV ORF 4 (735), pPIC9/KSHV 
ORF 4 (1436) and pPIC9/KSHV ORF 4 (1581) (labelled A1-3, B1-3 and C1-3 
respectively) isolated from E. coli transformants was subjected to restriction 
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endonuclease digestion and the DNA fragments were analysed by agarose gel 
electrophoresis (Figure 23). 
21226 -
5U8/-'973 _ 
2027 
158-' 
1375 
9-'7 -
831 -
564 -
1 2 3 4 5 6 7 8 9 10 
Figure 23. Agarose gel of the pPIC9/KSBV ORF4 constructs RE analysis 
Ethidium bromide stain of electrophoretically resolved [l% (w/v) agarose gel] Eco Rl and Not I 
digested pPIC9/KSHV ORF4 DNA constructs; Lane 1: A. DNA/Eco RI and Hind Ill molecular weight 
marker; Lanes 2 and 4: Eco RI and Not I digested pPIC9/KSHV ORF 4 (735) into which the KSHV 
ORF4 Eco RI/Not I 735 bp DNA fragment was successfully ligated; Lanes 3: Eco RI and Not I 
digested pPIC9/KSHV ORF 4 (735) into which the KSHV ORF4 Eco RI!Not 1735 bp DNA fragment 
was not ligated; Lanes 5-7: Eco RI and Not I digested pPIC9/KSHV ORF 4 (I 436) into which the 
KSHV ORF4 Eco RI!Not 11436 bp DNA fragment was successfully ligated; Lanes 8-10: Eco RI and 
Not I digested pPIC9/KSHV ORF 4 (1581) into which the KSHV ORF4 Eco RI!Not I 1581 bp DNA 
fragment was successfully ligated. 
The Eco RI- and Not I-cut pPIC9/KSHV ORF 4 (735) (Figure 23, lane 2 and 4) 
resolved into two visible bands corresponding to the expected 8000 bp vector and the 
735 bp DNA fragment while that ofthe Eco RI- and Not I-cut pPIC9/KSHV ORF 4 
(735) (Figure 23, lane 3) resolved into only one visible band corresponding to 8000 
bp vector DNA, showing that two out of the three constructs contained the 735 bp 
gene of interest. Furthermore, the Eco RI- and Not I-cut pPIC9/KSHV ORF 4 (1436) 
(Figure 23, lanes 5-7) resolved into two visible bands corresponding to the expected 
8000 bp vector and the 1436 bp DNA fragment showing that all three recombinants 
under investigation were transformed with pPIC9 containing the 1436 bp insert of 
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interest. Similarly, the Eco RI- and Not 1- cut pPIC9/KSHV ORF 4 (1581) (Figure 23 , 
lanes 8-1 0) resolved into two visible bands corresponding to the expected size of the 
vector, 8000 bp and the 1581 bp DNA fragment showing again that the three picked 
E. coli recombinants were successfully transformed with pPIC9 containing the 1581 
bp gene of interest. 
3.2 Transformation and Selection for Positive Clones 
Many transformants as selected by their ability to grow in the absence of histidine 
(His+) were obtained in all of the transformation experiments carried out. 
3.2.1 Screening for Mot and Mot8 Transformants 
After transformation of the chemically competent Pichia cells with pPIC9 DNA 
constructs containing the genes of interest, His+ GS 115 transformants were readily 
distinguished between Mut+ (Methanol _!!tilisation plus), which refers to the wild type 
ability of the cells to metabolize methanol as the sole carbon source, and Muts 
(Methanol !!tilisation slow) phenotype by patching selected colonies on MM versus 
MD plates. 
MD MM 
BC A BC A 
B c B c 
- --
-~" 
Figure 24. His+ GS115 P. pastoris transformants are mostly Mut5 phenotype 
His+ transformants, BC (Background control: Pichia transformed with pPIC9 vector without the 
insert), A [pPIC9/KSHV ORF4 (735)], B [pPlC9/KSHV ORF4 (1436)], C [pPIC9/KSHV ORF4 
(1581)], were screened for the Mut+ and Muts phenotype by patching selected colonies first on a MM 
plate and then similarly on a MD plate. 
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The screening of His+ transformants shows that transformation of the GS 115 with Sac 
I-linearised pPIC9 (BC) and pPIC9 constructs (A-C) favoured recombination at the 
A OXI gene. Most of the cell's alcohol oxidase activity is lost upon disruption of the 
AOX1 gene resulting in a strain that is phenotypically Mut8 . Consequently, these 
transformants cannot efficiently metabolise methanol as a carbon source and therefore 
grow poorly on MM medium (Figure 24). 
3.2.2 PCR analysis of Picllia transformants 
In order to confirm that the three different sized-KSHV ORF 4 gene had integrated 
into the P. pastoris genome, genomic DNA isolated from colonies transformed with 
empty pPIC9 or KCP-containing vectors was analysed by PCR with specific AOXI 
pnmers. 
1 2 3 
21226 -·1!!'11!!!1!'1 
5148/4973 
3530 
2027 
1538 
1375 
947 
831 
564 
4 5 6 7 8 9 10 11 12 13 
Figure 25. PCR analysis of the pPIC9/KSHV ORF 4 (735) Pichia transformants 
Ethidium bromide stain of electrophoretically resolved [l% (w/v) agarose gel] of the isolated genomic 
DNA; Lane 1: 'A DNNEco RI and Hind ill molecular weight marker; Lanes 2-9: pPIC9/KSHV ORF 4 
(735) Pichia recombinants. It can be seen that His+ transfonnants in lanes 2, 4-5, 7-8 contain insert 
[735 bp (gene of interest) + 492 bp (from the vector) = 1227 bp DNA fragment] unlike the 
transformants in lanes 3 and 6. Furthermore, the recombinant in lane 9 may be a Mut3 as there is no 
wild-type AOXI gene; Lane 10: GS115/pPIC9 (no insert), showing the 492 bp product and the wild-
type AOXI gene; Lane 11: pPIC9 with the gene of interest, showing the ell.-pected size of the gene of 
interest cloned into pPIC9 (735 bp +492 bp = 1227); Lane 12: pPIC9 alone, showing the 492 bp PCR 
product made from pPIC9 by priming with the 5' and 3' AOXl primers; Lane 13: PCR positive 
control, showing the 735 bp PCR product made from the KSHV genomic DNA from PEL by priming 
with the 5' 03-0668 and the 3' 03-0669 primers. 
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Figure 26. PCR analysis of the pPIC9/KSHV ORF 4 (1436) Pichia transformants 
Ethidium bromide stain of electrophoretically resolved (l% (w/v) agarose gel] of the isolated genomic DNA; Lane 
1: A DNA/Eco RI and Hind ill molecular weight marker, Lanes 2-4: pPIC9/KSHV ORF 4 (1436) Pichia 
recombinants, it can be seen that all the three His+ transformants in lanes 2-4 contain insert [1436 bp (gene of 
interest)+ 492 bp (from the vector)= 1928 bp DNA fragment] as well as the wild-type AOXl gene making them 
Mut ; Lane 5: GS115/pPIC9 (no insert), showing the 492 bp product and the wild-type AOXl gene; Lane 6: 
pPIC9 with the gene of interest, showing the expected size of the gene of interest cloned into pPIC9 (1436 bp +492 
bp = 1928); Lane 7: pPIC9 alone, showing the 492 bp PCR product made from pPIC9 by priming with U1e 5' and 
3' AOX1 primers. 
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Figure 27. PCR analysis of the pPIC9/KSHV ORF 4 (1581) Pichia transformants 
Ethidium bromide stain of electrophoretically resolved (I% (w/v) agarose gel] of the isolated genomic DNA; Lane 
1: A DNAIEco RI and Hind ill molecular weight marker, Lanes 2-4: pPIC9/KSHV ORF 4 (1581) Pichia 
recombinants. It can be seen that the His+ transformants in lanes 2 and 3 contain insert [1581 bp (gene of interest) 
+ 492 bp (from the vector)= 2073 bp DNA fragment] but may be Muf as there is no wild-type AOXl gene; Lane 
4, although from a His+ transformant, does not contain the gene of interest; Lane 5: GSII 5/pPIC9 (no insert), 
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showing the 492 bp product and the wild-type AOXI gene; Lane 6: pPIC9 with the gene of interest, showing the 
expected size of the gene of interest cloned into pPIC9 (1581 bp +492 bp = 2073 bp); Lane 7: pPIC9 alone, 
showing the 492 bp PCR product made from pPIC9 by priming with the 5' and 3' AOXl primers; Lane 8: PCR 
positive control, showing the 1581 bp PCR product made from the KSHV genomic DNA from PEL by priming 
with the 5' 03-0668 and the 3' 03-0671 primers. 
PCR products corresponding to fragments of the expected stzes of pPIC9/KSHV 
ORF4 (735), (1436), and (1581)-containing transformants were observed as 1227 bp, 
1928 bp and 2073 bp DNA fragments as per Figures 25, 26 and 27 respectively. 
3.3 Expression of Recombinant KCP in Pichia pastoris 
Recombinant colonies with the KSHV ORF 4 gene integrated in their genomes were 
initially used for small-scale [5 ml] expression experiments in BMMY medium. 
Small-scale expression was followed by medium-scale [100 ml] production ofKSHV 
ORF 4 proteins from recombinant P. pastoris colonies transformed with the three Sac 
!-digested pPIC9/KSHV ORF4 plasmid constructs. Culture media supernatants from 
colonies transformed with the pPIC9 empty vector digested with Sac I pre-and 96 h 
post-induction was included as a negative control in all of the protein expression 
experiments. 
3.3.1 Optimisation of methanol-induced production of the rKCPs 
The time-dependent induction of the heterologous production ofthe recombinant KCP 
proteins in P. pastoris [pPIC9/KSHV ORF4 (735)] (Figure 33 A), [(pPIC9/KSHV 
ORF4 (1436)] (Figure 34 B) and [pPIC9/KSHV ORF4 (1581)] (Figure 35 B) by 
. addition of methanol was investigated over a period of 4 days. KSHV ORF4 proteins 
were first detected in the culture supernatant at 48 h post-induction and the amount of 
protein expressed increased after 72 and 96 h. However, the presence of these proteins 
at their maximal expression level was found to occur after 96 h post-induction the 
time at which the cells were harvested and the supernatants collected. The theoretical 
subunit molecular mass of the small, medium and full-length KSHV ORF 4 
polypeptide as calculated from their primary amino acid sequence is 27163.5, 53901.4 
and 57897.6 Da, respectively. However, the expressed proteins migrated as bands of 
double their theoretical molecular sizes. This higher molecular mass may be the result 
of posttranslational-modification of the protein by the yeast such as glycosylation of 
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the proteins since the primary sequence contains a number of potential N-linked 
carbohydrate sites with high probability of glycosylation (Figure 6). 
3.3.2 Estimation of Protein Concentration in the Culture Media 
Intensities of SDS-PAGE bands (Figure 28) were scanned with a densitometer 
(Chemilmager™ 5500) and the concentraii;n of the P. pastoris-expressed KCP 
protein was qualifiedly est~ated by comparison with a standard curve obtained with 
known amounts of protein. 
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Figure 28. Coomassie-stained SDS-PAGE gel scanned with the Densiometer for 
estimation of protein concentration 
Lane 1: Broad range protein molecular weight marker (Prom ega); Lane 2: Yeast culture supernatant 
showing KCP-F 96-h post-induction with methanol [30 J.LIIoaded]; Lane 3: Yeast culture supernatant 
showing KCP-M 96-h post-induction [30 J.LI loaded]; Lane 4: Yeast culture supernatant showing KCP-
S 96-h post-induction and prior to ultrafiltration; Lanes 5 and 6: Yeast culture supernatant showing 
KCP-S 96-h post-induction and post to ultrafiltration [30 ~-tl loaded]; Lane 7: BC: Yeast culture 
supernatant of a recombinant colony transformed with pPIC9 empty vector 96-h post-induction. 
Table 18. SDS-PAGE gel (Figure 29) Densiometer scan Autogrid Results 
Protein Size I Lane Peak Protein Band % Protein Amt (ng) 
Name Intensity 
150 kDa protein std 1 2 8.8 200 ng x 0.088= 17.6 
225 kDa protein std 1 I 11.2 200 ng x 0.1 12 = 22.4 
l 00 kDa protein std 1 3 I 1.4 200 ng x 0.114 = 22.8 
75 kDa protein std 1 4 12.2 200 ng x 0.122 = 24.4 
25 kDa protein std 1 7 13.0 200 ng x 0.1 30 = 26 
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35 kDa protein std 1 6 18.3 200 ng x 0.183 = 36.6 
50 kDa protein std 1 5 25.2 600 ng x 0.252 = 151.2 
KCP-S 8 3 75.5 x, 
KCP-M 5 1 96.0 Xz 
KCP-F 2 1 26.4 XJ 
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Figure 29. Standard Curve used to estimate the concentration of the expressed 
KCPs present in the culture media 
, The concentration of the P. pastoris-expressed KCP proteins was quantitively estimated by comparison 
with a standard curve obtained with known amounts of protein standards. The slope of the curve (m) 
was found to be 0.5. 
The unknown protein concentrations were directly determined by use of the following 
equations: 
Where, c = 0 
Therefore, [KCP-S]: 75.5 % = 0.5 x Xt + 0 therefore, X1 = 151 ng 
:.151 ng in 30 J.!l-7 5033 ng in 1000 J.!l :. [KCP-S] = 5033 ng/ml = 5J.!g/ml 
Similarly, under these calculations, the yield of P. pastoris expressed KCP-M (X2) 
and KCP-F (X3) was about 6.4 and 1.76 J..lg per millilitre of yeast culture medium 
respectively. This protein concentration estimation correlates with the fact that the 
first two recombinant proteins, KCP- S and M were obtained from medium-scale 
expression [1 00 ml] whereas the last one, KCP-F shown here and used throughout the 
project was obtained from a small-scale experiment [5 ml]. 
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3.3.3 Small-scale Ammonium Sulphate Protein Precipitation 
SDS-PAGE analysis revealed that the rKCP-S and -F recombinant proteins 
precipitated to some degree at all ammonium sulphate saturation levels, while the best 
rKCP precipitation yield was reached at 80-90% ammonium sulphate saturation level 
(Figure 30). The precipitated proteins from t_!le media were redissolved in 50 J.tl of 
saline (0.9% NaCI) and were used in the hemolysis assay to determine whether the 
.. 
expressed proteins are biologically active. 
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. Figure 30. SDS-PAGE Analysis of rKCPs Precipitated from the Supernatant 
with Saturated Ammonium Sulphate 
Figure 30A: Lane 1: Broad range protein molecular weight marker; Lanes 2-8: precipitates prepared 
from cultured supernatants [500 ~I] of recombinant strain [pPIC9/KSHV ORF4 (735bp)] with 30, 40, 
50, 60, 70, 80 and 90% saturated ammonium sulphate, respectively. Figure 30B: Lane 1: Broad range 
protein molecular weight marker [225, 150, 100, 75, 50, 35 and 25 kDa (from top to bottom)]; Lanes 
2-9: precipitates prepared from cultured supernatants [I ml] of recombinant strain [pPIC9/KSHV 
ORF4 (158Ibp)] with 20, 30, 40, 50, 60, 70, 80 and 90% saturated ammonium sulphate, respectively. 
Arrows indicate maximal level of precipitated protein of interest. 
3.4 Synthesis of a Polyclonal Anti-KCP Peptide Antibody 
Upon selection of a suitable KCP peptide sequence common to all three different 
sized KCPs, the sequence was forwarded to a Brazillian research group, who kindly 
synthesised the peptide. Five milligrams of the chemically synthesised peptide was 
coupled to KLH and used to produce the polyclonal anti-KCP peptide antibody in 
rabbits. 
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3.4.1 HiT rap protein A purification of the anti-KCP Antibody 
Protein A that is derived from a strain of Staphylococcus aureus, contains five regions 
that bind to the Fe region of lgG. As an affmity ligand, protein A is immobilized to 
sepharose so that these regions are free to bind. One molecule of immobilized protein 
A can bind at least two molecules of lgG. SDS-PAGE analysis revealed that the 
polyclonal anti-KCP peptide antibody and other lgGs were successfully purified from 
the serum sample (starting .material) ilsing a protein-A sepharose column. Under 
reducing conditions, the interchain disulfide bonds of an lgG molecule are split and if 
the sulfhydyl groups are blocked, two heavy chains (molecular weight 50 kDa each) 
and two light chains (25 kDa each) are formed as shown by the eluted fractions in 
Figure 31, lanes 5-9. 
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Figure 31. SDS-PAGE Analysis of the Anti-KCP Antibody Purification Stages 
Lane 1: Broad range protein molecular weight marker [225, 150, 100, 75, 50, 35, 25 kDa (from top 
to bottom)]; Lane 2: Starting material: serum containing the antibody of interest prior binding to the 
column; Lane 3: Flow through: serum post binding and prior to purification; Lane 4: First [20 roM 
sodium phosphate buffer (pH 7.0)] wash out of 6 total washes; Lanes 5-9: Third-seventh [0.1 M citric 
acid (pH 3.0)] elutions respectively; Lane 10: BSA (2 mg/ml) used as a quantitive protein control. 
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3.4.2 Bio-Rad Antibody Quantification Microassay 
125 250 500 750 1000 1500 2000 
Concentration (ug/ml) 
Figure 32. BSA Standard Curve used to Determine Anti-KCP . Antibody 
Concentration 
The As9s readings of the standards were plotted against the known BSA concentrations and a standard 
curve was generated. The microplate reader (Anthos 2010) evaluation results revealed that the standard 
curve was 98.7% accurate and that the slope of the curve (m) was 1.89 x 10·5, which was used in the 
equation described below. 
The unknown antibody concentrations of the purified fractions were directly 
determined by use ofthe following equation: 
m = Yz- Ytl Xz- Xt or Y= mX + c 
Where, c = 0.00744 
The purified antibody concentration of elution fractions 3-6 (Figure 31, lanes 5-8) was 
3303 J.Lg/ml, 10484 J.Lg/ml, 5468 J.Lg/ml and 2934 J.Lg/ml respectively. 
3.5 Immunological Detection, SDS-PAGE and Western 
Blot Analysis of the rKCP proteins 
Expression of the viral proteins was confirmed by slot-blot serological analysis after 
blotting 100 J.Ll of culture media supernatant onto nitrocellulose Hybond-ECL 
membranes. Western blot analysis with the rabbit polyclonal antibody directed against 
a selected KSHV ORF 4 peptide (Figure 11) showed that the P. pastoris-
heterologously expressed soluble-, medium- and full-length KCPs migrated 
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electrophoretically as higher bands which most likely is due to glycosylation of the 
proteins as in addition to the presence of potential N- and 0-linked carbohydrate sites 
in the protein's primary sequence, diffused bands were obtained in all the westerns 
carried out, which is characteristic of glycoproteins. The time-course of expression of 
the KCP-S and KCP-M protein was also followed by Western blot analysis, which 
showed that the protein could be first detected at 48 h post-induction and the amount 
of protein built up after 72 and 96 h (Figure 33B and 34C). 
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Figure 33. Expression and Detection of the Recombinant KCP- S protein 
Figures 33A: Coomassie-stained SDS-PAGE gel of the induction profile of the KSHV ORF 4-S recombinant 
protein. Lane 1: Broad range protein molecular weight marker; Lane 2: supernatant before induction; Lane 3: 24 
h post-induction; Lane 4: "8 h post-induction; Lane 5: 72 h post-induction; Lane 6: 96 h post-induction; Lane 7: 
96 h post-induction concentrated supernatant using the pellicon XL device; Lane 8: BC pre-induction; Lane 9: 
BC 72 h post-induction; Lane 10: BC 96 h post-induction. Figure 33B: Western Blot detection of the expression 
profile using rabbit anti-KCP peptide polyclonal antibody. In addition to the protein of interest, the antibody 
recognised several larger and smaller bands that may represent multimer aggregates and degradation products 
respectively. The time-course expression of the protein was monitored every 24 h from 0 to 96 h (lanes 2-6) after 
induction, loading 30 J.ll of clarified supernatant per well. Arrows indicate maximal level of protein. 
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Figure 34. Expression and Detection of the Recombinant KCP - M protein 
Figure 34A: Slot-blot incubated with rabbit anti-KCP peptide polyclonal antibody, after medium-scale 
KCP-M protein expression with a P. pastoris recombinant colony, obtained upon transformation with 
Sac 1-digested pPIC9/KSHV ORF4 (1436 bp) DNA construct. 100 f..ll of supernatant from the pre-
induction sample (row l) and from the different time-points post-induction (rows 2-5) were blotted as 
indicated. Equal volumes of supernatant of a recombinant colony transformed with Sac !-digested 
pPIC9 empty vector (BC) pre-induction (row 6) and 96 h post-induction (row 7) samples were also 
included. Figures 348: Coomassie-stained SDS-PAGE gel of the induction profile of the KCP-M 
recombinant protein. Lane 1: Broad range protein molecular weight marker; Lane 2: supernatant 
before induction; Lane 3: 24 h post-induction; Lane 4: 48 h post-induction; Lane 5: 72 h post-
induction; Lane 6: 96 h post-induction; Lane 7: BC before induction; Lane 8: BC 48 h post-induction; 
Lane 9: BC 72 h post-induction; Lane 10: BC 96 h post-induction. Figure 35C: Western Blot 
detection of the expression profile using rabbit polyclonal anti-KCP peptide antibody. The time-course 
expression of the protein was monitored every 24 h from 0 to 96 h (lanes 2-6) after induction, loading 
30 1-1-l of clarified supernatant per well. Arrows indicate maximal level of protein. 
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Figure 35. Expression and Detection of the Recombinant KCP - F protein 
Figure 35A: Slot-blot incubated with anti-KCP peptide polyclonal antibody, after medium-scale 
KSHV ORF 4-F protein expression with a P. pastoris recombinant colony, obtained upon 
transformation with Sac !-digested pPIC9/KSHV ORF4 (1581 bp) DNA construct. 100 Ill of 
supernatant from the pre-induction sample (row I) and from the different time-points post-induction 
(rows 2-5) were blotted as indicated. Equal volumes of supernatant of a recombinant colony 
transformed with Sac !-digested pPIC9 empty vector (BC) pre-induction (row 6) and 96 h post-
induction (row 7) samples were included. Figures 358: Coomassie-stained SDS-PAGE gel of the 
KSHV ORF4-F recombinant protein induction profile. Lane 1: Broad range protein molecular weight 
marker; Lane 2: supernatant before induction; Lane 3: 24 h post-induction; Lane 4: 48 h post-
induction; Lane 5: 72 h post-induction; Lane 6: 96 h post-induction; Lane 7: BC before induction; 
Lane 8: BC 96 h post-induction. Figure 35C: Western Blot detection of the KCP-F in a different 
media using anti-KCP peptide polyclonal antibody. Lane 1: Broad range molecular weight marker; 
Lane 2: supernatant before induction (20 Ill]; Lane 3: 72 h post-induction [20 Ill]; Lane 4: 72 h post-
induction (100 Ill concentrated with the speedvac); Lane 5: KCP-M 96 h post-induction supernatant 
used as a positive control for Western blot analysis. 
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3.6 Fun~Honal and Structural Analysis of the Expressed 
rKCPs 
3.6.1 Recombinant KCP-S protein is Functional 
All three recombinant KSHV ORF 4 proteins ~xpressed in the yeast, Pichia pastoris, 
were tested for biological activity by determining their ability to inhibit complement-
mediated lysis of ssRBCs (Figure 36). The results show that the ammonium-sulphate 
precipitated-supernatant from a Pichia culture transformed with pPIC9/KCP-S 
contained a functional regulator of human complement cap~1Jle of binding 
complement proteins in a concentration-dependent fashion as 1 J.1l, 2 J.1l and 4 J.1l 
caused 12.3%, 36.85, and 82.5 % complement inhibition respectively as depicted in 
Figure 36. 
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Figure 36. Inhibition ofthe classical pathway-mediated Lysis ofssRBC by rKCP 
Supernatants from cultured recombinant (KCP-S, -M and - F) and control (BC) strains were tested for 
biological activity by determining their ability to inhibit complement classical pathway-mediated lysis 
of antibody-coated sheep erythrocytes. 
3.6.2 Truncated KCP-S Protein is N-Giycosylated 
Protein motif search engines were used to confirm the presence of 15 potential N-
glycosylation sites in the conceptually translated primary sequence ofthe KSHV ORF 
4 (Figure 6). To examine the recombinant KCP-S for N-linked glycosylation, the 
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enzyme that releases asparagine-linked oligosaccharides from glycoproteins (Figure 
12). The results show a shift in molecular weight between treated and untreated KCP-
S from 56 kDa to approximately 27 kDa, the protein's theoretical molecular weight 
(Figure 37), indicating the presence of functional N-glycosylation sites in this 
heterologously expressed truncated protein. 
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Figure 37. SDS-PAGE Analysis of Enzymatic Degivcosylation with PNGase F 
shows that truncated KCP is N-glycosvlated 
Coomassie-stained SDS-PAGE gel of the PNGase F enzyme digestion of the KCP-S. Lane 1: Broad 
range protein molecular weight marker; Lane 2 and 3: VCP from the WR strain which does not 
contain any N-linked carbohydrate sites was used as a PNGase F deglycosylation negative control; 
Lane 4: supernatant of culture from pPIC9/KSHV ORF 4 (735 bp) recombinant strain; Lane S: 
supernatant of culture from pPIC9/KSHV ORF 4 (735bp) recombinant strain after incubation with 
PNGase F. Plus (+) and negative (-) symbols indicate with and without PNGase F treatment 
respectively. 
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3.7 Immunohistochemical Studies of KS Tissues with 
Polyclonal Anti-KCP Peptide Antibody 
3.7.1 Pre~Immune and Antibody Controls oflmmunostaining 
The resuhs acquired for the antibody control were successful as no specific 
immunostaining of the cells took pla<!e in the absence of both the primary and the 
secondary antibody (Figure 38). 
Figure 38. The Primary and Secondary Controls showed no specific staining 
Paraffin-embedded nodular Kaposi's sarcoma tissue section (case no.6587/01 A1 8K) were cut at 2-4 
J.lm, mounted on APES-coated slides and heat fixed on a hot-plate at approximately 75°C for 30 min. 
Figure 38A: Following tissue fixation, the section underwent immunostaining by incubation With anti-
KCP primary antibody but no specific secondary antibody. Figure 388: Same as for figure 38A for the 
exception that the section was incubated with secondary antibody only and no primary antibody. Tissue 
sections were-counterstained -with haematoxylin, dehydrated, mounted in Entellan and visualised using 
light microscopy techniques. I' and 2' refers to primary and secondary antibodies respectively. 
Likewise, the results obtained for the pre-immune contro~ which is the rabbit's serum 
before being exposed to the antigen of origin were also successful. The background 
immunostaining detected for the pre-immune staining was not as intense as that ofthe 
antibody immunostaining particularly post sepharose protein-A-clean up of the lgG 
used in this study as per section 2.4.2. In addition, the staining was rather ubiquitous 
as opposed to the more defined staining patterns observed with the antibody 
immunostaining (Figure 39). 
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Figure 39. The pre-immune control indicates that the staining obtained with the 
anti-KCP primary antibody is more specific 
Paraffin-embedded nodular Kaposi ' s sarcoma tissue section (case no.6587/0l AlsK) were cut at 2-4 
f.J.m , mounted on APES-coated slides and heat fixed on a hot-plate at approximately 75°C for 30 min. 
Figure 39A: Following tissue fixation, the section underwent immunostaining by incubation with pre-
immune serum followed by incubation with peroxidase-conjugated goat anti-rabbit secondary antibody. 
Figure 398: Same as for Figure 39A, for the exception that the section was incubated with anti-KCP 
primary antibody before sepharose protein-A-clean up of the IgG. Figure 39C: Same as for Figure 39B 
for the exception that the section was incubated with anti-KCP primary antibody post to sepharose 
protein-A-clean up of the IgG. 
Figure 40. Positive Controls showing expected Immunostaining of the KS tissue 
Paraffin-embedded nodular Kaposi's sarcoma tissue section (case no.6587/0l Al 5K) were cut at 2-4 
f.J.ID , mounted on APES-coated slides and heat fixed on a hot-plate at approximately 75°C for 30 min. 
Figure 40A: Following tissue fixation, the section underwent immunostaining by incubation with 
monoclonal mouse anti-human CD31, an antibody which predominantly displays staining of the cell 
membrane, followed by incubation with peroxidase-conjugated goat anti-mouse secondary antibody. 
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mouse anti-CD34, which as anti-CD31 , it is primarily used to label endothelial cells but unlike anti-
CD31, it strongly stains the endothelial cell cytoplasm. Figure 40C: Same as for Figure 40A, for the 
exception that the section was incubated with anti-Cyclin DI as a positive control for nuclear staining. 
Tissue sections were counterstained with haematoxylin, dehydrated, mounted in Entellan and 
visualised using light microscopy techniques. 
Figure 41. Diflerent Stages ofKS displaying HHV 8 Nuclear Positivity in the 
Lesional Spindle Cells 
Paraffin-embedded patch (case no. 1418/03 Bl), plaque (case no. 13132/99Al) and nodular (case no. 
12362/02 AI) Kaposi ' s sarcoma tissue sections were cut at 2-4 f..Lm , mounted on APES-coated slides 
and heat fixed on a hot-plate at approximately 75°C for 30 min. Following tissue fixation , the sections 
underwent immunostaining by incubation with mouse anti-LANA monoclonal antibody, followed by 
incubation with peroxidase-conjugated goat anti-mouse secondary antibody. Tissue sections were 
counterstained with haematoxylin, dehydrated, mounted in Entellan and visualised using light 
microscopy techniques. 
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3.7.2 Immunohistochemical Detection of Endogenous KCP Protein 
in Kaposi's sarcoma 
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Figure 42. Immunohistochemical Analysis of Various Early Patch Stage KS with 
anti-KCP Peptide Primary Antibody (lmmunoperoxidase, 200x) 
Paraffin-embedded patch Kaposi's sarcoma tissue sections (1: case no. 13360/99A 1; 2: 8230/00; 3: 
1835/0lAl ; 4: l418/03Bl) were cut at 2-4 J-lffi , mounted on APES-coated slides and heat fixed on a 
hot-plate at approximately 75°C for 30 min. Figure 42A: Cellular morphology by H&E staining of the 
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early patch stage KS tissue sections showing jagged vascular channels, elongated spindle cells lining 
clear slit-like spaces and permeating through dermal collagen bundles, small degree of inflammation 
and red blood cells; Figure 428: Post tissue fixation, these sections underwent immunostaining by 
incubation with polyclonal rabbit anti-KCP primary antibody, followed by incubation with peroxidase-
conjugated goat anti-rabbit secondary antibody. Tissue sections were counterstained with 
haematoxylin , dehydrated, mounted in Entellan and visualised using light microscopy techniques . 
Figure 43. Immunohistochemical Analysis of Various Intermediate Plague Stage KS 
with anti-KCP Peptide Primary Antibody (lmmunoperoxidase, 200x) 
Paraffin-embedded plaque Kaposi 's sarcoma tissue sections (1: case no. 13132199AI ; 2: 7973/02Al; 3: 
12830/00A I) were cut at 2-4 ~-tm, mounted on APES-coated slides and heat fixed on a hot-plate at approximately 
75°C for 30 min. Figure 43A: Cellular morphology by H&E staining of the intermediate plaque stage KS, 
showing a greater number of elongated spindle cells when compared to the early stage, dilated lymphatics, 
lymphocytes and plasma cells at the site of proliferation and a small number of erythrocytes can also be visualised. 
Figure 438: Post tissue fixation, these sections underwent immunostaining by incubation with polyclonal rabbit 
anti-KCP primary antibody, followed by incubation with peroxidase-conjugated goat anti-rabbit secondary 
antibody. Figure 43C: Same as Figure 43B case I at a higher magnification showing possible endothelial staining. 
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Figure 44. Immunohistochemical Analysis of Various Late/Advanced Nodular Stage KS 
with anti-KCP Peptide Primary Antibody (lmmunoperoxidase, 200x) 
Paraffin-embedded nodular Kaposi ' s sarcoma tissue sections (1: case no. 6587/0IAI ; 2: 1182/0IAI; 3: 7973/02; 
4: 12362/02) were cut at 2-4 1-1m, mounted on APES-coated slides and heat fixed on a hot-plate at approximately 
75°C for 30 min. Figure 44A: Cellular morphology by H&E staining of the advanced nodular stage KS tissue 
sections, showing fascicular growth of the more rounded-shaped spindle cells, more prominent lymphocytic 
infiltrates, the presence of light eosinophilic, hyaline bodies both within and between the tumour cells. Large 
deposits of hemosiderin can also be seen. Figure 448: Post tissue fixation, these sections underwent 
immunostaining by incubation with polyclonal rabbit anti-KCP primary antibody, followed by incubation with 
peroxidase-conjugated goat anti-rabbit secondary antibody. Tissue sections were counterstained with 
haematoxylin, dehydrated, mounted in Entellan and visualised using light microscopy techniques. 
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CHAPTER FOUR 
DISCUSSION 
4.1 Immunohistochemical Detection of the KCP Protein in 
Kaposi's sarcoma 
Finding a cure against mv and a means of alleviating the pain of those infected as 
well as improving their quality of life is presently a national priority in South Africa. 
It is a known fact that often other opportunistic pathogens such as KSHV are the 
leading cause of death of highly immunosuppressed individuals, particularly amongst 
AIDS patients. KSHV causes Kaposi's sarcoma (KS), an angiogenic skin lesion 
originating from the tumour of endothelial cells, which has been recognized a~ one of 
the most abundant tumours found in many parts of Southern Africa and which can 
occasionally become highly invasive and aggressive, and capable of causing death. 
Apart from KS, other proliferative diseases unmistakably related to KSHV infection 
include some plasma cell forms of Multicentric Castleman's Disease (MCD) which is 
a .B-cell lymphoproliferative disorder, and a bo·dy cavity-based or primary effusion 
lymphoma (BCBL or PEL) which also infects B-cells (Moore and Chang, 2001). 
The complement system, which is part of the innate immune defence system, 1s 
composed of a group of serum proteins that interact with each other in a cascade-type 
reaction causing the splitting of subsequent proteins into fragments (Walport, 2001). 
The powerful nature of the complement system, either in the presence or absence of 
antibodies, can lead to virus neutralization and opsonisation, lysis of virus-infected 
cells and amplification of inflammatory and specific immune responses(Blom, 2004). 
Considering the potentially destructive nature of the complement proteins which do 
not have the ability to differentiate between self and non-self tissue and therefore 
destroy any cell including host cells (Sahu and Lambris, 2001), the host tissue have 
specific inhibitors/regulators of the complement system on their cell surface. Viruses 
are obligate intracellular parasites and ultimately depend on the cell machinery of the 
host to survive and propagate. Since the complement proteins implicated in the 
cascade activation process are not able to discriminate between self and n<;m-self, 
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viruses are highly vulnerable to the complement system. Therefore, during co-
evolution, viruses such as KSHV have developed and acquired clever strategies to 
overcome the complement system of the host in order to succeed as pathogens (Spiller 
et al, 2003a). 
KSHV like other large DNA viruses encodes genes whose protein products explicitly 
undermine the immune system responses, including the complement cascade thereby 
leading to persistent infection and pathogenesis within the host. One such protein 
product was predicted by sequence analysis to be encoded by the ORF 4 and in order 
to determine if there is a link between this protein and Kaposi's sarcoma lesions, 
biopsies from KS-IDV patients were tested for the presence of endogenous KCP 
involved in complement regulation. A disruption in the cell cycle regulatory 
mechanism takes place when cells acquire cancerous properties and hence their 
uncontrollable proliferation. Therefore, to determine the localisation of endogenous 
KCP in response to viral-induced transformation was also a motivation for this 
immunohistochemical study. 
The immunohistochemical studies were performed usmg a polyclonal anti-KCP 
peptide primary antibody made against a number of different epitopes situated in the 
N-terminus of the KCP polypeptide and designed as part of the MSc project for 
immunodetection and Western blot analysis of the heterologously expressed 
recombinant KCPs. 
For every scientific experiment that is performed, it is important to have controls so 
that any results obtained may be regarded as significant. For this same reason, an 
antibody control as well as a pre-immune control as shown in Figure 38 and 39 
respectively, was carried out in order to show that if any immunostaining was 
obtained it might indeed be regarded as specific and reliable. In addition, other 
appropriate controls were used for proper interpretation of results. As a positive 
control, it was shown that llliV-infection could be detected in all three stages of KS, 
namely the early patch stage, the intermediate plaque stage and the most advanced 
nodular stage by nuclear staining using a mouse monoclonal anti-LANA antibody 
(Figure 41). However, only one out ofthe 4 cases for each stage ofthe disease stained 
positive for llliV-8. Furthermore, three other controls namely anti-CD31, anti-CD34 
and anti-Cyclin Dl (Figures 40 A-C respectively) were used as positive controls for 
qualitative immunohistochemistry of the paraffin-embedded tissue sections viewed by 
light microscopy. 
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EnVision+™ (DAKO) was the system of choice to perform the immunohistochemical 
studies. Even with the best of systems, problems can sometimes occur, such as 
extremely high background staining, colour development in the wrong sections, or the 
staining of interest may be rather weak or absent. Because most often not all the 
reasons for undesirable staining are clear, trying to optimize the staining and therefore 
solving the problem may require the testing of a number of different controls on the 
tissue sections. 
At the beginning of the study, the immunostaining of the KS tissue sections with the 
poly clonal anti-KCP peptide antibody resulted in an enormous degree of inappropriate 
background staining (Figure 39B). All the positive controls mentioned above resulted 
in the expected staining: ·clean nuclear staining when tissue sections were incubate~ 
with anti-LANA (Figure 41) and Cyclin D1 (Figure 40C), and strong cytoplasmic 
staining as well as cell membrane staining with the endothelial cell markers, CD34 
and CD31 as shown in Figures 40B and 40A respectively. Therefore, from these set of 
results it was deduced that the non-specific staining obtained with the anti-KCP · 
peptide antibody was not due to endogenous enzyme developing the substrate, in 
other words, the endogenous peroxidase was appropriately blocked with aqueous 1% 
hydrogen peroxide and in general the immunohistochemical technique was performed 
successfully. Furthermore, the secondary antibody, no primary antibody negative 
control (Figure 38B) indicated that the background staining was not caused by cross-
reactivity between the peroxidase-conjugated goat anti-rabbit secondary antibody and 
endogenous immunoglobulins or other tissue proteins, which may take place if the 
secondary antibody reacts with identical or closely related amino acid sequences of 
these proteins. 
The first step m troubleshooting the inappropriate background staining was to 
optimize the concentration of primary antibody used as the optimal concentration 
should be the amount capable of producing clean specific staining. Therefore, a series 
of dilutions of the primary antibody were tested and yet no significant improvement 
of the improper staining took place (results not shown). 
It is a possibility that the antigen of interest may have been destroyed during 
embedding or fixation of the tissue sections and therefore an antigen unmasking 
technique referred to as heat induced epitope retrieval (IllER) was carried out in order 
to recover antigen damaged by fixation. HIER was tried out with two different buffers 
EDT A (pH 8) and citrate buffer (pH 6), in order to determine at which pH the IllER 
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was most efficient, thereby leading to a more optimum staining pattern. After 
visualizing the slides using light microscopy, the buffer of choice for unmasking of 
the antigen was EDT A (pH 8). Further troubleshooting of the inappropriate 
background staining had to be continued and in case the concentration of the 
polyclonal IgG of interest was too low for positive immunostaining, the polyclonal 
IgG was enriched for using a protein-A sepharose column. SDS-PAGE analysis 
(Figure 31) revealed that the IgG immunoglobulins were successfully concentrated 
from the serum sample (starting material) using this column. Immunostaining under 
exactly the same conditions of a KS tissue section, incubated with polyclonal anti-
KCP peptide primary antibody post protein A-sepharose purification, revealed a 
significant improvement in the level of background staining (Figure 39C) when 
compared to the same tissue section incubated with the test antibody prior to the IgG 
purification step (Figure 39B). 
Once the background staining was substantially diminished, 4 different KS cases 
corresponding to the three different stages of disease progression were investigated 
for the presence of endogenous KCP, using the EnVision+™ system, HIER with 
EDTA (pH 8) and the polyclonal anti-KCP peptide primary antibody at 1:10 000. 
One of the most remarkable characteristics of tumour viruses such as KSHV is their 
ability to express protein homologs to cellular proteins, in order to evade the host 
immune system as described in Chapter 1 section 1.3.2. 
KSHV encodes a complement inhibitor homologue, which because of its biological 
function is believed to be used by the virus as an active strategy to overcome the 
complement system and to infect endothelial cells. As shown in panel B of Figures 
42-44, endogenous KCP was not detected by the polyclonal anti-KCP peptide 
antibody, in the nuclei or in the cytoplasm of the spindle cells of the KS lesion 
vascular channels, therefore no statistical conclusions could be drawn between the 
three stages of KS with the use of this antibody. The fact that the anti-KCP did not 
detect the presence of a KCP population within the tumour cells could simply mean 
that the expression of this protein is ceased upon viral infection of the spindle cells. 
This may be attributed to the fact that the ORF 4 gene is not an essential gene for 
replication of the virus but only for its initial interaction with the host during 
infection. Furthermore, the localisation of KCP may be a rather transient process, as 
the protein could be quickly degraded after the virus has successfully infected its host 
and ceases synthesizing endogenous KCP during latent infection. 
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Probably by usmg a more sensitive detection technique such as fluorescent 
microscopy, and a monoclonal anti-KCP made against native KCP such as the one 
synthesised by Spiller et al (2003a), which recognises one specific epitope would 
have been more successful in recognising a distinct population of endogenous KCP 
protein within the KS tissue samples, and this may indeed be considered for future 
work regarding this study. 
4.2 Heterologous Production of KCP in the methylotrophic 
yeast Pichia pastoris 
The P. pastoris yeast expression system has become a very popular means for 
heterologous protein production. It is as easy to work with as E. coli or 
Saccharomyces cerevisia as it is simple to grow and manipulate in large quantities in 
a ~ontrolled manner. In addition, it has been both genetically and biochemically 
unravelled, thus providing a favourable alternative for the high-level production of 
foreign proteins. As a eukaryotic organism, it possesses many of the advantages of 
higher eukaryotic expression systems including protein processing, protein folding 
and posttranslational modification. As methylotrophic yeast, Pichia is capable of 
utilising methanol as its unique carbon and energy source (Sreekrishna et al, 1997). 
The metabolism of methanol takes place in the peroxisome, a specialised cell 
organelle, which prevents hydrogen peroxide toxicity during the oxidation of 
methanol to formaldehyde in the presence of molecular oxygen (Oden, 1994). 
Methanol oxidase, the first enzyme in the methanol utilisation pathway, has a low 
affinity for 02 and as a result the yeast compensates by synthesising large quantities 
of this enzyme. Therefore, the highly inducible and tightly regulated methanol 
oxidase gene (AOXJ) promoter has been engineered in expression vectors to drive the 
synthesis of foreign proteins in Pichi a (Sreekrishna et al, 1997). 
The 8.0 kb expression vector pPIC9 was the plasmid selected for the recombinant 
expression of the three different sized KCPs because it has been used successfully for 
the secreted expression of recombinant VCP in P. pastoris (Smith et al, 2000) and it 
was readily available in the laboratory. 
The three DNA-portions of the KSHV ORF 4 encompassmg SCRs 1 to 4 were 
successfully amplified from a KSHV DNA template by PCR (Figure 14) using a 
KSHV ORF 4-specific forward primer and three consecutive KSHV ORF· 4-specific 
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reverse primers. For the heterologous production of the KCPs in P. pastoris, PCR 
products were inserted by ligation into pPIC9 to generate three recombinant plasmids, 
pPIC9/KSHV ORF 4 (735), pPIC9/KSHV ORF 4 (1436) and pPIC9/KSHV ORF 4 
(1581) coding for a soluble protein comprising of the 4 sushi domains (S-), a larger 
protein lacking the putative transmembrane binding domain (M-) and the full-length 
ORF 4 (F-) respectively (Figure 20). Integration of the three different sized KSHV 
ORF 4 genes into the P. pastoris genome was carried out by homologous 
recombination with these pPIC9/KSHV ORF 4 DNA constructs. 
Double stranded plasmid DNA template, pPIC9/KSHVORF 4 (735), 
pPIC9/KSHVORF 4 (1436) and pPIC9/KSHVORF 4 (1581) isolated from· E. coli 
transformants was subjected to restriction endonuclease digestion and the DNA 
fragments were analysed by agarose gel electrophoresis (Figure 23). 
Recombinant colonies with the KSHV ORF 4 gene integrated in their genomes were 
initially used for small expression experiments in BMMY medium. Expression and 
secretion of the KCP-M and KCP-F viral proteins into the media was confirmed by. 
immunoblot using a slot-blot apparatus after blotting I 00 J..ll of culture media 
supernatant onto nitrocellulose Hybond-ECL membranes (Figure 34A and 35A . 
respectively). 
Small-scale expression was followed by medium-scale production of KSHV ORF 4 
proteins from recombinant P. pastoris colonies transformed with the three Sac !-
digested pPIC9/KSHV ORF 4 plasmid constructs. Culture media supernatants from 
colonies transformed with the pPIC9 empty vector (no insert) digested with Sac I pre-
and 96 h post-induction was included as negative controls in all of the protein 
expression and detection experiments, in order to show that the protein of interest was 
solely detected in the supernatant of recombinant strains, transformed with pPIC9 
constructs expressing the genes of interest. 
The time-course of expression of the KCP-S, KCP-M and KCP-F proteins was 
monitored by SDS-PAGE (Figure 33A, 34B and 35B respectively), and in the case of 
the first two recombinant proteins the induction profile was also followed by Western 
blot analysis, which showed that the protein could be first detected at 48 h post-
induction and the amount of protein continue to build until after 72 and 96 h (Figure 
33B and 34C respectively) the latter being the time chosen to harvest the cells before 
they begin to lyse and release unwanted proteases into the media. In addition, the 
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polyclonal anti-KCP peptide antibody recognised several larger and smaller bands 
that may represent multimer aggregates and degradation products respectively. 
Intensities of SDS-PAGE bands were scanned with a densitometer and the 
concentration of the P. pastoris-expressed KCP protein was quantitively estimated by 
comparison with a standard curve obtained with known amounts of protein (Figure 
29). Under these conditions, the yield of P. pastoris expressed KCP-S, KCP-M and 
KCP-F was about 5, 6.4 and 1.76 J..Lg per millilitre of yeast culture medium 
respectively. This protein concentration estimation correlates with the first two 
recombinant proteins, KCP-S and -M obtained from medium-scale expression [100 
ml] whereas the full-length KCP-F protein was obtained from a small-scale 
experiment [5 ml]. In the case of the latter the amount of detectable protein in the 
media was very low and as a result only upon concentration of 100 J..Ll of protein 
sample, a successful Western blot of the protein was obtained (Fig 35C). 
Transformants expressing detectable protein varied dramatically amongst different 
clones even from the same transformation procedure. Several recombinant colonies 
were analysed for protein expression, and although the presence of insert was 
confirmed by PCR, not all clones expressed detectable amounts of protein. This may 
be explained in terms of the limitations of using the P. pastoris such as sensitivity to 
temperature, humidity and other weather elements. 
On the other hand, the small-scale expressions showed that both Mut+ and Mut5 
recombinant P. pastoris transformants were able to express the KSHV ORF 4 protein 
provided that a good clone was selected and used for the expression. According to the 
Invitrogen manual, Mut+ colonies are capable of producing larger quantities of protein 
in shorter periods of time because the AOXJ gene is kept intact and therefore its 
product, which accounts for the majority of the alcohol oxidase activity, increases the 
cell's ability to metabolise methanol as the sole carbon source. The AOXJ gene 
promoter is strictly regulated and induced by methanol to high levels and 
consequently it is used to drive expression of the genes of interest. Therefore, Mut+ 
transformants were preferably used throughout this study. 
In order to determine whether or not the P. pastoris-expressed recombinant KCP 
proteins retained their functional activity, the ability of these proteins in medium to 
inhibit the complement classical pathway-mediated lysis of antibody-coated sheep 
erythrocytes was investigated. The results obtained, noticeably demonstrate that 
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unlike the ammonium-sulphate precipitated-supernatant from a Pichia culture 
transformed with pPIC9/KCP-M and F, the ammonium-sulphate precipitated-
supernatant from a Pichia culture transformed with pPIC9/KCP-S contained a 
functional protein capable of binding complement proteins in a concentration-
dependent fashion. If taking into account the low percentage complement inhibition 
caused by the same volume of background control, in other words, supernatants from 
Pichia culture transformed with pPIC9 (empty vector) that underwent the same 
induction and concentration steps as the test samples, it is clear that a KSHV 
functional regulator of human complement was successfully expressed in P. pastoris 
using the pPIC9/KCP-S construct (Figure 36). 
The lack of biological activity obtained in the case of the other two recombinant 
KCPs may be attributed to the fact that unfractionated media was used co~t~iping -· · ---·. 
many native contaminating bands (Figures 34 and 35B) and thereforeitis possible 
that something in the yeast media may have inhibited the activity of KCP-M and 
KCP-F. Another possibility is that these two recombinant KCPs may have been 
differently folded before being secreted into the media. Therefore perhaps some ofthe 
complement binding sites may have been covered or modified in some way causing 
insufficient biological activity (1) because of their considerable molecular sizes and 
(2) the three non-conservative amino acid mutations (Figure 19) probably introduced 
during PCR-amplification. However, it is possible that these point mutations are 
natural occurring polymorphisms especially since the isolate available in the database 
is from a different source and from a different continent. The former discussed cause 
ofthe point mutations might have been avoided if a higher fidelity polymerase such as 
Pfu was used and the PCR product was sequenced instead of the intermediate 
plasmid. 
In addition, only the full length KCP clone was sequenced therefore unknown point 
mutations may have been present in the other PCR cloned regions, which may be the 
reason why only the truncated version of KCP was able to inhibit complement-
mediated lysis of sensitised sheep red blood cells. 
Furthermore, the rKCP-F should not be secreted as it contains a functional 
transmembrane domain (Spiller et a!, 2003a) nevertheless it may have undergone 
shedding, in other words cleavage of the ectodomain may have taken place resulting 
in the release of a soluble but inactive protein. Ectodomain shedding is a well 
recognized, but not fully understood biochemical process that represents an important 
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and efficient strategy of activity regulation in a number of transmembrane proteins 
(Werb and Yan, 1998). 
The presence of glycans on other proteins belonging to the RCA family has been 
shown to extensively influence their biological activities. For example, the MCP 
isoforms with a larger 0-glycosylation domain was found to bind C4b more 
efficiently than the smaller and less glycosylated isoforms (Liszewski et al, 1998). In 
order to examine rKCP-S for N-linked glycosylation, the supernatant from culture of 
the recombinant strain containing partially purified protein, was treated with PNGase 
F and subjected to SDS-PAGE analysis. The results show a shift in molecular weight 
between treated and untreated KCP-S from 56 kDa to approximately 27 kDa, the 
protein's theoretical molecular weight (Figure 37), indicating the presence of 
functional N-glycosylation sites in the heterologously expressed truncated KCP 
protein, which could effectively contribute to its significant bioactivity as shown in 
Figure 36. 
In addition, Western blot analysis with the rabbit polyclonal antibody directed against 
a selected KSHV ORF 4 peptide, common to all three KCP recombinant proteins, 
showed that the P. pastoris-heterologously expressed soluble-, medium- and full-
length KCPs migrated electrophoretically as higher bands, which most likely is due to 
glycosylation of the proteins as in addition to the presence of potential N- and 0-
linked carbohydrate sites in the protein's primary sequence, diffused bands were 
obtained in all the westerns carried out, which is characteristic of glycoproteins. 
Protein glycosylation therefore may be another reason attributing to the lack of 
biological activity of the KCP isoforms besides KCP-S. 
In broad terms, knowledge acquired from this study may be implemented in health 
and disease, in the sense that inadequate activation and regulation of the complement 
system is regarded as a caus~ of tissue destruction. This in turn, has been shown to 
lead to the progress of a large number of medical conditions such as Alzheimer's 
disease, traumatic brain injury (TBI), ischemia, arthritis, rejection of xenogeneic 
transplants (Daly and Kotwal, 1998; Hicks eta!, 2002; Sacks eta!, 2003; Low and 
Moore, 2005) just to name a few. Therefore, the use of CCPs and its derivatives as 
inhibitors of undesirable complement activation is presently a very attractive area of 
research. 
More specifically, knowledge acquired from this expression study may provide some 
new insight into the utility and limitations of the P. past oris system for the production 
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of recombinant KCP. Perhaps with the use of different vectors, expression cassettes or 
even different transformation techniques the heterologous production of KCP may be 
greatly enhanced, which can then be used in various structure-function· studies. 
Additionally, in future a His-tag version of KCP may be considered for expression 
and easy purification of the protein from mammalian cells. It is however difficult to 
predict whether proper post-translational modifications such as glycosylation and 
protein folding will occur. It may be essential to remove the His-tag after purification 
since addition of His residues might lead to a stretch of charge on the protein, which 
may in turn influence its activity. 
Furthermore, it is of major significance to understand how CCPs such as the KCP 
protein, perform their biological functions at the structural level in order to gain 
insight for the development of new and more efficient therapeutic inhibitors of 
complement. 
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APPENDIX A 
PLASMIDS AND PICHIA STRAINS 
Plasmid Relevant characteristics Source of 
Reference 
pGEMT-Easy 3.0 kb, AmpK, T7 promoter, SP6 Prom ega 
promoter 
pGEMT/KSHV ORF4 (735) 3.8 kb, AmpK, T7 promoter, SP6 This study 
promoter, 735 bp KCP gene 
pGEMTIKSHV ORF4 4.5 kb, AmpK, T7 promoter, SP6 This study 
(1436) promoter, 1436 bp KCP gene 
pGEMT/KSHV ORF4 4.6 kb, AmpK, T7 promoter, SP6 This study 
(1581) promoter, 1581 bp KCP gene 
pPIC9 8.0 kb, AmpR, HIS4, P AOXI. a.-factor Invitrogen 
signal seq 
pPIC9/KSHV ORF4 (735) R . 8.8 kb, Amp , HIS4, P AOXI. a.-factor This study 
signal seq, 735 bp KCP gene 
pPIC9/KSHV ORF4 (1436) 9.5 kb, AmpR, HIS4, PAoxi. a.-factor This study 
signal seq, 1436 KCP gene 
pPIC9/KSHV ORF4 (1581) 9.6 kb, AmpR, HIS4, PAoXI. a.-factor This study 
signal seq, 1581 bp KCP gene 
Strains Relevant Characteristics Source of 
Reference 
GS115 Wildtype, genotype his4, phenotype Mut+ Invitrogen 
GS115/pPIC9 GS 115 transformed with pPIC9 This study 
GS115/pPIC9/KSHV ORF4 GS 115 transformed with pPIC9/KSHV This study 
(735) ORF4 (735) 
GS115/pPIC9 KSHV ORF4 GS115 transformed with pPIC9/KSHV This study 
(1436) ORF4 (1436) 
G~115/ pPIC9/KSHV ORF4 GS 115 transformed with pPIC9/KSHV This study 
(1581) ORF4 (1581) 
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APPENDIXB 
LIST OF MATERIALS AND SUPPLIERS 
MATERIAL 
o Ampicillin 
o Ammonium Persulphate 
o APES 
o BM Chemiluminescence Western Blotting kit 
o Broad Range Protein Molecular Weight Marker 
o Coomassie brilliant blueR- 250 
o DAB liquid 
o DNeasy kit for DNA purification from yeast 
o ECL Western Blotting Kit 
o EDTA 
o En Vision System 
o Ethidium Bromide 
o Expand High Fidelity PCR System 
o HiTrap Protein A sepharose column 
o Lamda DNA/ Eco RI+Hind III 
o Lyticase 
o Miniprep plasmid isolation kit 
o Nitrocellulose Hybond- ECL membrane 
o Normal goat serum 
o PCR Nucleotide mix 
o pGEM-T Easy Vector System I 
o Pichia EasyComp kit 
o Pfu DNA Polymerase 
o PNGaseF 
o Ponceau S 
o Restriction endonucleases 
o Taq DNA Polymerase 
o Tween-20 
o X-ray film 
o Wizard SV gel and PCR clean-up system 
SUPPLIER 
Boehringer 
Boehringer 
Sigma 
Roche 
Prom ega 
Sigma 
Dako 
Qiagen 
Amersham 
BDH 
Dako 
Sigma 
Roche 
Amersham 
Prom ega 
Sigma 
Qiagen 
Amersham 
Dako 
Pro mega 
Prom ega 
Invitrogen 
Prom ega 
Sigma 
Sigma 
Roche 
Prom ega 
Merck 
Amersham 
Prom ega 
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